Use these links to rapidly review the documentTABLE OF CONTENTS INOVIO BIOMEDICAL CORPORATION Index to Consolidated Financial Statements

Table of Contents



UNITED STATES
SECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549

FORM 10-K

ý

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934FOR THE FISCAL YEAR ENDED DECEMBER 31, 2008ORo

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934FOR THE TRANSITION PERIOD
FROM                                  TO


COMMISSION FILE NO. 001-14888

INOVIO BIOMEDICAL CORPORATION(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

DELAWARE(State or other jurisdiction of
incorporation or organization)

33-0969592(I.R.S. Employer Identification No.)11494 SORRENTO VALLEY ROAD
SAN DIEGO, CALIFORNIA(Address of principal executive offices)

92121-1318(Zip Code)


REGISTRANT'S
TELEPHONE NUMBER, INCLUDING AREA CODE:(858) 597-6006

SECURITIES
REGISTERED PURSUANT TO SECTION 12(B) OF THE ACT:

COMMON STOCK, $0.001 PAR VALUE

NYSE Amex(Title of Class)

(Name of Each Exchange on Which Registered)


SECURITIES
REGISTERED PURSUANT TO SECTION 12(G) OF THE ACT:NONE

Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities
Act. Yes o    No ý

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the
Act. Yes o    No ý

Indicate by check mark whether the Company (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past
90 days. Yes ý    No o

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be
contained, to the best of Registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to
this Form 10-K. ý

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting
company. See definitions of "large accelerated filer," "accelerated filer," and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer o

Accelerated filer o

Non-accelerated filer o (Do not check if a smaller reporting company)

Smaller reporting company ý


Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the
Act). Yes o    No ý

The aggregate market value of the voting and non-voting common equity (which consists solely of shares of Common Stock) held by
non-affiliates of the Registrant as of June 30, 2008 was approximately $47,498,118 based on $1.08, the closing price on that date of the Registrant's Common Stock on the NYSE Amex.

The
number of shares outstanding of the Registrant's Common Stock, $0.001 par value, was 44,041,800 as of March 16, 2009.

DOCUMENTS INCORPORATED BY REFERENCE

None.



---





Table of Contents



TABLE OF CONTENTS



PART I

3ITEM 1. BUSINESS

3ITEM 1A. RISK FACTORS

22ITEM 2. PROPERTIES

42ITEM 3. LEGAL PROCEEDINGS

43ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY
HOLDERS

43PART II

44ITEM 5. MARKET FOR COMPANY'S COMMON EQUITY, RELATED STOCKHOLDER
MATTERS AND ISSUER REPURCHASES OF EQUITY SECURITIES

44ITEM 6. SELECTED CONSOLIDATED FINANCIAL DATA

46ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS

46ITEM 7A. QUALITATIVE AND QUANTITATIVE DISCLOSURES ABOUT MARKET
RISK

59ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY
DATA

61ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON
ACCOUNTING AND FINANCIAL DISCLOSURE

61ITEM 9A. CONTROLS AND PROCEDURES

61ITEM 9B. OTHER INFORMATION

61PART III

62ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE COMPANY

62ITEM 11. EXECUTIVE COMPENSATION

68ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
MANAGEMENT

78ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

80ITEM 14. PRINCIPAL ACCOUNTANT FEES AND
SERVICES

81PART IV

81ITEM 15. EXHIBITS AND FINANCIAL STATEMENT
SCHEDULES

81SIGNATURES

87CONSOLIDATED FINANCIAL STATEMENTS

F-1


1

---





Table of Contents

Unless stated to the contrary, or unless the context otherwise requires, references to "Inovio," "the company," "our company," "our," or "we" in this report
include Inovio Biomedical Corporation and subsidiaries.

FORWARD-LOOKING STATEMENTS

This annual report contains forward-looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995, including statements with regards to our revenue, spending, cash flow, products, actions, intentions, plans, strategies and objectives. These statements are not based on historical
facts or of current conditions. All such forward-looking statements are inherently uncertain. We have based those forward-looking statements on, among other things, projections and estimates regarding
the economy in general, the biomedical industry and other factors that impact our results of operations and financial condition. Forward-looking statements include, without limitation, any statement
that may predict, forecast, indicate or simply state future results, performance or achievements, and may contain the words "believe," "anticipate," "expect," "estimate," "intend," "plan," "project,"
"will be," "will continue," "will result," "could," "may," "might," "should" or any variations of such words with similar meanings, including the negatives of such words. Any such statements are
subject to risks and uncertainties that could cause our actual results to differ materially from those which are management's current expectations or forecasts. Such information is subject to the risk
that such expectations or forecasts, or the assumptions underlying such expectations or forecasts, become inaccurate and there can be no assurance
that the forward-looking information in this report will in fact transpire or prove to be accurate. All subsequent written and oral forward looking statements attributable to us or persons acting on
our behalf are expressly qualified in their entirety by this introduction.

Our forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance
or achievements to be materially different from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statements. Certain of these risks,
uncertainties and other factors are discussed in Item 1A"Risk Factors" and elsewhere in this report. We operate in a very competitive and rapidly changing environment. New risk
factors emerge from time to time and we cannot predict all such risk factors, nor can we assess the impact of all such risk factors on our business or the extent to which any factor, or combination of
factors, may cause actual results to differ materially from those contained in any forward looking statements. Given these risks and uncertainties, investors should not place undue reliance on
forward-looking statements which reflect management's view only as of the date of this report, as a prediction of actual results. We undertake no obligation to amend this report or revise publicly
these forward-looking statements (other than pursuant to requirements imposed on registrants pursuant to Item 1A under Part II of Form 10-Q) to reflect subsequent
events or circumstances. Readers should also carefully review the risk factors described in other documents we file with the Securities and Exchange Commission, or SEC, particularly our quarterly
reports on Form 10-Q, and the cautionary statements contained in our press releases from time-to-time which may contain forward-looking
information.

Investors should also be aware that while we do, from time to time, communicate with securities analysts, we do not disclose any material non-public
information or other confidential commercial information to them. Accordingly, individuals should not assume that we agree with any statement or report issued by any analyst, regardless of the content
of the report. Thus, to the extent that reports issued by securities analysts contain any projections, forecasts or opinions, such reports are not our responsibility.

2

---





Table of Contents

PART I

ITEM 1.    BUSINESS

Overview

Inovio Biomedical Corporation, or "Inovio," a Delaware corporation, organized in 2001, is a San Diego-based biomedical company focused
on the development of next-generation vaccines to prevent or treat cancers and chronic infectious diseases. Such vaccines, which could potentially protect millions of people from
debilitation or death from diseases without adequate treatments, may represent multi-billion dollar market opportunities. Historically, successful development of this new generation of
vaccinesDNA vaccineshas been hindered by the lack of safe, efficient and cost effective DNA delivery methods capable of enabling their potency. However, Inovio's
electroporation-based DNA delivery technology has shown potential in pre-clinical and clinical studies to play a pivotal role in facilitating delivery and enhancing the potency of
preventive and therapeutic vaccines.

Inovio
is a leader in developing DNA delivery solutions based on electroporation, which uses brief, controlled electrical pulses to create temporary pores in cell membranes and enable
increased cellular uptake of a useful biopharmaceutical. Once the DNA vaccine enters a cell, it can then "express" the proteins it was encoded to produce. These proteins, or antigens, are designed to
be uniquely associated with a targeted cancer or infectious disease, and may then stimulate a more powerful immune response if the immune system encounters the targeted disease at a subsequent time.

Inovio's
business strategy to realize value for the company and its stockholders is as follows:

First,
Inovio has leveraged its patented technologies through licensing and collaborations, such as its licensing arrangements with Merck & Co., Inc., or "Merck,"
Wyeth Pharmaceuticals, or "Wyeth" and Vical Inc., or "Vical," among other research-driven biopharmaceutical companies as well as government and non-government agencies. Inovio is
licensing the use of its electroporation-based DNA delivery systems for partners to use in conjunction with their proprietary DNA vaccines or DNA-based immunotherapies. These arrangements
provide Inovio with some combination of upfront payments, development fees, milestone payments, royalties and a supply agreement. These partners are pursuing development of proprietary agents or
conducting research using Inovio's technology. However, there is no assurance that these licensing partners will continue these electroporation-based activities. Currently, Merck has completed
electroporation-based treatments in their initial Phase I cancer trial. Merck licensed from Inovio a second target in December of 2007 for which it has filed an IND. There is no assurance that
Merck will continue to develop either program into a Phase II study. In addition, Wyeth continues to evaluate internal strategic options prior to initiating further development of
electroporation-based infectious disease programs.

Second,
Inovio is pursuing proprietary vaccine development or co-development, resulting in whole or partial ownership in promising vaccines to prevent or treat cancers and
chronic infectious diseases.

Inovio's
technology is protected by an extensive patent portfolio covering in vivo electroporation. Inovio's patent portfolio encompasses a range of apparatuses, methodologies,
conditions, and applications including oncology, gene delivery, vascular, transdermal as well as ex vivo electroporation.

Inovio's Core Technology

Most drugs and biologics must enter into a cell through a cell membrane in order to perform their intended function. However, gaining
entry into a cell through the outer cell membrane can be a significant challenge. In the 1970s it was discovered that the brief application of high-intensity, pulsed electric fields can
create temporary and reversible permeability, or pores, in the cell membrane. This pulse-induced permeabilization of the cellular membrane is generally referred to as electroporation. One observable
effect of cell membrane electroporation is less restricted exchange of molecules

3

---



Table of Contents

between
the cell exterior and interiorthe benefit being that it allows and enhances the uptake of, for example, a biopharmaceutical agent previously injected into local tissue. The extent
of membrane permeabilization depends upon various electrical, physical, chemical, and biological parameters.

The
transient, reversible nature of this electrical permeabilization of membranes is the underlying basis of Inovio's electroporation instruments, which are designed to harness this
phenomenon by delivering controlled electrical pulses into tissue to facilitate the uptake of useful biopharmaceuticals. Inovio's technology generates electric fields in target tissues to induce
electroporation, which increases cellular uptake even for large molecules such as DNA. Most cell types and tissue can be successfully electroporated as long as applicators with the appropriate
configuration of needle electrodes can be used to expose cells and tissues to the electric field.

DNA
vaccines have potential as therapeutic agents for treating various diseases. One of the key obstacles to the successful development and commercialization of DNA vaccines has been the
limitations associated with current delivery systems. Alternative approaches based on the use of viruses and lipids are complex and expensive, and have in the past created concerns regarding safety.
Electroporation provides a straightforward, cost effective method for delivering DNA into cells with high efficiency and minimal complications (as compared to viral vectors) and, importantly, inducing
clinically relevant levels of gene expression.

Inovio
has multiple systems designed to create different electroporation conditions for different applications. The current systems consist of two basic components: a pulse generator and
an applicator that is inserted into selected tissue.

MedPulser® DNA Electroporation System

Inovio's MedPulser® DNA Electroporation System was designed to create conditions to deliver DNA into tumor cells that
promote optimal responses to gene-based immunotherapeutic cytokines. The cytokine-encoding plasmid is first injected with a syringe/needle into the selected tumor. Using a remote control,
the pulse generator is switched on. High-voltage electrical pulses are generated and delivered through an attached electrical cord into the injected tissue through an electrode-needle
array on the applicator. The electrode-needle array consists of a total of six needle-electrodes. The needle-electrode arrays are available in different sizes and configurations to facilitate access
to tumors of different sizes and in different locations.

MedPulser® DNA Delivery System

The MedPulser® DNA Delivery System (DDS) was developed to optimize the delivery of DNA into muscle cells. The modified
system is similar to the MedPulser® Electroporation System. The primary differences are in the parameters of the electric pulses delivered by the generator and the needle- electrode
configuration of the applicator. The pulse is designed specifically for DNA delivery with a lower strength electrical field of longer duration than for tumor electroporation. The applicator has a four
needle-electrode array consisting of one set of opposite pairs. They are available in a range of configurations to meet the requirements of a variety of applications.

Elgen System

The Elgen® DNA Delivery System, Inovio's newest generation of electroporation systems, is designed primarily for muscle
delivery. It consists of a computer-controlled, motorized two needle delivery device that injects DNA and delivers electroporation pulses through one pair of needles. An earlier prototype version of
this experimental system is currently under evaluation in Inovio's clinical trial for a prostate cancer vaccine at the University of Southampton in the U.K.

4

---



Table of Contents

Choice of Tissue for DNA Delivery

Muscle Delivery

Inovio's proprietary electroporation method consists of a DNA delivery system designed to introduce a plasmid vector into muscle, skin
or tumor tissue. The plasmid(s) may be encoded for therapeutic protein(s) for gene therapy, or antigens for immunization.

Skeletal
muscle has been a core focus because it is mainly composed of large elongated cells with multiple nuclei. Muscle cells are non-dividing, hence long-term
expression can be obtained without integration of the gene of interest into the genome. Muscle cells have been shown to have a capacity for secretion of proteins into the blood stream. Secreted
therapeutic proteins may therefore act systemically and produce therapeutic effects in distant tissues of the body. In this respect, the muscle functions as a factory for the production of the
biopharmaceutical needed by the body. It is envisioned that delivery of DNA by electroporation to muscle cells will circumvent the costly and complicated production procedures of viral gene delivery
vectors, protein-based drugs, conventional vaccines and monoclonal antibodies. This approach may therefore provide long-term stable expression of a therapeutic protein or monoclonal
antibody at a sustained level.

For
vaccination the DNA cause muscle cells to produce antigenic proteins that the immune system will identify as foreign and against which it will mount an immune response. As with
conventional vaccines, the immune system will then develop memory of this antigen (and related disease) for future reference. Intra muscular delivery by electroporation of DNA encoded antigens has
been shown to induce both humoral (antibody) and cellular (T-cell) immune responses. Inovio is currently collaborating in three clinical programs (Merck, Tripep and the University of
Southampton) related to DNA delivery to muscle for immunization.

Tumor Delivery

Inovio has an extensive intellectual property position relating toin vivodelivery of
genes directly into tumor cells. Tumor cells can be readily transfected with genes encoding selected cytokines or potentially lethal proteins for the treatment of a variety of cancers. The goal of
effective tumor delivery is the ultimate elimination of the transfected tumor, and Inovio has experienced very few concerns regarding the safety of the procedure in its trials to date. A
Phase I/II clinical immunotherapy trial conducted by Vical was designed to deliver IL-2 directly to accessible melanoma lesions. In December 2008, Inovio announced final results of
a similar clinical study conducted by Moffitt to deliver IL-12 directly to accessible melanoma lesions.

Skin Delivery

While Inovio has generated preclinical and preliminary clinical evidence that intramuscular electroporation-based DNA delivery will be
effective for a number of vaccines, electroporation of the skin may also be a relevant route of administration. Skin or intradermal administration is important and is becoming an attractive site for
immunization given its high density of antigen presenting cells (APCs). Unlike muscle, skin is the first line of defense against most pathogens and is therefore very rich in immune cells and
molecules. Skin specifically contains certain cells that are known to help in generating a robust immune response. With intradermal administration of electroporation, Inovio may be able to demonstrate
a comparable immune response to muscle delivery. Inovio will continue to invest research and patenting resources into developing a viable skin electroporation system for clinical evaluation.

5

---



Table of Contents

Applications of DNA Vaccine Technology

Inovio and its partners are developing DNA delivery technology for two broad applications:

Cancer

Cancer is a disease of uncontrolled cell growth. Although cancer has been a major focus of pharmaceutical companies for decades, cancer
remains one of the leading causes of death in the United States. Traditionally, three approaches have been available for treatment of cancer: surgery, radiation therapy, and chemotherapy. When
detected early and still confined to a single location, cancer may be cured by surgery or radiation therapy. However, neither surgery nor radiation therapy can cure cancer that has spread throughout
the body. Although chemotherapy can sometimes effectively treat cancer that has spread throughout the body, a number of non-cancerous cells, such as bone marrow cells, are also highly
susceptible to chemotherapy. As a result, these types of treatments cause significant side effects and morbidity. Finally, it is common to see cancer return after apparently successful treatment by
each of these means. The limitations of current cancer treatments are clearly demonstrated by the mortality rate of this disease.

For
many decades, it has been suggested that the immune system should also be able to recognize cancer cells as abnormal and destroy these cells. However, cancer cells have developed
mechanisms that allow them to escape the surveillance of the immune system. Immunotherapy, a process which uses the patient's own immune system to treat cancer, may have advantages over surgery,
radiation therapy, and chemotherapy. Many cancers appear to have developed the ability to "hide" from the immune system. A treatment that can augment the immune response against tumor cells by making
the cancer more "visible" to the immune system would likely represent a significant improvement in cancer therapy. Immune- enhancing proteins such as IL-2 and IL-12, used by
partners in Phase I/II trials, have shown encouraging results. There is also a need to stimulate a stronger cellular immune response (i.e. generating T-cells) to specifically
attack cancerous cells. This requires the use of technology such as DNA vaccines.

Electroporation
offers effective delivery of DNA and may help Inovio develop novel cancer therapies. Inovio's current clinical-stage approaches consist of directly injecting tumors with
certain plasmids followed by intratumoral electroporation as well as directly delivering certain plasmids into muscle followed by intramuscular electroporation. Upon uptake into cells, the plasmid
directs the production of the encoded immunostimulatory proteins. The convenience and ability to repeat administration may offer advantages over current modalities of therapy. In addition, cancer
therapies using non-viral DNA delivery may offer an added margin of safety compared with viral-based delivery, as no viral DNA/RNA or viral particles are contained in the formulation.
Studies in animals have demonstrated the safety and potential efficacy of electroporation-based delivery. Subsequently, in human studies, a very low incidence of treatment- related serious adverse
events has been observed.

In
addition to immunotherapy approaches, numerous cancer antigens have been identified over the past few decades and better identification tools are under development by others. Inovio
will continue to evaluate opportunities to acquire or partner cancer antigens that may be useful for large market cancers such as breast, lung and prostate.

Infectious Diseases

DNA vaccines for infectious diseases use portions of the genetic code of a pathogen to cause the host to produce proteins of the
pathogen that may induce an immune response. Compared with conventional vaccines that use live, weakened, or dead pathogens to produce an immune response, this method potentially offers superior
safety and ease of manufacturing, as well as convenient storage and handling characteristics. DNA vaccines have the potential to induce potent T-cell responses against target pathogens as
well as trigger production of antibodies. Over the past decade, many scientific

6

---



Table of Contents

publications
have documented the effectiveness of DNA vaccines in contributing to immune responses in dozens of species, including non-human primates and humans. Since electroporation can
increase uptake of DNA into cells, it may consequently increase the potency of DNA vaccines. Increased T-cell responses and antibody production when DNA vaccines are delivered using
electroporation has been demonstrated in a large number of species including non human primates.

Vaccines
are generally recognized as the most cost-effective approach for infectious disease healthcare. However, the technical limitations of conventional vaccine approaches
have constrained the development of effective vaccines for many diseases. Development of vaccines based on conventional methods requires significant infrastructure in research and manufacturing. In
addition, the safety risks associated with certain conventional vaccine approaches may offset their potential benefits. Inovio believes its potential vaccine products may be simpler to manufacture
than vaccines made using live viruses or protein subunit approaches, including those involving mammalian, avian or insect cells, or egg-based culture procedures. In addition, Inovio's DNA
delivery technologies may accelerate certain aspects of vaccine product development such as non-clinical evaluation and manufacturing.

Similar
to the requirements for fighting cancer, it is apparent that an effective approach for addressing chronic infections, which are also deadly and debilitating, requires the ability
to generate a strong cellular immune response. This new generation of vaccinesDNA vaccinesis showing this capability. In addition to the targets already partnered, Inovio has
been evaluating other potential disease targets in its internal development program.

Business Strategy

Inovio's objective is to be a biomedical company focused on developing and commercializing products that address significant unmet
medical needs and, as a result, improve patients' quality of life. To achieve this objective, Inovio's business strategy currently includes the following key elements.

Therapeutic Drug and DNA Delivery

Inovio develops equipment designed to enable the use of electroporation to achieve efficient and cost-effective delivery
into patients of DNA vaccines targeting a variety of illnesses. Although there are many diseases for which improved drug or DNA delivery is important, Inovio believes that its greatest opportunities
lie in applying electroporation to DNA-based therapies (including immunotherapy) in the areas of cancer and chronic infectious diseases.

Advancing Inovio's Product Pipeline

The strategy to advance Inovio's product pipeline has two key components: Inovio has leveraged its patented technologies through
licensing arrangements with companies such as Merck, Wyeth and Vical, among other research-driven biopharmaceutical companies, as well as collaborations with government and non-government
agencies. These partners are pursuing development of proprietary agents or conducting research using Inovio's electroporation-based DNA delivery systems. Resources used to support Inovio's partners in
these efforts are funded by its partners. In addition, these arrangements provide Inovio with some combination of upfront payments, development fees, milestone payments, royalties and a supply
agreement.

In
addition to expanding and providing electroporation delivery expertise, Inovio is directing resources to proprietary vaccine development or co-development, resulting in
whole or partial ownership in DNA vaccine candidates. Inovio is focusing on the development of DNA-based therapies in the areas of cancer and chronic infectious diseases. The selection of
targets for Inovio's independent or co-development programs is driven by four key criteria: complexity of the product development program, competition, cost of development and commercial
opportunities. Inovio intends to retain significant participation in product development and commercialization of any DNA vaccines and

7

---



Table of Contents

therapeutics
in pre-clinical and human trials that receive regulatory approval, although it may choose to secure additional partnerships to accelerate product development and
commercialization. Inovio currently has a collaborative commercialization agreement with Tripep AB to co-develop a novel DNA hepatitis C virus (HCV) therapeutic vaccine.

Expand Market Opportunity

Inovio is continually evaluating and implementing opportunities to enhance its core technologies and assessing other DNA delivery
technologies. Inovio is developing future product candidates based on these technologies through pre-clinical and clinical testing to determine their safety and efficacy. Inovio also seeks
to develop additional applications for its technologies by testing new approaches to disease control or prevention. These efforts could lead to further independent product development or licensing
opportunities. In addition, Inovio continually evaluates compatible technologies or products that may be of potential interest for in-licensing or acquisition.

Expand the Application of Inovio's Technologies and Enable Product Development Through Strategic Collaborations

In pre-clinical trials and early clinical trials, Inovio's technology has enabled high levels of DNA uptake and gene
expression without significant acute side effects. Based on the results obtained, Inovio believes that its technology is well positioned and is as capable as competing technologies to meet the
delivery requirements for DNA vaccines and immunotherapy. Inovio's strategy is to develop DNA vaccine and immunotherapy applications with major pharmaceutical, biotechnology and government agency
partners wherever reasonable and/or possible to license its DNA delivery technology for specific genes or specific medical indications. In most partnering situations, Inovio provides proprietary
instruments and expertise to optimize the delivery of DNA for particular applications and the partner company provides its proprietary gene, allowing Inovio access to complementary technologies or
greater resources. Inovio believes that
entering into selective collaborations as part of its product development programs can enhance the success of Inovio's product development and commercialization, diversify Inovio's product portfolio
and enable Inovio to better manage its operating costs. Inovio's collaboration with partners allows pre-clinical research, clinical trials and mutually beneficial opportunities to expand
Inovio's product pipeline, which may lead to the introduction of a new treatment and/or products in the marketplace at a rate and range which Inovio may not be able to support on its own.
Additionally, such collaborations enable Inovio to leverage investment by its collaborators and reduce its net cash burn while retaining significant economic rights. Inovio's goal is to enter into
additional agreements to license its electroporation technology for use in the delivery of DNA for specific targets.

8

---



Table of Contents

Products and Product Development

Together with Inovio's licensees and collaborators, Inovio is currently developing a number of DNA-based vaccines and
therapeutics for the prevention or treatment of cancer and chronic infectious diseases. Inovio's current independent development focus is on these areas as well. The table below summarizes progress in
Inovio's independent, collaborative and out-licensed product development programs as of December 5, 2008.

Pre-Clinical
Studies

Development StatusProduct Area

Product Target and
Indication(s)

In Vitro

In Vivo

Phase
I

Phase
II

Phase
III

Phase
IV

DevelopmentDNA Delivery Immunotherapy

Malignant Melanoma

X

X


X










Moffitt/RMRMetastatic Melanoma

X

X


X
*









VicalDNA Delivery Tumor-associated antigen therapeutic vaccines

HER-2 and CEA-expressing cancers

X

X


IP










MerckProstate Cancer

X

X


IP










Univ. of SouthamptonhTERT-expressing cancers

X

X


IP










MerckUnspecified Cancer

X

X













InovioDNA Delivery Infectious disease vaccine

HCV Vaccine

X

X


IP










Tripep/InovioCMV Vaccine

X

X













VicalUnspecified Targets

X

X













WyethBiodefense Targets

X

IP













US ArmyHIV Vaccine

X

IP













National Cancer InstituteHIV Vaccine

X

IP













International AIDS Vaccine InitiativeUnspecified Targets

X

IP













Inovio


---

DNA Vaccines and Immunotherapies

The technical limitations of conventional vaccine approaches have constrained the development of effective vaccines for many diseases.
In addition, the safety risks associated with certain conventional vaccine approaches may offset their potential benefits. In the broader vaccine marketplace, it is important to note a changing
dynamic. Traditionally, vaccines have been predominantly focused on the pediatric market, intended to protect children from diseases that could cause them serious harm. Today, there is a growing
interest in vaccines against diseases that may affect adolescents and adults, which include both sexually transmitted diseases and infections that strike opportunistically, such as during pregnancy or
in immuno-compromised individuals, including the geriatric population. Inovio believes its technologies, because of their potential safety and development time advantages, could be ideally suited for
the development of this new generation of vaccines. Preclinical studies in animals have demonstrated the safety and potential efficacy of this approach.

DNA
vaccines are intended to prevent a disease (prophylactic vaccines) or to treat an existing disease (therapeutic vaccines). A DNA vaccine consists of DNA plasmid molecules encoding a
selected antigen or fragment of an antigen that are introduced into cells of humans or animals with the purpose of evoking an immune response to the encoded antigen. Information encoded in the vaccine
DNA plasmid molecules directs the cells to produce proteins that may then trigger the immune system to mount one or both of two responses: the production of antibodies, also known as humoral immune

9

---



Table of Contents

response,
and/or the activation of T-cells and "killer cells," collectively termed cell-mediated immune response. These responses can neutralize or eliminate infectious agents
(viruses, bacteria, and other microorganisms) or abnormal cells (e.g. malignant tumor cells). DNA vaccines have several advantages over traditional vaccines in that they are
non-pathogenic (meaning they cannot cause the disease), may be effective against diseases which cannot be controlled by traditional vaccines, and are relatively fast, easy and inexpensive
to design and produce. DNA vaccines are stable under normal environmental conditions for extended periods of time and do not require continuous refrigeration. Another potentially major advantage of
DNA vaccines is their short development cycle. For example, DNA vaccines against newly identified viral agents may be developed within weeks or months, as opposed to the years often required to
develop a traditional vaccine candidate.

DNA
vaccines against cancer use a portion of the genetic code of a cancer antigen to cause a host to produce proteins of the antigen that may induce an immune response.

Inovio
has acquired considerable expertise in the delivery and efficacy evaluation of DNA vaccines, both against infectious agents and complex diseases, such as cancer. In most cases
Inovio has chosen skeletal muscle as the target tissue for vaccine delivery as this muscle is known to facilitate robust and long-lasting immune responses. However, skin is also an
attractive target for DNA vaccination and Inovio has developed and patented technology for DNA delivery into skin cells as well.

Inovio
is building a DNA franchise around the use of Inovio's proprietary electroporation technology together with gene-based treatments. Inovio's development efforts involve
license agreements with Wyeth, Merck and Vical, in which these companies are supporting the development and registration of therapies using Inovio's devices. To date, most of Inovio's DNA vaccine
development programs have been primarily initiated by corporate partners who sustain the majority of the development expenses and have the ability to conduct the commercialization activities.

Cancer: DNA-Based Immunotherapies

In December 2004, Inovio initiated a Phase I clinical trial sponsored by the H. Lee Moffitt Cancer Center using its
MedPulser® DNA Electroporation System to deliver plasmid DNA coding for IL-12 to tumors with the aim of treating malignant melanoma. The study was designed to assess the use of
electrical pulses generated by Inovio's proprietary electroporation technology to deliver into tumor cells a plasmid DNA encoding a cytokine, interleukin-12, which stimulates adaptive and
innate immunity. In December, 2008, Inovio reported that final results of this trial was presented in the peer-reviewedJournal of Clinical
Oncologyin a paper prepared by Drs. Adil Daud, Richard Heller et al, titled, "Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With
Metastatic Melanoma."

The
paper concluded: "This first human trial, to our knowledge, of gene transfer utilizing in vivo DNA electroporation in metastatic melanoma showed that it is safe, effective,
reproducible, and titratable." The findings showed not only regression of treated melanoma skin lesions, but also regression of distant untreated lesions, suggesting a systemic immune response to the
localized treatment.

Highlights
of the study results, as reported in the paper, include:



10

---





Table of Contents



In
July 2005, Inovio announced, along with its partner, Vical, the initiation of a human Phase I clinical study of an investigational method of delivering plasmid DNA coding for
interleukin-2 (IL-2), a potent immune system stimulant, for patients with recurrent metastatic melanoma. Intravenous delivery of IL-2 protein is already approved as
a treatment for metastatic melanoma, but frequently causes severe systemic toxicities. The novel treatment approach being studied in this trial involves direct injection into a tumor lesion of plasmid
DNA (pDNA) encoding IL-2, followed by electroporation in which local application of electrical pulses is intended to enhance the uptake of pDNA into tumor cells. The pDNA is designed to
cause cells within the tumor to produce high levels of IL-2 protein locally and thereby stimulate the immune system to attack the tumor without the systemic toxicities associated with
injected IL-2. Interim results on 19 patients from this trial were presented in June, 2007, and demonstrated that intratumoral delivery of pDNA encoding IL-2 into melanoma
tumors, followed by electroporation, was administered safely following sedative premedication. No serious adverse events related to the study drug or to the administration procedure were reported and
the treatment was well-tolerated. The majority of related adverse events were localized to the treatment site, with the most frequent being mild injection site pain. Individual tumor
responses were seen in 12 of 39 (31%) evaluated tumors after injection of different escalating doses (0.5 to 5 mg per tumor). Treated tumors (7 of 18, or 38%) showed local responses more frequently
than did untreated tumors (5 of 21, or 24%). No overall clinical responses by standard RECIST (Response Evaluation Criteria in Solid Tumors) criteria were observed among the 19 subjects evaluated
following one or two cycles of treatment. Two subjects (11%) showed activity in distant, untreated tumors, including one subject showing shrinkage and disappearance of lung tumors. This trial has
completed enrollment of 26 patients.

Cancer: DNA Vaccines

In April 2005, The University of Southampton initiated a U.K. Medicines and Healthcare products Regulatory Agency (MHRA) approved
Phase I/II clinical trial undertaken in collaboration with Inovio. The study uses Inovio's electroporation technology to deliver a therapeutic plasmid-based DNA vaccine to skeletal muscle with
the aim of treating recurrent prostate cancer. The trial, sponsored and led by the University of Southampton, is investigating whether the DNA vaccine, developed at the University of Southampton, can
stimulate patients to develop immune responses against prostate cancer and whether use of Inovio's electroporation system enhances this response. In June, 2008, Inovioreported that Dr. Christian
H. Ottensmeier, MD, PhD, Cancer Research UK Senior Clinical Research Fellow at the University of Southampton,
presented updated interim data from this clinical study at the American Society of Gene Therapy 11th Annual meeting. The data reaffirmed that, post-treatment, this therapy has
proven to be safe and well-tolerated. Additional data further validated higher levels of antibody

11

---



Table of Contents

and
anti-DOM CD4 responses achieved in patients treated using electroporation. This academic study is a phase I/II study of 30 HLA A2+ patients with biochemical failure of prostate
cancer. The study is testing a DNA fusion vaccine, developed in Southampton, encoding for an immunostimulant sequence from tetanus linked to a sequence from prostate specific membrane antigen
(PSMA27). The study is also evaluating electroporation as a novel delivery strategy for DNA vaccines compared to DNA delivered without electroporation.

Patient
enrollment for this study has been completed. Monitoring of antibody responses was completed for the 20 patients at the first and second dose levels. Monitoring of CD4 cellular
immunity had been completed for the 10 patients at the lowest dose. These 10 patients had additionally been assessed for CD8 T-cell responses. Reported interim results
included:



In
November 2005, Merck initiated a Phase I clinical trial of a DNA cancer vaccine based on Inovio's DNA gene delivery technology that uses pDNA encoding human epidermal growth
factor receptor 2, or HER-2, and carcinoembryonic antigen, or CEA. As a result of Merck reaching this milestone, Inovio received a payment of $2.0 million. The Phase I trial
is evaluating the safety, tolerability and immunogenicity of the vaccine.

In
December 2007, Inovio received an additional $2.0 million milestone payment from Merck, resulting from the filing of a second Investigational New Drug (IND) application to the
Food and Drug Administration ("FDA") by Merck for a DNA-based vaccine using Inovio's DNA delivery technology. The milestone relates to Inovio's collaboration and license with Merck
initiated in May 2004 for the development of certain DNA vaccines. Further development of the product may lead to additional milestone payments and royalties to Inovio. Inovio received this milestone
payment for its contribution to the collaboration, which has so far demonstrated the high level of gene delivery and expression that is thought to be necessary for the induction of a therapeutic
immune response. Merck has funded all clinical development costs of these candidates to date.

As
of October, 2008, Merck had begun to enroll patients for this study, which is using a DNA vaccine encoding for hTERT to target non-small cell lung and prostate cancers.
The vaccine is delivered using Inovio's electroporation DNA delivery technology.

Inovio
reported in September, 2008, that in a preclinical study of a proprietary DNA-based therapeutic vaccine, in mice with metastatic melanoma treated with a DNA vaccine
via intramuscular delivery, six of eight (75%) were tumor-free at the conclusion of the study.

Numerous
cancer antigens have been identified over the past few decades and better identification tools are under development by others. Inovio will continue to evaluate opportunities to
acquire or partner cancer antigens that may be useful in large market cancers such as breast, lung and prostate.

12

---



Table of Contents

Infectious Diseases: DNA Vaccines

In January 2006, Inovio signed an agreement with Sweden-based Tripep to co-develop a therapeutic vaccine for hepatitis C
virus (HCV) using electroporation. The vaccine is based on Tripep's proprietary HCV antigen construct and delivered to infected individuals using Inovio's MedPulser® DNA Delivery System.
The study is being conducted at the Karolinska Institute's University Hospital in Sweden. The terms of the development agreement call for each party to fund a portion of the Phase I and
subsequent Phase II trials and thereafter share profit according to their contribution. Inovio has 33% ownership in the overall product with the option to increase this to 50% after the
completion of the Phase I/II trial.

In
November, 2008, Inovio announced that Tripep had reported interim results indicating that in the third and highest dose cohort of the study, two of three subjects demonstrated
reductions in viral load of 93% and 99.7%. This compares to previously reported middle dose cohort results demonstrating an 87% and 98% reduction in HCV in two of three subjects; no
anti-viral effect was observed in the low dose cohort. No safety issues have been noted to date in the trial. These data suggest a potential dose response of the vaccine and support the
inclusion of three additional subjects in the high dose cohort.

In
November 2006, Inovio entered into a collaboration and license agreement with Wyeth to develop DNA vaccines against multiple infectious disease targets. For further discussion about
this agreement, see "Partnerships and Collaborations"below. The selection of targets for its proprietary infectious disease program is driven by three
key criteria: the complexity of the product development program, competition, and commercial opportunities.

Inovio
reported in July, 2008, that in a preclinical study of a proprietary DNA-based therapeutic vaccine, 100% of immunized mice given a lethal challenge of highly
pathogenic H5N1 influenza virus (A/Vietnam/1203/04) survived and showed only minor weight loss. The DNA vaccine design was based on a different influenza strain (H1N1) than the influenza strain used
in the challenge, providing evidence that a universal vaccine based on conserved genes common to multiple strains of seasonal influenza and even potential pandemic influenza may have the possibility
to provide widespread protection against such viruses.

DNA Vaccines for Biodefense

With the adoption of the Project Bioshield Act in 2004 by the U.S. government, there is an opportunity to secure development funding
for proof-of-principle DNA vaccine studies for biowarfare pathogens. Inovio has been successful in securing funding from the U.S. government. Inovio believes DNA vaccines
delivered with electroporation for bio-defense have the following advantages:



As
resources obtained from government funding can be leveraged to enhance the development of technology in the area of cancer and chronic infectious disease, Inovio will continue to
pursue opportunities in the area of biodefense. As an example of potential applications in the area of biodefense, one of Inovio's partners (RMR, LLC) is currently employing its skin
electroporation technology in the pre-clinical development of an anthrax vaccine under a Department of Defense Small Business Innovation Research Program (SBIR) grant. Inovio currently has
commercial rights to this skin electroporation system. The technology may also be useful with respect to targets such as the

13

---



Table of Contents

Lassa
fever virus currently being studied by the U.S. Army in collaboration with Inovio (as further outlined under Partnerships and Collaborations below).

Gene Therapy

Over the past decade, classic gene therapy or treatment of inherited disorders has proven difficult. Electroporation of genes encoding
therapeutic proteins has, however, demonstrated the potential to resolve these difficulties. In vivo production of proteins such as Factor IX for hemophilia and EPO for anemia represent large market
opportunities. Pre-clinical studies for Inovio's partners have demonstrated multiple desirable characteristics of Inovio's approach, including:



The
major technical hurdle for use of Inovio's technology for classic gene therapy is the induction of an unwanted immune response to the transgene product due to the highly efficient
delivery and expression seen with electroporation. As this problem may take significant resources to overcome, Inovio has decided not to focus on this market in the near term.

Animal Health/Veterinary

While Inovio is primarily focused on the use of Inovio's technology in the development of novel human therapeutics, it retains certain
rights to veterinary applications and may seek to exploit these rights in the future.

Additional Applications of Inovio's DNA Delivery Technology

In addition to using Inovio's electroporation technology for drug and vaccine delivery, it can be used for research to validate new
drug targets and to deliver molecules. Such use of Inovio's technology may facilitate transition into clinical development. Inovio continues to pursue, on a limited basis, research and opportunities
in the areas of stem cells, ex vivo applications and RNAi.

Collaborations

In September 2008, Inovio announced it has received a contract for $933,000 from the Department of Defense (US Army) to continue
research and development of DNA-based vaccines delivered via its proprietary electroporation system. The contract, titled "Design and Engineering of the Elgen Gene Delivery System for
Screening and Validation of Vaccine Candidates of Military Relevance," will run through May 2010. This project is focused on identifying DNA vaccine candidates with the potential to provide rapid,
robust immunity to protect against bio-warfare and bioterror attacks.

In
November 2006, Inovio entered into a collaboration and license agreement with Wyeth for a worldwide non-exclusive license to Inovio's technology for certain infectious
disease targets, for which Inovio received an upfront payment of $4.5 million. Inovio will also receive research support, annual maintenance fees, royalties on any net product sales and,
contingent upon the achievement of clinical and regulatory milestones, payments of up to $60.0 million over the term of the agreement.

We
may not receive any future payments from Wyeth and we believe Wyeth is evaluating internal strategic options prior to initiating further development of electroporation based
infectious disease programs.

14

---



Table of Contents

In
October 2006, Inovio announced that it acquired from Valentis, Inc. certain DNA delivery and expression assets, including Valentis' DNAvax® polymer delivery system
and GeneSwitch® gene regulation technology.

In
July 2006, Inovio announced it extended its license with RMR Technologies, LLC ("RMR") by exercising an existing option to license certain patented technology relating to the
delivery of gene-based therapeutics into skin. This extends a long-standing relationship with the University of South Florida scientists and RMR founders Drs. Heller (now
Executive Director, Frank Reidy Research Center for Bioelectrics, Old Dominion University), Jaroszeski, and Gilbert. This relationship dates back to the co-development of Inovio's
MedPulser® Electroporation Instrument for treatment of solid tumors, including head and neck cancers. RMR is the collective effort of three scientists in collaboration with the University
of South Florida and the H. Lee Moffitt Cancer Center and Research Institute. The license included other patents involving the delivery of genes or drugs via ex vivo, intratumoral, and intramuscular
electroporation. Recent pre-clinical studies suggest that, for certain indications, needle-less skin electroporation of DNA plasmids encoding selected antigens may also be
effective at inducing desired immune responses. The patented technology licensed from RMR covers various skin electroporation electrode designs and methods, including a needle-less design
using a flexible material. RMR has agreed to collaborate in an effort to develop research prototypes into commercial grade electrodes for skin delivery as well as other novel forms of
electroporation-assisted DNA delivery. Inovio has agreed to provide RMR with other development expertise pertinent to projects such as RMR's SBIR-funded pre-clinical study
using RMR's proprietary dermal electrodes to deliver a DNA vaccine against anthrax. In connection with the acquisition of this exclusive license, Inovio issued 86,956 shares of Inovio common stock at
a price of $2.30 per share, worth $200,000 on the date of issuance.

Inovio
also licensed from RMR patents that claim the intratumoral delivery method used in the ongoing clinical trial at the Moffitt Cancer Center & Research Institute, which is
delivering the gene encoding IL-12 directly to melanoma lesions. RMR, Inovio, the University of South Florida and Moffitt Cancer Center have been collaborating in the development of this
novel therapy for melanoma for the past two years.

In
May 2006, Inovio announced the acquisition, under a license with Sphergen SARL, of rights to several patent families relating to the use of electroporation technology. The rights
Inovio licensed included two patents with broad claims regarding electroporation of nucleic acids in muscle and tumor tissue. This intellectual property acquisition enhanced the breadth of Inovio's
patent portfolio directed to the use of electroporation technology to deliver therapeutic biopharmaceuticals. The license also includes grants of rights to know-how, future improvements,
and provisions for exclusivity in applications to human medicine.

In
January 2006, Inovio signed a collaborative agreement with Tripep to co-develop a therapeutic hepatitis C virus (HCV) DNA vaccine using electroporation. Under the terms of
this agreement, Inovio pledged certain electroporation equipment toward an ongoing Phase I/II study of the proprietary Tripep vaccine in exchange for a minimum of 33% of the licensing revenues
or commercial income that might be derived from the vaccine. Under the terms of the agreement, Tripep will only commercialize the electroporation-based vaccine with Inovio equipment. If Inovio decides
not to continue to support the co-development, Inovio will retain a profit share of sub-licensing fees or commercial revenues going forward.

In
May 2005, Inovio announced that Merck exercised an option for a non-exclusive license for an additional antigen to be used with Inovio's MedPulser® DNA
Delivery System. This option exercise was provided for under the 2004 license and research collaboration agreement between Merck and Inovio, and brought the total number of antigens licensed by Merck
to three. Inovio received an option fee for the additional target antigen. Under the terms of Inovio's licensing agreement with Merck,

15

---



Table of Contents

Inovio
is eligible for milestone and royalty payments if certain development goals and commercialization of the device are achieved by Merck.

In
April 2005, Inovio announced the initiation of a U.K. Medicines and Healthcare products Regulatory Agency (MHRA) approved Phase I/II clinical trial undertaken in collaboration
with the University of Southampton. Inovio's electroporation technology is being used to deliver a therapeutic plasmid-based DNA vaccine to skeletal muscle with the aim of treating recurrent prostate
cancer. The trial, sponsored and led by the University of Southampton, is investigating whether the DNA vaccine, developed at the University of Southampton, can stimulate patients to develop immune
responses against prostate cancer and whether use of Inovio's electroporation system enhances this response.

In
October 2004, Inovio announced an agreement with Vical wherein Vical licensed Inovio's DNA delivery technology for use with HIV, cytomegalovirus (CMV) and melanoma (using pDNA
IL-2) targets. This agreement was based on an option agreement established with Vical in October of 2003 for a worldwide license for the use of Inovio's proprietary in vivo electroporation
delivery technology in combination with Vical's proprietary vaccines.

In
May 2004, Inovio announced a significant licensing deal with Merck for the development of Merck's DNA cancer and infectious disease vaccines. The terms of the agreement include
milestone and royalty payments for successful completion of the clinical development of the vaccines by Merck. Under the terms of the agreement, Merck reimbursed Inovio for the
co-development of a proprietary electroporation system for the delivery of Merck's DNA vaccines. This development and commercialization agreement was an extension of an initial evaluation
agreement established in 2003. Merck received the right to use Inovio's proprietary technology for two specific antigens with an option
to extend the agreement to include a limited number of additional target antigens. In addition, Merck obtained a non-exclusive license to the intellectual property related to the initial
two specific antigens. Merck is responsible for all development costs and clinical programs.

The
research carried out under the above agreements may result in new long-term license agreements with the other parties and may provide Inovio with additional data that
Inovio believes will assist it in assessing the efficacy of using its MedPulser® DNA Electroporation System for delivery of DNA vaccines and gene therapies. The data should further assist
Inovio in its licensing and commercialization efforts. In addition to the above collaboration and licensing arrangements, Inovio may develop proprietary DNA therapeutic product through early stage
clinical trials and partner the product for late stage clinical development and marketing. Inovio may have to negotiate license(s) for genes or other components of the product if they are not in the
public domain.

Market

Inovio's product development strategy is focused on pursuing significant product opportunities where Inovio's technology is considered
enabling. During 2007, Inovio prioritized its efforts after assessing different market opportunities based on an evaluation of technology risk, market size and partner interest in DNA vaccines. Based
on Inovio management's assessment of the market opportunities, oncology applications appear to represent the best market opportunities, followed by applications for infectious diseases, gene therapy
for protein deficiency diseases and biodefense DNA vaccines.

Inovio
believes there is a significant unmet clinical need to develop more efficacious vaccines that stimulate cellular immunity (i.e. can induce T-cell responses) and
can be applied to diseases such as cancer, hepatitis C or HIV infection. For these applications, Inovio's scientists believe that DNA vaccines may offer an improvement over conventional vaccination.
Inovio's scientists believe that electroporation of DNA is critical to maximizing the efficiency of DNA vaccination and meeting unmet clinical needs for therapeutic vaccines, which some industry
analysts consider to be a multi-billion dollar market opportunity.

16

---



Table of Contents

Competition

Although there are many competing technologies for DNA delivery, Inovio believes electroporation has a unique strategic position
compared to such technologies for the following reasons:



Minimal or No Delivery Related Side Effects

Any company that is developing a DNA based delivery technology, such as viral delivery systems, lipid-based systems, or electroporation
technology with an aim to carry out in vivo gene delivery for the treatment of various diseases, is a potential competitor of Inovio. Currently there are five key DNA delivery technologies: viral,
lipids, naked DNA, "gene gun" and electroporation. All are promising technologies, but they each also have their unique obstacles to overcome. Management believes Inovio's electroporation system is
strongly positioned to succeed as the dominant delivery method for DNA vaccines.

Viral
vectors can be highly effective, however, there continue to be concerns regarding potential mutations, unwanted immune responses against the vector itself (preventing its use for
re-administration or booster shots) and other side effects. Viral technology has yet to show predictable, consistent safety and is very expensive. Lipids can be effective, but may also
have toxicity issues and are relatively expensive. Naked DNA is widely considered to be safe and is relatively inexpensive, but is not very effective. The gene gun technology (using gold particles as
carriers of DNA for skin delivery) looks promising, however, there are data suggesting that electroporation offers equal or better efficacy and may offer broader utility without requiring a carrier.
Not requiring a carrier allows electroporation to have a unique advantage over competing technologies because it eliminates one additional component that may independently propagate side effects and
create manufacturing and quality control challenges.

Competitive
advantages of electroporation over other delivery systems are summarized on Table 1 below:



Carrier/Vector Type

Carrier/Vector Issues

Efficacy

EconomicsViral

Mutations Immune Response Infection Symptoms

+++++

$$$$$Lipids

Toxicity

++

$$Particle Gun

Manufacturability

++++

$$$Naked DNA

No Vector

+

$(Electroporation Enhanced)

No Vector

++++

$


Enabling DNA vaccines

Commercial and academic institutions have been trying for over 15 years to develop DNA vaccines with sufficiently potent immune
responses to make them commercially viablewithout much success. One facet of DNA vaccine research and development ("R&D") has been to combine an adjuvant component to help initiate a
general immune response to complement the specific immune response induced by the DNA vaccine, but adjuvants complicate manufacturing and may generate additional unwanted side effects.

17

---





Table of Contents

In addition to being a highly efficient delivery method of plasmid to muscle cells, Inovio has shown that the mild electrical pulses of electroporation also have
an adjuvant effect. This adjuvant effect seems to be related to more CpG-containing plasmid gaining access to intracellular toll-like receptors, which stimulate innate immune
responses, and to slight muscle damage, which can lead to a danger signal to the immune system(1). To date, few, if any, common adjuvants seem to be required to augment immune responses observed after
DNA vaccine delivery with electroporation.

---

General
observations to date suggest that for many DNA encoded antigens there has to be an increase in gene expression of 10-100-fold (compared to naked DNA) in
order to achieve a therapeutic benefit in large animals including man. Electroporation is currently the only method whereby one can routinely see increases in gene expression approaching or exceeding
100 to 1000 fold, thereby making the development of a large number of vaccines and therapeutics possible. In effect, electroporation increases the trivial levels of gene expression seen with naked DNA
alone to the therapeutic levels needed for the development of successful commercial products. This puts Inovio in a unique position relative to competing technologies.

Competitive Technologies in the Area of DNA Delivery

Effective DNA delivery technologies are crucial for DNA vaccines. Many of the leading scientists in these fields have pointed out that
the major obstacle to success has been the lack of safe, efficient, and economical methods of delivering DNA. Of the more than 800 gene therapy and DNA vaccine clinical trials started in the U.S. to
date, none have progressed to regulatory approval. Inovio believes that existing DNA delivery alternatives have been a significant bottleneck to the successful development and commercialization of
these promising next generation of vaccines. The following descriptions highlight the issues of the existing alternatives.

Viral DNA Delivery

This technology utilizes a virus as a carrier to deliver genetic material into target cells. The method is very efficient for
delivering vaccine antigens and has the advantage of mimicking real viral infection so that the recipient will mount a broad immune response against the vaccine. The greatest limitation of the
technology is problems with unwanted immune responses against the viral vector, limiting its use to patients who have not been previously exposed to the viral vector and making repeated administration
difficult. In addition, complexity and safety concerns increase the cost of vaccines and complicate regulatory approval.

Ballistic DNA Delivery (Gene Gun)

This technology utilizes micron sized DNA-coated gold particles that are shot into the skin using compressed gas. The
method has matured considerably over the last 15 years and has been shown to be an efficient method to deliver a number of vaccine antigens. Since the DNA is dry coated, excellent stability of
the vaccine can be achieved. The method is limited
to use in skin and only a few micrograms of genetic material can be delivered each time. This may limit the utility of the method for targets such as cancer where higher doses of vaccine antigens and
stronger T-cell responses are needed.

Lipid DNA Delivery

A number of lipid formulations have been developed that increase the effect of DNA vaccines. These work by either increasing uptake of
the DNA into cells or by acting as an adjuvant, alerting the immune system. While there has been steady progress in this field, lipid delivery tends to be less efficient than viral vectors and is
hampered by concerns regarding toxicity and increased complexity.

18

---



Table of Contents

"Naked" DNA Delivery

The simplest DNA delivery mode is the injection of "naked" plasmid DNA into target tissue, usually skeletal muscle. This method is safe
and economical but inefficient in terms of cell transfection, the process of transferring DNA into a cell across the outer cell membrane. Unfortunately, it is the least effective way of delivering DNA
since only an extremely small fraction (approximately one out of twenty million) of the DNA molecules are taken up by the cells. While the method may have provided some utility for the field of gene
therapy, a number of clinical studies over the last decade have shown that the method is inadequate for delivering DNA vaccines into large animals and humans.

"Naked" DNA Delivery With Electroporation

When naked DNA injection is followed by electroporation of the target tissue, transfection is significantly greater with resultant gene
expression generally enhanced from 100 to 1000-fold. This increase makes many DNA vaccine candidates potentially feasible without unduly compromising safety or cost.

In
December 2004, the first patient was treated using Inovio's electroporation system to deliver a plasmid DNA-based immunotherapy and Inovio has initiated, together with
partners, additional Phase I clinical trials using Inovio's electroporation technology to deliver DNA-based immunotherapies or DNA vaccines. To date Inovio scientists have not
observed any serious adverse events that can be attributed to the use of electroporation in these clinical DNA studies.

Inovio
believes that the greatest obstacle to making DNA vaccines and immunotherapy a reality, namely the safe, efficient, and economical delivery of DNA plasmid constructs into target
cells, and also believes that electroporation may become the method of choice for DNA delivery into cells in many applications.

There
are other companies with electroporation intellectual property and devices. Inovio believes it has significant competitive advantages over other companies focused on
electroporation for multiple reasons:



While
other companies have and continue to develop electroporation devices and possess certain patents relating to the use of electroporation, Inovio believes it has a strongly
researched position and that its patent estate provides it with the potential to block competition in key areas of focus.

Medical Device Manufacturing

Inovio is a medical device manufacturer and, as such, operates in a regulated industry. Inovio must comply with a variety of
manufacturing, product development and quality regulations in order to be

19

---



Table of Contents

able
to distribute Inovio's products commercially around the world. In Europe, Inovio must comply with the MDD. Inovio has a Quality System certified by its international Notified Body to be in
compliance with the international Quality System Standard, ISO13485, and meeting the Annex II Quality System requirements of the MDD. Inovio completed an Annex II Conformity Assessment
procedure and achieved its CE Mark of the MedPulser® electroporation system in March 1999. Inovio completed an Annex II Conformity Assessment procedure and achieved its CE Mark of
the Elgen electroporation system in November 2006.

In
the U.S., Inovio is required to maintain facilities, equipment, processes and procedures that are in compliance with quality systems regulations. Inovio's systems have been
constructed to be in compliance with these regulations and its ongoing operations are conducted within these systems. Commercially distributed devices within the U.S. must be developed under formal
design controls and be submitted to the FDA for clearance or approval. As Inovio prepares for U.S. marketing, all development activity is performed according to formal procedures to ensure compliance
with all design control regulations.

Inovio
employs modern manufacturing methods and controls to optimize performance and control costs. Internal capabilities and core competencies are strategically determined to optimize
Inovio's manufacturing efficiency. Inovio utilizes contract manufacturers for key operations, such as clean room assembly and sterilization, which are not economically conducted in-house.
Inovio outsources significant sub-assemblies, such as populated printed circuit boards, for which capital requirements or manufacturing volumes do not justify vertical integration. As
Inovio transitions from late-stage development activities into higher volume manufacturing activities, internal capabilities will be modified and added, as appropriate, to meet its
changing priorities.

Currently,
the durable electronic generator in the MedPulser® and Elgen system is assembled from outsourced populated printed circuit boards, and then tested, packaged and
inventoried
at Inovio's manufacturing facility. The disposable applicators used with the MedPulser® system are assembled and sterilized in a clean room at outside contract manufacturers. Additional
current and future manufacturing of applicators for clinical trials and commercial distribution is planned to be done using a combination of internal manufacturing and outside contract manufacture.

Intellectual Property

Inovio's success and ability to compete depends upon its intellectual property. Inovio maintains a broad-based patent portfolio (both
original and in-licensed technologies) that as of December 5, 2008, includes over 62 issued U.S. patents and 181 issued foreign counterpart patents, all of which collectively
include claims to methods and/or devices for clinical use in the electroporation medical arts. Specifically, patented subject matter, as well as subject matter pending in the U.S. and foreign patent
offices, includes method and device claims for delivering by electroporation medically important substances to the interior of cells in various body tissues such as a patient's muscle, skin, and other
organs.

Inovio's
core technology is centered on five broad, medically relevant "indication" categories including oncology, gene therapy/delivery (including vaccination with expressible vectors),
vascular administration (e.g. by catheter), transdermal administration (including delivery of substances for cancer, gene therapy, and cosmetic applications), and ex vivo administration
(e.g. by electroporation of cells outside the body and introducing the created cells to the patient).

Supporting
Inovio's primary business focus, its intellectual property in gene therapy and DNA delivery enjoys a broad scope of patent protection, such as found in U.S. patent
numbers 5,273,525 and in-licensed patents 6,110,161, 6,261,281, 6,610,044, 6,958,060 and 6,939,862, which include claims reciting methods and apparatus for implanting macromolecules
(e.g. DNA and pharmaceutical compounds) into selected tissues of a patient by electroporation. U.S. patent number 6,763,264, with

20

---



Table of Contents

claims
reciting methods of delivering expression vectors and molecules, and U.S. patent number 6,697,669, with claims reciting methods of in vivo electroporation of skin and muscle, provide
broad-based coverage to the company. Other of Inovio's patents protect its proprietary methodology of electroporation wherein the electroporation process is carried out using "opposed-paired" electric
field pulsing. Such patents include, and are not limited to, U.S. patent numbers 6,241,701, 6,120,493, 6,233,482, and 5,702,359C1. It is important to understand that patents having claims
directed to methods of delivering substances to tissues using electroporation and devices for such methods, are generally applicable to DNA delivery and oncological applications.

With
respect to oncology, U.S. patent number 6,569,149 provides broad claim coverage directed to a method for the application of electric fields to a tissue of a patient having a
"cell proliferation disorder" for the purpose of introducing molecules into cells of the tissue to treat the cell proliferation disorder. Such method comprises providing an array of multiple opposed
pairs of electrodes connected to a generator, wherein at least two pairs of electrodes, after being placed in selected tissue along with the substance being electroporated, are activated
simultaneously with electric pulses. Likewise, in-licensed patent 6,528,315 claims methods of electroporation of DNA to tumor cells in a broad manner.

Inovio
has a number of issued U.S. and foreign patents claiming a widely used gene regulation technology called GeneSwitch® that permits control of gene expression from DNA
sequences via a small molecule that can be administered orally. For example, U.S. patents 5,364,791 and 6,599,698 claim various aspects of this unique regulation system that may be used in gene
therapy products. In addition to electroporation technology for gene delivery, the company also acquired a group of patents claiming the delivery of DNA using polymers (e.g., 6,040,295 and
6,514,947) and lipids (e.g., 6,387,395 and 6,235,310) that are useful in the development of certain DNA vaccines.

Inovio's
patent portfolio is also active with respect to vascular, transdermal, and ex vivo applications of electroporation technology. For example, U.S. patent 5,704,908 includes claims
directed to an electroporation balloon catheter. Additionally, U.S. patent 6,342,247 is directed to methods of increasing vasodilation, an important indication in maintaining blood flow in certain
patients with vessel occlusion problems. U.S. patents 6,697,669, 6,654,636, 5,810,762, and 5,439,440 provide claims to transdermal application of electric fields to surface tissues, while U.S. patents
6,027,488, 6,746,441, 6,800,484, and 6,150,148 include claims to electroporation of cells in vitro. Such electroporated cells could be used either in laboratory settings or for introduction into
patient blood stream or other tissues.

Of
further importance to Inovio, the currently issued patents provide a strong base for the claimed subject matter for the various indications to at least the year 2017 and numerous
claims will be in force to between 2018 and 2020.

Corporate History and Headquarters

Inovio was originally incorporated on June 29, 1983, under the laws of California as Biotechnologies & Experimental
Research, Inc. On December 10, 1991, the entity changed its corporate name to BTX, Inc. and again on February 8, 1994 changed it to Genetronics, Inc. On
April 14, 1994, the board of directors approved a share exchange agreement with Consolidated United Safety Technologies Inc. On September 2, 1997, the company listed on the
Toronto Stock Exchange ("TSE") as Genetronics Biomedical Ltd, under the laws of British Columbia, Canada, which wholly-owned Genetronics, Inc. On June 15, 2001, the entity
completed a change in jurisdiction of incorporation from British Columbia, Canada, to the state of Delaware. This change was accomplished through a continuation of Genetronics Biomedical Ltd.
into Genetronics Biomedical Corporation, a Delaware corporation. On January 17, 2003, Genetronics voluntarily de-listed from the TSE, where Inovio's common stock had been listed
since September 2, 1997. On March 31, 2005, the corporate

21

---



Table of Contents

name
changed from Genetronics Biomedical Corporation to Inovio Biomedical Corporation. Inovio conducts its business through its U.S. wholly-owned subsidiary, Genetronics, Inc., a Norwegian
wholly-owned subsidiary, Inovio AS, and a wholly-owned subsidiary in the Republic of Singapore, Inovio Asia Pte. Ltd., which may be a platform for future research and development efforts.

Inovio's
principal executive offices are located at 11494 Sorrento Valley Road, San Diego, California 92121-1318, and the telephone number is
(858) 597-6006.

Available Information

Our Internet website address iswww.inovio.com. We make our annual report on
Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, Forms 3, 4, and 5 filed on behalf of directors and executive
officers, and any amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities and Exchange Act of 1934, available free of charge on our website as soon
as reasonably practicable after we electronically file such material with, or furnish it to, the Securities and Exchange Commission (the "SEC"). You can learn more about us by reviewing such filings
on our website or at the SEC's website atwww.sec.gov.

Employees

As of March 16, 2009, Inovio employed 27 people on a full-time basis and 9 people under consulting and project
employment agreements. Of the combined total, 22 were in product research, which includes research and development, quality assurance, clinical, engineering, and manufacturing, and 14 were in general
and administrative, which includes corporate development, information technology, legal, investor relations, finance, and corporate administration. None of Inovio's employees are subject to collective
bargaining agreements.

ITEM 1A.    RISK FACTORS

You should carefully consider the following factors regarding information included in this Annual Report. The
risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business
operations. If any of the following risks actually occur, our business, financial condition and operating results could be materially adversely affected.

NEGATIVE CONDITIONS IN THE GLOBAL CREDIT MARKETS MAY IMPAIR THE LIQUIDITY OF A PORTION OF OUR INVESTMENT PORTFOLIO AND OUR ABILITY TO MAINTAIN OVERALL LIQUIDITY, NEGATIVELY
IMPACTING OUR OPERATIONS AND FINANCIAL CONDITION.

The capital and credit markets have been experiencing extreme volatility and disruption for more than twelve months and the volatility
and disruption have reached unprecedented levels. In some cases, the markets have exerted downward pressure on availability of liquidity and credit capacity for certain issuers. We need liquidity to
pay our operating expenses, make timely principal and interest payments on our debt and replace certain maturing liabilities

Our
investment securities consist of high-grade (AAA rated) auction rate securities ("ARS") issued primarily by municipalities, with a par value of approximately
$13.6 million. The recent negative conditions in the global credit markets have prevented some investors from liquidating their holdings, including their holdings of ARS. In early March 2008,
we were informed that there was insufficient demand at auction for all six of our high-grade ARS. As a result, these affected securities are currently not liquid, and we could be required
to hold them until they are redeemed by the issuer or to maturity. In the event we need to access the funds that are in an illiquid state, we will not be able to do so

22

---



Table of Contents

without
a loss of principal, until a future auction on these investments is successful, the securities are redeemed by the issuer or they mature.

In
December 2008, we, via our wholly-owned subsidiary Genetronics, Inc., or "Genetronics", which holds the ARS, accepted an offer of ARS Rights from UBS. The ARS Rights permit us
to require UBS to purchase our ARS at par value at any time during the period of June 30, 2010 through July 2, 2012. If we do not exercise our ARS Rights, the ARS will continue to accrue
interest as determined by the auction process or the terms of the ARS if the auction fails. If the ARS Rights are not exercised before July 2, 2012 they will expire and UBS will have no further
obligation to buy our ARS. UBS has the discretion to purchase or sell our ARS at any time without prior notice so long as we receive a payment at par upon any sale or disposition. UBS will only
exercise its discretion to purchase or sell our ARS for the purpose of restructurings, dispositions or other solutions that will provide us with par value for our ARS. As a condition to accepting the
offer of ARS Rights, we released UBS from all claims except claims for consequential damages relating to its marketing and sales of ARS. We also agreed not to serve as a class representative or
receive benefits under any class action settlement or investor fund.

In
conjunction with the acceptance of the rights offering, Genetronics also amended its existing loan agreement with UBS Bank USA, increasing the existing credit line up to
$12.1 million, with the ARS pledged as collateral. Genetronics fully drew down on the line of credit in December 2008. Although the Company has been able to regain limited liquidity through
this line of credit secured by the ARS and expects redemption of the ARS pursuant to the rights obtained, the line of credit may not provide sufficient liquidity for the Company's current operational
needs.

Without
sufficient liquidity, we will be forced to curtail our operations, and our business will suffer. In the event current resources, including our ARS and the related line of credit,
do not satisfy our needs, we may have to seek additional financing. The availability of additional financing will depend on a variety of factors such as market conditions, the general availability of
credit, the volume of trading activities, the overall availability of credit to the financial services industry, our credit ratings and credit capacity, as well as the possibility that customers or
lenders could develop a negative perception of our long- or short-term financial prospects if we incur large investment losses or if the level of our business activity
decreases due to a downturn in available funding, partnership opportunities and other fluctuations. The crisis in the global financial markets currently places significant limitations on the general
availability of credit and the number and level of interest of investors. Similarly, our access to funds may be impaired if regulatory authorities take negative actions
against us. Further, even if financing becomes available, the cost to us may be significantly higher than in the past. Our results of operations, financial condition, and cash flows position could be
materially adversely affected by these disruptions in the financial markets, including the resulting lack of liquidity in our current investments and availability of financing for future liquidity.

WE WILL HAVE A NEED FOR SIGNIFICANT FUNDS IN THE FUTURE AND THERE IS NO GUARANTEE THAT WE WILL BE ABLE TO OBTAIN THE FUNDS WE NEED.

Developing new medical devices and conducting clinical trials is expensive. Our product development efforts may not lead to commercial
products, either because our product candidates fail to be found safe or effective in clinical trials or because we lack the necessary financial or other resources or relationships to pursue our
programs through advance phases of clinical trials to commercialization. Our capital and future revenue may not be sufficient to support the expenses of our operations, the development of a commercial
infrastructure and the conduct of our pre-clinical research and clinical trials, although based upon our current budgeting and cash flow models, we believe that we can support our
operations during the next 12 months.

23

---



Table of Contents

Our
plans for conducting research, furthering development, continuing current and future pre-clinical and clinical trials and, eventually, marketing our human-use
equipment will involve substantial costs. The extent of such costs will depend on many factors, including some of the following:



We
plan to fund operations by several means. We will attempt to enter into contracts with partners that will fund either general operating expenses or specific programs or projects. Some
funding also may be received through government grants. However, we may not be able to enter into any such contracts or may not receive such grants or, if we do, our partners and the grants may not
provide enough funding to meet our needs.

In
the past, we have raised funds through the public and private sale of our stock, and we are likely to seek to do this in the future. However, due to the significant fluctuations in
the market price of our common stock as a result of the extreme fluctuations in the global financial markets recently, there may not be sufficient investor interest in such sales at such time as we
seek to raise additional funds, or if there is interest, it may not be at a price or on terms favorable to us. Further, sale of our stock to new investors results in dilution of the ownership
interests of our existing stockholders. The greater the number of shares sold, the greater the dilution. A high degree of dilution can make it difficult for the price of our stock to increase, among
other things. Dilution also weakens existing stockholders' voting power. Although we would consider also utilizing debt to fund our operations, such as our current use of our Line of Credit secured by
our ARS, given the constriction of available credit and the fluctuation of interest rates in the global financial markets currently, additional debt financing

24

---



Table of Contents

may
also be unavailable when needed, or available solely on terms not favorable to us. Thus, we cannot assure you that we will be able to raise additional capital or secure alternate financing to fund
operations on terms that are favorable to us, if at all. Further, on July 7, 2008, we announced the signing of a definitive merger agreement with VGX Pharmaceuticals, Inc., a
privately-held corporation; we cannot assure you that the merger, if completed, will in any way negate or mitigate the need for future capital nor can we project how it may impact our
ability to raise future funds.

ANY ACQUISITION WE MIGHT MAKE MAY BE COSTLY AND DIFFICULT TO INTEGRATE, MAY DIVERT MANAGEMENT RESOURCES OR DILUTE STOCKHOLDER VALUE.

We have considered and made strategic acquisitions in the past, including the acquisition of Inovio AS, and in the future, may acquire
or invest in complementary companies, products or technologies. As part of our business strategy, we may acquire assets or businesses principally relating to or complementary to our current
operations, and we have in the past evaluated and discussed such opportunities with interested parties. Any acquisitions we undertake will be accompanied by issues commonly encountered in business
acquisitions, which could adversely affect us, including:



In
addition, geography and/or language barriers may make the integration of businesses more difficult. We may not be successful in overcoming these risks or any other problems
encountered in connection with any of our acquisitions.

On
July 7, 2008, we announced the signing of a definitive merger agreement with VGX Pharmaceuticals, Inc., a privately-held corporation. In addition to the
general risks and uncertainties of any business combination noted above, some of the inherent uncertainties we currently face in the proposed merger include:



25

---



Table of Contents



We
may not be successful in overcoming these risks or any other issues encountered in connection with the proposed merger, we cannot assure you that the merger will be consummated, and
we cannot assure you that the results of the merger, if completed, will meet the expectations of the parties and their stockholders.

THE NYSE AMEX MAY DELIST OUR SECURITIES FROM QUOTATION ON ITS EXCHANGE IF WE ARE UNABLE TO MAINTAIN A SUFFICIENT STOCK PRICE, AND IF SO, WE MAY BE UNABLE TO RELIST OUR
SECURITIES ON THE NYSE AMEX OR ANOTHER NATIONAL SECURITIES EXCHANGE DUE TO THE LEVEL OF PERCEIVED MARKET VALUE OF SHARES OF OUR COMMON STOCK.

Our securities are currently listed on the NYSE Amex (the "NYSE Amex"), a national securities exchange, and in recent months have
experienced a significant drop in market price. The NYSE Amex may seek to delist our securities from trading on its exchange if the NYSE Amex determines that the market price of our common stock has
been persistently too low or if we fail to maintain compliance with other requirements of continued listing on the NYSE Amex. If NYSE Amex finds that we are non-compliant, it will issue a
warning letter, which will require the Company to respond regarding potential actions it intends to take to support the market price. If such actions are not found sufficient by the NYSE Amex, if we
cannot get any required approvals for such actions from its stockholders, or we otherwise cannot or do not complete such actions in a timely manner, the NYSE Amex will initiate the delisting process.
If the NYSE Amex delists our securities from trading on its exchange and we are unable to relist our securities on the NYSE Amex or another national securities exchange due to the level of the
perceived market price of shares of its common stock, the Company could face significant material adverse consequences, including:



26

---



Table of Contents



Any
of these consequences would likely have a material adverse impact on our financial condition and operations, and would result in a potential decrease in liquidity of our common
stock.

IF WE DO NOT HAVE ENOUGH CAPITAL TO FUND OPERATIONS, THEN WE WILL HAVE TO CUT COSTS.

If we are unable to raise additional funds under terms acceptable to us and in the interests of our stockholders, then we will have to
take measures to cut costs, such as:



If
it became necessary to take one or more of the above-listed actions, then our perceived valuation may be lower, which could impact the market price for our common stock. Further, the
effects on our operations, financial performance and stock price may be significant if we do not or cannot take one or more of the above-listed actions in a timely manner if and when needed, and our
ability to do so may be limited significantly due to the instability of the global financial markets and the resulting limitations on available financing to us and to potential licensees, buyers and
investors.

THE MARKET FOR OUR STOCK IS VOLATILE, WHICH COULD ADVERSELY AFFECT AN INVESTMENT IN OUR STOCK.

Our share price and trading volume are traditionally highly volatile, and such volatility has been exacerbated by the crisis in the
global financial markets which has resulted in extreme fluctuations in market performance overall throughout the recent weeks. Such volatility is not unusual for biomedical companies of our size, age,
and with a discrete market niche and is likely to continue even if the global markets stabilize. It also is common for the trading volume and price of biotechnology stocks to be unrelated to a
company's operations, i.e. to increase or decrease on positive or no news. Our stock has exhibited this type of behavior in the past, and will likely exhibit it in the future. The historically
low trading volume of our stock, in relation to many other biomedical companies of our size, makes it more likely that a severe fluctuation in volume, either up or down, will affect the stock price.

Some
factors that we would expect to depress the price of our stock include:



27

---



Table of Contents



These
factors, as well as the other factors described in this report, could significantly affect the price of our stock. In addition, we announced on July 7, 2008, a pending
merger transaction; the uncertainties inherent in such transactions regarding timing, potential for success, impacts on operations and dilution to our current stockholders may further exacerbate
fluctuations in our stock price. We believe that quarter-to-quarter or annual comparisons of our operating results are not a good indicator of our future performance.
Nevertheless, these fluctuations may cause us to perform below the expectations of public market analysts and investors. If this happens, the price of shares of our common stock would likely decline.

SALES OF SUBSTANTIAL AMOUNTS OF OUR SHARES, OR EVEN THE AVAILABILITY OF OUR SHARES FOR SALE, IN THE OPEN MARKET COULD CAUSE THE MARKET PRICE OF OUR SHARES TO DECLINE.

Under our registration statement that the SEC declared effective on May 25, 2006, we have registered an aggregate of
$75.0 million of our equity securities that we may issue from time to time, in one or more offerings at prices and on terms that we will determine at the time of each offering. Under that
registration statement, we have registered multiple kinds of our equity securities, including our common stock, preferred stock, warrants and a combination of these securities,
or units. Through December 31, 2008, we have "taken-down" from our shelf registration statement, and issued and sold, an aggregate of 9,035,378 shares of our common stock valued at
$26.9 million and warrants to purchase up to 1,575,919 shares of our common stock valued at $3.9 million and, if those warrants are fully exercised, we will have issued an additional
1,575,919 shares of our common stock under that shelf registration statement. In other words, the shares of common stock we have sold in offerings from our shelf registration statement as of the date
of this report represent approximately 36% of the value of the aggregate equity securities from our shelf registration statement (41% if the warrants we have sold from our shelf registration statement
are fully exercised). While that amount is only approximately 24% of our outstanding shares of common stock as of December 31, 2008, future issuances and sales of our common stock or securities
exercisable for or convertible into our common stock pursuant to our existing shelf registration statement, if in substantial numbers, and even the availability for issuance of the securities
registered under our shelf registration statement, could adversely affect the market price of our shares.

28

---





Table of Contents

In addition to the shares and warrants we have issued from our shelf registration statement, during 2007 we also issued 2,201,644 shares of our common stock and
warrants to purchase up to 938,475 shares of our common stock in other recent offerings, as well as other restricted shares pursuant to consulting arrangements and other registered securities pursuant
to our stock incentive plan in 2007 and 2008. Further, effective February 15, 2008, the SEC revised Rule 144, which provides a safe harbor for the resale of restricted securities,
shortening applicable holding periods and easing other restrictions and requirements for resales by our non-affiliates, thereby enabling an increased number of our outstanding restricted
securities to be resold sooner in the public market. Further, if we complete our pending merger transaction, as announced July 7, 2008, we will issue a significant number of registered shares
which will substantially dilute our current stockholders and which will be freely tradable for non-affiliates of the post-merger company.

Sales
of substantial amounts of our stock at any one time or from time to time by the investors to whom we have issued them, or even the availability of these shares for sale, could
cause the market price of our common stock to decline.

WE HAVE A HISTORY OF LOSSES, WE EXPECT TO CONTINUE TO INCUR LOSSES AND WE MAY NOT ACHIEVE OR MAINTAIN PROFITABILITY.

As of December 31, 2008, we had an accumulated deficit of $152.8 million. We have operated at a loss since 1994, and we
expect this to continue for some time. The amount of the accumulated deficit will continue to increase, as it will be expensive to continue research, development and clinical efforts. If these
activities are successful and if we receive approval from the FDA to market equipment, then even more funding will be required to market and sell the equipment. The outcome of these matters cannot be
predicted at this time. We are evaluating additional potential partnerships and collaborative agreements as a way to further fund operations, but there is no assurance we will be able to secure
partnerships or other arrangements that will provide the required funding, if at all. We will continue to rely on outside sources of financing to meet our capital needs beyond next year. In the past,
we have raised funds through the public and private sale of our stock, and we are likely to seek to do this in the future. However, due to the significant fluctuations in the market price of our
common stock as a result of the extreme fluctuations in the global financial markets recently, there may not be sufficient investor interest in such sales at such time as we seek to raise additional
funds, or if there is interest, it may not be at a price or on terms favorable to us.

Further,
there can be no assurance, assuming we successfully raise additional funds, that we will achieve positive cash flow. If we are unable to raise additional funds under terms
acceptable to us and in the interests of our stockholders, then we will have to take measures to cut costs, such as delaying, scaling back or discontinuing one or more of our gene delivery programs or
other aspects of operations, including laying off personnel or stopping or delaying planned preclinical research and the initiation or continuation of clinical trials.

OUR DEPENDENCE UPON NON-MARKETED PRODUCTS, OUR LACK OF EXPERIENCE IN MANUFACTURING AND MARKETING HUMAN-USE PRODUCTS, AND OUR CONTINUING DEFICIT MAY
RESULT IN EVEN FURTHER FLUCTUATIONS IN OUR TRADING VOLUME AND SHARE PRICE.

Even if we were to achieve successful clinical results in our programs, successful approval, marketing, and sales of our
human-use equipment are also critical to the financial future of our company. Our human-use products are not yet approved for sale in the United States and other jurisdictions
and we may never obtain these approvals regardless of whether we achieve successful clinical trial results utilizing such human-use products. Even if we do obtain approvals to sell our
human-use products in the United States, these sales may not be as large or as timely as we expect.

29

---



Table of Contents

These
uncertainties may further cause our operating results to fluctuate dramatically in the next several years.

OUR ABILITY TO UTILIZE OUR NET OPERATING LOSSES AND CERTAIN OTHER TAX ATTRIBUTES MAY BE LIMITED.

As of December 31, 2008, we had net operating losses (NOLs) of approximately $59.4 million for federal income tax
purposes and approximately $58.0 million for state income tax purposes. We also had federal research tax credit carryforwards of approximately $1.2 million as of December 31,
2008. Utilization of the NOLs and tax credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986, and similar state provisions
due to ownership change limitations that have occurred previously or that could occur in the future. These ownership changes may limit the amount of NOL and tax credit carryforwards and other deferred
tax assets that can be utilized to offset future taxable income and tax, respectively. In general, an ownership change, as defined by Section 382, results from transactions increasing ownership
of certain stockholders or public groups in the stock of the corporation by more than 50 percentage points over a three-year period. An analysis was performed of ownership activity
through December 31, 2008 which indicated that multiple ownership changes have occurred in previous years which created annual limitations on the Company's ability to utilize NOL and tax credit
carryovers. Such limitations will result in approximately $12.7 million of tax benefits related to NOL and tax credit carryforwards that will expire unused. Any limitation on our net operating
loss carryforwards that could be used to offset post-ownership change in taxable income would adversely affect our liquidity and cash flow, as and when we become profitable.

IF WE ARE UNABLE TO DEVELOP COMMERCIALLY SUCCESSFUL PRODUCTS IN VARIOUS MARKETS FOR MULTIPLE INDICATIONS, OUR BUSINESS WILL BE HARMED AND WE MAY BE FORCED TO CURTAIL OR
CEASE OPERATIONS.

We cannot assure you that we will successfully develop any products, or if we do, that they will be commercially successful. If we fail
to develop or successfully commercialize any products, we may be forced to refocus, curtail or cease operations. Our ability to achieve and sustain operating profitability depends on our ability,
directly or with strategic partners, to successfully commercialize our products in Europe, Asia and in the US. This will depend in large part on our ability to commence, execute and complete clinical
programs and obtain regulatory approvals for our products. Clinical trials are still necessary before we can seek regulatory approval to sell our products. We cannot assure you that we will receive
approval for our products in the United States or in other countries or, if approved, that we or a partner will achieve a significant level of sales. If we fail to partner or commercialize our
products, we may be forced to curtail or cease operations.

We
are also in the pre-clinical stages of research and development with other new product candidates using our electroporation technology. These new indications and product
candidates will require significant costs to advance through the development stages. Even if such product candidates are advanced through clinical trials, the results of such trials may not gain FDA
approval. Even if approved, our products may not be commercially successful.

PRE-CLINICAL AND CLINICAL TRIALS OF HUMAN-USE EQUIPMENT ARE UNPREDICTABLE, AND IF WE EXPERIENCE UNSUCCESSFUL TRIAL RESULTS, OUR BUSINESS WILL SUFFER.

Before any of our human-use equipment can be sold, the FDA or applicable foreign regulatory authorities must determine that
the equipment meets specified criteria for use in the indications for which approval is requested, including obtaining appropriate regulatory approvals. Satisfaction of regulatory requirements
typically takes many years, and involves compliance with requirements covering research and development, testing, manufacturing, quality control, labeling and promotion of drugs for

30

---



Table of Contents

human
use. To obtain regulatory approvals, we must, among other requirements, complete pre-clinical research and clinical trials demonstrating that our product candidates are safe and
effective for a particular cancer type or other disease. Regulatory approval of a new treatment is never guaranteed. The FDA will make this determination based on the results from our
pre-clinical testing and clinical trials and has substantial discretion in the approval process. Despite the time and experience exerted, failure can occur at any stage, and we could
encounter problems causing us to abandon pre-clinical research and clinical trial activities.

In
addition, any of our clinical trials for treatment using our therapy may be delayed or halted at any time for various other reasons, including:



If
any of the above events arise during our pre-clinical research, clinical trials or data review, we would expect this to have a serious negative impact on our company. Any
termination of ongoing enrollment or other delay or change in the conduct of our clinical trials may not always be understood or accepted by the capital markets and announcements of such scientific
results and related actions may adversely affect the market price of our common stock. We have experienced such problems in the past when we stopped further patient enrollment in two Phase III pivotal
studies for squamous cell head and neck cancer in 2007.

Any
delays or difficulties we have encountered or will encounter in our pre-clinical research and clinical trials, may delay or preclude regulatory approval. Our product
development costs will increase if we experience delays in testing or regulatory approvals or if we need to perform more extensive or larger clinical trials than planned. Any such events could also
delay or preclude the commercialization of our therapy or any other product candidates.

Clinical
trials are unpredictable, especially human-use trials. Results achieved in early stage clinical trials may not be repeated in later stage trials, or in trials with
more patients. When early positive results were not repeated in later stage trials, pharmaceutical and biotechnology companies have suffered significant setbacks. Not only are commercialization
timelines pushed back, but some companies, particularly smaller biotechnology companies with limited cash reserves, have discontinued business after releasing news of unsuccessful clinical trial
results. We cannot be certain the results we observed in our pre-clinical testing will be confirmed in clinical trials or the results of any of our clinical trials will support FDA
approval. If we experience unexpected, inconsistent or disappointing results in connection with a clinical or pre-clinical trial our business will suffer.

A
delay in our pre-clinical research or our clinical trials, for whatever reason, will probably require us to spend additional funds to keep our product(s) moving through the
regulatory process. If we do not have or cannot raise additional funds, then the testing of our human-use products could be

31

---



Table of Contents

discontinued.
In the event our pre-clinical research or our clinical trials are not successful, we will have to determine whether to continue to fund our programs to address the
deficiencies, or whether to abandon our clinical development programs for our products in tested indications. Loss of our human-use product line would be a significant setback for our
company.

Because
there are so many variables inherent in pre-clinical research or clinical trials, we cannot predict whether any of our future regulatory applications to conduct
clinical trials will be approved by the FDA or other regulatory authorities, whether our clinical trials will commence or proceed as planned, and whether the trials will ultimately be deemed to be
successful. To date, our experience has been that submission and approval of clinical protocols has taken longer than desired or expected.

OUR BUSINESS IS HIGHLY DEPENDENT ON RECEIVING APPROVALS FROM VARIOUS REGULATORY AUTHORITIES AND WILL BE DRAMATICALLY AFFECTED IF APPROVAL TO MANUFACTURE AND SELL OUR
HUMAN-USE EQUIPMENT IS NOT GRANTED OR IS NOT GRANTED IN A TIMELY MANNER.

The production and marketing of our human-use equipment and our ongoing research, development, pre-clinical
testing, and clinical trial activities are subject to extensive regulation. Numerous governmental agencies in the U.S. and internationally, including the FDA, must review our applications and decide
whether to grant regulatory approval. All of our human-use equipment must go through an approval process, in some instances for each indication for which we want to label it for use (such
as use for transfer of a certain gene to a certain tissue). These regulatory processes are extensive and involve substantial costs and time.

We
have limited experience in, and limited resources available, for such regulatory activities. Failure to comply with applicable regulations can, among other things, result in
non-approval, suspensions of regulatory approvals, fines, product seizures and recalls, operating restrictions, injunctions and criminal prosecution.

Any
of the following events can occur and, if any did occur, any one could have a material adverse effect on our business, financial conditions and results of
operations:



WE CANNOT PREDICT THE SAFETY PROFILE OF THE USE OF OUR ELECTROPORATION SYSTEM WHEN USED IN COMBINATION WITH OTHER THERAPIES.

Our current clinical trials involve the use of our electroporation system in combination with certain DNA vaccines. While the data we
have evaluated to date suggest the use of electroporation does not alone have significant adverse effects nor increase the adverse effects of other therapies, we cannot predict if this outcome will
continue to be true or whether possible adverse side effects directly

32

---



Table of Contents

attributable
to the vaccines provided by our partners and collaborators will compromise the safety profile of our electroporation-based DNA delivery system when used in certain combination therapies.
In some instances, clinical results may not clearly indicate whether possible adverse effects are related to our technology versus other study related factors.

WE COULD BE SUBSTANTIALLY DAMAGED IF PHYSICIANS AND HOSPITALS PERFORMING CLINICAL TRIALS USING OUR EQUIPMENT DO NOT ADHERE TO PROTOCOLS DEFINED IN CLINICAL TRIAL AGREEMENTS.

We work and have worked with a number of hospitals to perform clinical trials, primarily in the field of oncology. We depend on these
hospitals to recruit patients for our trials, to perform the trials according to our protocols, and to report the results in a thorough, accurate and consistent manner. Although we have agreements
with these hospitals which govern what each party is to do with respect to each protocol, patient safety, and avoidance of conflict of interest, there are risks that the terms of the contracts will
not be followed, such as the following:

Possible Deviations from Protocol.The hospitals or the physicians working at the hospitals may not perform the trials correctly.
Deviations from our
protocol may make the clinical data not useful and the trial could become essentially worthless.

Potential for Conflict of Interest.Physicians working on protocols may have an improper economic interest in our company, or other
conflict of
interest. When a physician has a personal stake in the success of the trial, such as when a physician owns stock, or rights to purchase stock of the trial
sponsor, it can create suspicion that the trial results were improperly influenced by the physician's interest in economic gain. Not only can this put the clinical trial results at risk, but it can
also cause serious damage to a company's reputation.

Patient Safety and Consent Issues.Physicians and hospitals may fail to secure formal written consent as instructed or report adverse
effects that
arise during the trial in the proper manner, which could put patients at unnecessary risk. Physicians and hospital staff may fail to observe proper safety measures such as the mishandling of used
medical needles, which may result in the transmission of infectious and deadly diseases, such as HIV. This increases our liability, affects the data, and can damage our reputation.

If
any of these events were to occur, then it could have a material adverse effect on our ability to receive regulatory authorization to sell our human-use equipment, and on
our reputation. Negative events that arise in the performance of clinical trials sponsored by biotechnology companies of our size and with limited cash reserves have resulted in companies going out of
business. While these risks are always present, to date, our contracted physicians and clinics have been successful in collecting significant data regarding the clinical protocols under which they
have operated, and we are unaware of any conflicts of interest or improprieties regarding our protocols.

EVEN IF OUR PRODUCTS ARE APPROVED BY REGULATORY AUTHORITIES, IF WE FAIL TO COMPLY WITH ON-GOING REGULATORY REQUIREMENTS, OR IF WE EXPERIENCE UNANTICIPATED
PROBLEMS WITH OUR PRODUCTS, THESE PRODUCTS COULD BE SUBJECT TO RESTRICTIONS OR WITHDRAWAL FROM THE MARKET.

Any product for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data and
promotional activities for such product, will be subject to continual review and periodic inspections by the FDA and other regulatory bodies. Even if regulatory approval of a product is granted, the
approval may be subject to limitations on the indicated uses for which the product may be marketed or to certain requirements resulting in costly post-marketing testing and surveillance to
monitor the safety or efficacy of the product. Later discovery of previously unknown

33

---



Table of Contents

problems
with our products, including unanticipated adverse events of unanticipated severity or frequency regarding manufacturer or manufacturing processes or failing to comply with regulatory
requirements, may result in restrictions on such products or manufacturing processes, withdrawal of the products from the market, voluntary or mandatory recall, fines, suspension of regulatory
approvals, product seizures or detention, injunctions or the imposition of civil or criminal penalties.

FAILURE TO COMPLY WITH FOREIGN REGULATORY REQUIREMENTS GOVERNING HUMAN CLINICAL TRIALS AND MARKETING APPROVAL FOR OUR HUMAN-USE EQUIPMENT COULD PREVENT US FROM
SELLING OUR PRODUCTS IN FOREIGN MARKETS, WHICH MAY ADVERSELY AFFECT OUR OPERATING RESULTS AND FINANCIAL CONDITIONS.

For marketing our MedPulser® Electroporation System outside the United States, the requirements governing the conduct of
clinical trials, product licensing, pricing and reimbursement vary greatly from country to country and may require additional testing. The time required to obtain approvals outside the United States
may differ from that required to obtain FDA approval. We may not obtain foreign regulatory approval on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities
in other countries, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other countries or by the FDA. Failure to comply with these regulatory
requirements or to obtain required approvals could impair our ability to develop these markets and could have a material adverse affect on our results of operations and financial condition.

OUR ABILITY TO ACHIEVE SIGNIFICANT REVENUES FROM SALES OR LEASES OF HUMAN-USE PRODUCTS WILL DEPEND ON ESTABLISHING EFFECTIVE SALES, MARKETING AND DISTRIBUTION
CAPABILITIES OR RELATIONSHIPS AND WE CURRENTLY LACK SUBSTANTIAL EXPERIENCE IN THESE AREAS.

To market our products, we will need to develop sales, marketing and distribution capabilities. In order to develop or otherwise obtain
these capabilities, we may have to enter into marketing, distribution or other similar arrangements with third parties in order to sell, market and distribute our products successfully. To the extent
that we enter into any such arrangements with third parties, our product revenue is likely to be lower than if we marketed and sold our products directly, and our revenues will depend upon the efforts
of these third parties.

We
have limited experience in sales, marketing and distribution of clinical and human-use products and we currently have no sales, marketing or distribution capability. If we
decide to market and sell our human-use products directly, we must develop a marketing and sales capability. This would involve substantial costs, training and time. We may be unable to
develop sufficient sales, marketing and distribution capabilities to commercialize our products successfully. Regardless of whether we elect to use third parties or seek to develop our own marketing
capability, we may not be able to successfully commercialize any product.

WE RELY ON COLLABORATIVE AND LICENSING RELATIONSHIPS TO FUND A PORTION OF OUR RESEARCH AND DEVELOPMENT EXPENSES. IF WE ARE UNABLE TO MAINTAIN OR EXPAND EXISTING
RELATIONSHIPS, OR INITIATE NEW RELATIONSHIPS, WE WILL HAVE TO DEFER OR CURTAIL RESEARCH AND DEVELOPMENT ACTIVITIES IN ONE OR MORE AREAS.

Our partners and collaborators fund a portion of our research and development expenses and assist us in the research and development of
our human-use equipment. These collaborations and partnerships help pay the salaries and other overhead expenses related to research. In the past, we have encountered operational
difficulties after the termination of an agreement by a former partner. Because this partnership was terminated, we did not receive significant milestone payments which we had expected and were forced
to delay some clinical trials as well as some product development. We

34

---



Table of Contents

may
experience such operational difficulties or termination of such relationships without anticipated payment again in the future.

We
also rely on scientific collaborators at companies and universities to further expand our research and to test our equipment. In most cases, we lend our equipment to a collaborator,
teach him or her how to use it, and together design experiments to test the equipment in one of the collaborator's fields of expertise. We aim to secure agreements that restrict collaborators' rights
to use the equipment outside of the agreed upon research, and outline the rights each of us will have in any results or inventions arising from the work.

Nevertheless,
there is always potential that:



We
cannot guarantee that any of the results from these collaborations will be successful. We also cannot be sure that we will be able to continue to collaborate with individuals and
institutions that will further develop our products, or that we will be able to do so under terms that are not overly restrictive. If we are not able to maintain or develop new collaborative
relationships, it is likely that our research pace will slow down and that it will take longer to identify and commercialize new products, or new indications for our existing products.

A SMALL NUMBER OF LICENSING PARTNERS ACCOUNT FOR A SUBSTANTIAL PORTION OF OUR REVENUE IN EACH PERIOD AND OUR RESULTS OF OPERATIONS AND FINANCIAL CONDITION COULD SUFFER IF WE
LOSE THESE LICENSING PARTNERS OR FAIL TO ADD ADDITIONAL LICENSING PARTNERS IN THE FUTURE.

We derive a significant portion of our revenue from a limited number of licensing partners in each period. Accordingly, if we fail to
sign additional future contracts with major licensing partners, if a licensing contract is delayed or deferred, or if an existing licensing contract expires or is cancelled and we fail to replace the
contract with new business, our revenue would be adversely affected. Until commercialization of our Medpulser® Electroporation System, we expect that a limited number of licensing partners
will continue to account for a substantial portion of our revenue in each quarter in the foreseeable future. During the years ended December 31, 2008 and 2007, one licensing partner, Merck,
accounted for approximately 30% and 68%, respectively, of our consolidated revenue. During the year ended December 31, 2008 and 2007 another licensing partner, Wyeth, accounted for 40% and 23%,
respectively, of our consolidated revenue. We expect revenues from Wyeth and Merck to be significantly lower in 2009, as Wyeth evaluates internal strategic options prior to initiating further
development of electroporation-based infectious disease programs and development activities for Merck will be limited for the foreseeable future. Further, Wyeth has recently agreed to be acquired by
Pfizer Inc. and Merck has recently agreed to acquire Schering-Plough Corporation. Development and funding priorities may change as a result of these transactions, which may lead to the
suspension or

35

---



Table of Contents

termination
of our relationships with Wyeth or Merck. Any such suspension or termination would likely adversely affect our business.

IF WE CANNOT MAINTAIN OUR EXISTING CORPORATE AND ACADEMIC ARRANGEMENTS AND ENTER INTO NEW ARRANGEMENTS, WE MAY BE UNABLE TO DEVELOP PRODUCTS EFFECTIVELY, OR AT ALL.

Our strategy for the research, development and commercialization of our product candidates may result in us entering into contractual
arrangements with corporate collaborators, academic institutions and others. We have entered into sponsored research, license and/or collaborative arrangements with several entities, including Merck,
Wyeth, Vical, Valentis, the U.S. Navy, Chiron and the University of South Florida, as well as numerous other institutions that conduct clinical trials work or perform pre-clinical research
for us. Our success depends upon our collaborative partners performing their responsibilities under these arrangements and complying with the regulations and requirements governing clinical trials. We
cannot control the amount and timing of resources our collaborative partners devote to our research and testing programs or product candidates, or their compliance with regulatory requirements which
can vary because of factors unrelated to such programs or product candidates. These relationships may in some cases be terminated at the discretion of our collaborative partners with only limited
notice to us.

Merck
can terminate its May 2004 license and collaboration agreement with us at any time in its sole discretion, without cause, by giving ninety days' advance notice to us. If this
agreement is terminated by Merck at any time during the first two years of the collaboration term, then Merck shall continue, for a six-month period beginning on the date of such
termination, to make payments previously approved by the project's joint collaboration committee in relation to scientists and outside contractors engaged by us in connection with the agreement.
During the years ended December 31, 2008 and 2007, Merck accounted for approximately 30% and 68%, respectively, of our consolidated revenue.

In
addition, some of our sponsored research, license and/or collaborative arrangements contain "Change of Control" or other protective provisions that may be triggered by our pending
merger with VGX Pharmaceuticals, announced July 7, 2008, if completed, which may enable pre-mature termination of such arrangements or otherwise may impact the status of such
arrangements for the post-merger company. For example, our agreement with Wyeth requires that we provide Wyeth with certain notifications of a pending qualifying transaction and enables
Wyeth to terminate our arrangement if such notice and certain other written assurances regarding the priority and commitment to the arrangement are not timely provided to Wyeth by the Company and/or
the other Change of Control transaction party prior to consummation of such transaction. Similarly, our arrangement with Merck requires certain notice of a Change of Control transaction and also
enables termination under limited circumstances as a result. Other arrangements require that we seek and obtain prior written consent from the collaborative party ahead of the consummation of any
Change of Control transaction. Although we intend to comply with applicable notice and other documentation requirements pursuant to such "Change of Control" provisions in these and other collaborative
arrangements, we cannot assure you that, to the extent such rights exist, our partners will not seek to terminate or alter their arrangements with us in relation to the closing of the proposed merger
transaction.

Whether
or not we complete the proposed merger, we may not be able to maintain our existing arrangements, enter into new arrangements or negotiate current or new arrangements on
acceptable terms, if at all. Some of our collaborative partners may also be researching competing technologies independently from us to treat the diseases targeted by our collaborative programs.

36

---



Table of Contents

WE MAY BE SUBJECT TO STOCKHOLDER LITIGATION, WHICH WOULD HARM OUR BUSINESS AND FINANCIAL CONDITION.

We may have actions brought against us by stockholders relating to our proposed merger with VGX, past transactions, changes in our
stock price or other matters. Any such actions could give rise to substantial damages, and thereby have a material adverse effect on our consolidated financial position, liquidity, or results of
operations. Even if an action is not resolved
against us, the uncertainty and expense associated with stockholder actions could harm our business, financial condition and reputation. Litigation can be costly, time-consuming and
disruptive to business operations. The defense of lawsuits could also result in diversion of our management's time and attention away from business operations, which could harm our business.

WE RELY HEAVILY ON OUR PATENTS AND PROPRIETARY RIGHTS TO ATTRACT PARTNERSHIPS AND MAINTAIN MARKET POSITION.

The strength of our patent portfolio is an important factor that will influence our success. Patents give the patent holder the right
to prevent others from using its patented technology. If someone infringes upon the patented material of a patent holder, the patent holder has the right to initiate legal proceedings against that
person to protect its patented material. These proceedings, however, can be lengthy and costly. We perform an ongoing review of our patent portfolio to confirm that our key technologies are adequately
protected. If we determine that any of our patents require either additional disclosures or revisions to existing information, we may ask that such patents be reexamined or reissued, as applicable, by
the United States Patent and Trademark Office.

The
patenting process, enforcement of issued patents, and defense against claims of infringement are inherently risky. Because we rely heavily on patent protection, we face the following
significant risks:

Possibility of Inadequate Patent Protection for Product.The United States Patent and Trademark Office or foreign patent offices may
not grant
patents of meaningful scope based on the applications we have already filed and those we intend to file. If we do not have patents that adequately protect our human-use equipment and
indications for its use, then we will not be competitive.

Potential That Important Patents Will Be Judged Invalid.Some of the issued patents we now own or license may be determined to be
invalid. If we have
to defend the validity of any of our patents, the costs of such defense could be substantial, and there is no guarantee of a successful outcome. In the event an important patent related to our drug
delivery technology is found to be invalid, we may lose competitive position and may not be able to receive royalties for products covered in part or whole by that patent under license agreements.

Danger of Being Charged With Infringement.Although we are not currently aware of any parties intending to pursue infringement claims
against us,
there is the possibility that we may use a patented technology owned by another person and/or be charged with infringement. Defending or indemnifying a
third party against a charge of infringement can involve lengthy and costly legal actions, and there can be no guarantee of a successful outcome. Biotechnology companies comparable to us in size and
financial position have discontinued business after losing infringement battles. If we or our partners were prevented from using or selling our human-use equipment, then our business would
be materially adversely affected.

Freedom to Operate Issues.We are aware that patents related to electrically-assisted drug delivery have been granted to, and patent
applications
have been filed by our potential competitors. We or our partners have received licenses from some of these patents, and will consider receiving additional licenses in the future. Nevertheless, the
competitive nature of our field of business and the fact that

37

---



Table of Contents

others
have sought patent protection for technologies similar to ours make these potential issues significant.

In
addition to patents, we also rely on trade secrets and proprietary know-how. We try to protect this information with appropriate confidentiality and inventions agreements
with our employees, scientific advisors, consultants, and collaborators. We cannot be sure that these agreements will not be breached, that we will be able to protect ourselves if they are breached,
or that our trade secrets will not otherwise become known or be independently discovered by competitors. If any of these events occur, then we face the potential of losing control over valuable
company information, which could negatively affect our competitive position.

IF WE ARE NOT SUCCESSFUL IN DEVELOPING OUR CURRENT PRODUCTS, OUR BUSINESS MODEL MAY CHANGE AS OUR PRIORITIES AND OPPORTUNITIES CHANGE AND OUR BUSINESS MAY NEVER DEVELOP TO
BE PROFITABLE OR SUSTAINABLE.

There are many products and programs that seem promising to us which we could pursue. However, with limited resources, we may decide to
change priorities and shift programs away from those that we have been pursuing for the purpose of exploiting our core technology of electroporation. The choices we make will be dependent upon
numerous contemporaneous factors, some of which we cannot predict. We cannot be sure that our business model, as it currently exists or as it may evolve, will enable us to become profitable or to
sustain operations.

SERIOUS AND UNEXPECTED SIDE EFFECTS ATTRIBUTABLE TO GENE THERAPY MAY RESULT IN GOVERNMENTAL AUTHORITIES IMPOSING ADDITIONAL REGULATORY REQUIREMENTS OR A NEGATIVE PUBLIC
PERCEPTION OF OUR PRODUCTS.

The gene therapy or DNA vaccine product candidates under development could be broadly described as gene therapies. A number of clinical
trials are being conducted by other pharmaceutical companies involving gene therapy, including compounds similar to or competitive with, our product candidates. The announcement of adverse results
from these clinical trials, such as serious unwanted and unexpected side effects attributable to treatment, or any response by the FDA to such clinical trials, may impede the progress of our clinical
trials, delay or prevent us from obtaining regulatory approval, or negatively influence public perception of our product candidates, which could harm our business and results of operations and reduce
the value of our stock.

The
U.S. Senate has held hearings concerning the adequacy of regulatory oversight of gene therapy clinical trials, as well as the adequacy of research subject education and protection in
clinical research in general, and to determine whether additional legislation is required to protect volunteers and patients who participate in such clinical trials. The Recombinant DNA Advisory
Committee, or RAC, which acts as an advisory body to the National Institutes of Health, has expanded its public role in evaluating important public and ethical issues in gene therapy clinical trials.
Implementation of any additional review and reporting procedures or other additional regulatory measures could increase the costs of or prolong our product development efforts or clinical trials.

As
of December 31, 2008, to our knowledge, there have not been any serious adverse events in any gene therapy clinical trials in which our technology was used. In the future, if
one or a series of serious adverse events were to occur during a gene therapy clinical trial in which our technology was used, we would report all such events to the FDA and other regulatory agencies
as required by law. Such serious adverse events, whether treatment-related or not, could result in negative public perception of our treatments and require additional regulatory review or other
measures, which could increase the cost of or prolong our gene therapy clinical trials or require us to halt our clinical trials altogether.

The
commercial success of our products will depend in part on public acceptance of the use of gene therapy products or gene-induced products, which are a new type of disease
treatment for the

38

---



Table of Contents

prevention
or treatment of human diseases. Public attitudes may be influenced by claims that gene therapy products or gene-induced products are unsafe, and these treatment methodologies
may not gain the acceptance of the public or the medical community. Negative public reaction to gene therapy products or gene-induced products could also result in greater government
regulation and stricter clinical trial oversight.

WE HAVE THE POTENTIAL FOR PRODUCT LIABILITY ISSUES WITH HUMAN-USE EQUIPMENT.

The testing, marketing and sale of human-use products expose us to significant and unpredictable risks of equipment product
liability claims. These claims may arise from patients, clinical trial volunteers, consumers, physicians, hospitals, companies, institutions, researchers or others using, selling, or buying our
equipment. Product liability risks are inherent in our business and will exist even after the products are approved for sale. If and when our human-use equipment is commercialized, we run
the risk that use (or misuse) of the equipment will result in personal injury. The chance of such an occurrence will increase after a product type is on the market.

We
have obtained liability insurance in connection with our ongoing business and products, and we may purchase additional policies if such policies are determined by management to be
necessary. However, our existing insurance and the insurance we purchase may not provide adequate coverage in the event a claim is made and we may be required to pay claims directly. If we did have to
make payment against a claim, it would impact our financial ability to perform the research, development, and sales activities that we have planned.

If
and when our human-use equipment is commercialized, there is always the risk of product defects. Product defects can lead to loss of future sales, decrease in market
acceptance, damage to our brand or reputation, product returns and warranty costs, and even product withdrawal from the market. These events can occur whether the defect resides in a component we
purchased from a third party or whether it was due to our design and/or manufacturer. We expect that our sales agreements will contain provisions designed to limit our exposure to product liability
claims. However, we do not know whether these limitations will be enforceable in the countries in which the sale is made. Any product liability or other claim brought against us, if successful and of
sufficient magnitude, could negatively impact our financial performance.

WE CANNOT BE CERTAIN THAT WE WILL BE ABLE TO MANUFACTURE OUR HUMAN-USE EQUIPMENT IN SUFFICIENT VOLUMES AT COMMERCIALLY REASONABLE COSTS.

Our manufacturing facilities for human-use products will be subject to quality systems regulations, international quality
standards and other regulatory requirements, including pre-approval inspection for our human-use equipment and periodic post-approval inspections for all
human-use products. While we have undergone and passed a quality systems audit from an international body, we have never undergone a quality systems inspection by the FDA. We may not be
able to pass an FDA inspection when and if it occurs. If our facilities are found not to be compliant with FDA standards in sufficient time, prior to a launch of our product in the United States, then
it will result in a delay or
termination of our ability to produce our human-use equipment in our facility. Any delay in production will have a negative effect on our business. While there are no target dates set
forth for launch of our products in the United States, we plan on launching each product once we successfully perform a Phase III clinical study involving a particular use of our technology,
obtain the requisite regulatory approval, and engage a partner who has the financial resources and marketing capacity to bring our products to market.

Our
products must be manufactured in sufficient commercial quantities, in compliance with regulatory requirements, and at an acceptable cost to be attractive to purchasers. We rely on
third

39

---



Table of Contents

parties
to manufacture and assemble most aspects of our equipment, and thus cannot directly control the quality, timing or quantities of equipment manufactured or assembled at any given time.

Disruption
of the manufacture of our products, for whatever reason, could delay or interrupt our ability to manufacture or deliver our products to customers in a timely basis. This would
be expected to affect revenue and may affect our long-term reputation, as well. In the event we provide product of inferior quality, we run the risk of product liability claims and
warranty obligations, which will negatively affect our financial performance.

THERE IS A POSSIBILITY THAT OUR TECHNOLOGY WILL BECOME OBSOLETE OR LOSE ITS COMPETITIVE ADVANTAGE.

The vaccine development and delivery business is very competitive, fast moving and intense, and expected to be increasingly so in the
future. Other companies and research institutions are developing drug delivery systems that, if not similar in type to our systems, are designed to address the same patient or subject population.
Therefore, we cannot promise that our products will be the best, the safest, the first to market, or the most economical to manufacture and use. If competitors' products are better than ours, for
whatever reason, then we could become less profitable from product sales and our products could become obsolete.

There
are many reasons why a competitor might be more successful than us, including:

Financial Resources.Some competitors have greater financial resources and can afford more technical and developmental setbacks than we
can.

Greater Experience.Some competitors have been in the biomedical business longer than we have. They have greater experience than us in
critical areas
like clinical testing, obtaining regulatory approval and sales and marketing. This experience or their name recognition may give them a competitive advantage over us. In certain international markets,
local companies may be given preferential treatment by local physicians and hospitals.

Superior Patent Position.Some competitors may have better patent protection over their technology than we have or will have in order to
protect our
technology. If we cannot use our patents to prevent others from copying our technology or developing similar technology, or if we cannot obtain a critical license to another's patent that we need to
manufacture and use our equipment, then we would expect our competitive position to weaken.

Faster to Market.Some companies with competitive technologies may move through stages of development, approval, and marketing faster
than us. If a
competitor receives FDA approval before us, then it will be authorized to sell its products before we can sell ours. Because the first company "to market" often has a significant advantage over
others, a second place position could result in less than anticipated sales.

Reimbursement Allowed.In the U.S., third party payers, such as Medicare, may reimburse physicians and hospitals for competitors'
products but not
for our own human-use products. This would significantly affect our ability to sell our human-use products in the U.S. and would have a negative impact on revenue and our
business as a whole. Outside of the U.S., reimbursement and funding policies vary widely.

IF WE LOSE KEY PERSONNEL OR ARE UNABLE TO ATTRACT AND RETAIN ADDITIONAL, HIGHLY SKILLED PERSONNEL REQUIRED TO DEVELOP OUR PRODUCTS OR OBTAIN NEW COLLABORATIONS, OUR BUSINESS
MAY SUFFER.

We depend, to a significant extent, on the efforts of our key employees, including senior management and senior scientific, clinical,
regulatory and other personnel. The development of new

40

---



Table of Contents

therapeutic
products requires expertise from a number of different disciplines, some of which is not widely available. We depend upon our scientific staff to discover new product candidates and to
develop and conduct pre-clinical studies of those new potential products. Our clinical and regulatory staff is responsible for the design and execution of clinical trials in accordance
with FDA requirements and for the advancement of our product candidates toward FDA approval. Our manufacturing staff is responsible for designing and conducting our manufacturing processes in
accordance with the FDA's Quality System Regulations. The quality and reputation of our scientific, clinical, regulatory and manufacturing staff, especially the senior staff, and their success in
performing their responsibilities, are significant factors in attracting potential funding sources and collaborators. In addition, our Chief Executive Officer and Chief Financial Officer and other
executive officers are involved in a broad range of critical activities, including providing strategic and operational guidance. The loss of these individuals, or our inability to retain or recruit
other key management and scientific, clinical, regulatory, manufacturing and other personnel, may delay or prevent us from achieving our business objectives. We face intense competition for personnel
from other companies, universities, public and private research institutions, government entities and other organizations.

WE MAY NOT MEET ENVIRONMENTAL GUIDELINES AND AS A RESULT COULD BE SUBJECT TO CIVIL AND CRIMINAL PENALTIES.

Like all companies in our industry, we are subject to a variety of governmental regulations relating to the use, storage, discharge and
disposal of hazardous substances. Our safety procedures for handling, storage and disposal of such materials are designed to comply with applicable laws and regulations. While we believe we are
currently in compliance with all material applicable environmental regulations, if we are found to not comply with environmental regulations, or if we are involved with contamination or injury from
these materials, then we may be subject to civil and criminal penalties. This would have a negative impact on our reputation and finances, and could result in a slowdown or even complete cessation of
our business.

CHANGES IN FOREIGN EXCHANGE RATES MAY AFFECT OUR FUTURE OPERATING RESULTS.

In January 2005, we acquired Inovio AS, a Norwegian company. During the years ended December 31, 2008 and 2007, Inovio AS
contributed approximately $135,000 and $159,000 to our revenue, respectively, which amounted to approximately 6% and 3% of our total revenue. Inovio AS conducts its operations primarily in foreign
currencies, including the Euro, Norwegian Kroner and Swedish Krona. In September 2006, we established Inovio Asia Pte. Ltd., a company incorporated in the Republic of Singapore, which conducts
its operations primarily in Singaporean dollars. Fluctuation in the values of these foreign currencies relative to the U.S. dollar will affect our financial results which are reported in U.S. dollars
and will cause U.S. dollar translation of such currencies to vary from one period to another. We cannot predict the scope of any fluctuations in the values of these foreign currencies relative to the
U.S. dollar nor the effect of exchange rate fluctuations upon our future operating results.

OUR RESTRUCTURING OF OUR NORWEIGIAN SUBSIDIARY, INOVIO AS, MAY NOT REALIZE THE EFFICIENCIES ANTICIPATED AND COULD RESULT IN ADDITIONAL, UNANTICIPATED LIABILITIES, WHICH
WOULD HAVE A NEGATIVE EFFECT ON OUR FINANCIAL CONDITION.

On December 31, 2007, our wholly-owned Norwegian subsidiary Inovio AS transferred certain patent and other intellectual property
rights ("IPR") to our wholly owned U.S. subsidiary Genetronics, Inc. The value assigned to these rights was $1.9 million, which was determined by and was the responsibility of management
of Inovio, who considered in part preliminary work performed by a valuation specialist in Norway. All Norwegian tax gains associated with this transfer of the patents and

41

---



Table of Contents

IPR
was offset by prior year tax loss carry forwards. Subsequent to year-end, Inovio changed the name of Inovio AS to Inovio Tec AS. Simultaneously, we incorporated a new Norwegian
wholly-owned subsidiary under the name Inovio AS, for the purpose of organizing a research effort directed towards the development of specific cancer vaccine candidates. In January 2008, all
employees, employee agreements, lease agreements and fixed assets were transferred from Inovio Tec AS to Inovio AS, and the parties intend to enter into a licensing agreement governing use of future
IPR shortly. Further, although we and our board of directors retain ultimate control over and responsibility for Inovio AS, Inovio AS now has a distinct board of directors, consisting of two members
of our board of directors and two Norwegian personnel, intended to allow more efficient balancing of U.S. legal and regulatory concerns with Norwegian legal and regulatory concerns in the course of
decision-making.

This
restructuring of our Norwegian operations is intended to better focus the research and development efforts conducted in Norway on our strategic programs and easing access to
previously
developed IPR for Inovio and its other subsidiaries. We expect funding for this program to be about $5.0 million over the next several years. Although designed to be tax-neutral to
the parties, we cannot assure you that the tax authorities in Norway or the U.S. will agree with the valuation of the transferred assets or the procedures through which the transfers were made. If
such disagreements were to arise, we may face unanticipated tax liabilities in Norway or the U.S. arising from the asset transfer. Further, as there will be an ongoing licensing relationship between
the parties post-transfer, it is possible that such arrangements will receive heightened scrutiny for potential transfer pricing issues, which could result in additional liability to us.
We believe that the new Inovio AS is now appropriately organized and staffed, and has the necessary resources and commitments for future resources to conduct its research and development efforts in
support of our business strategy. However, we cannot assure readers that Inovio AS will not require further staff or financing beyond these initial commitments, or that we will be able to provide such
resources if and when requested. To the extent Inovio AS or we face additional tax or transfer pricing issues, our operating results and overall financial condition may be adversely affected. In
particular, if we are unable to provide additional support for Inovio AS when requested, Inovio AS may not be able to reach previously specified targets and milestones in a timely manner, undermining
its financial stability and the commercial potential for its prostate cancer vaccine program.

OUR FACILITIES ARE LOCATED NEAR KNOWN EARTHQUAKE FAULT ANDWILDFIRE ZONES, AND THE OCCURRENCE OF AN EARTHQUAKE, SIGNIFICANT WILDFIRE, OR OTHER CATASTROPHIC DISASTER COULD
CAUSE DAMAGE TO OUR FACILITIES AND EQUIPMENT.

Our facilities are located near known earthquake fault zones and areas prone to severe seasonal wildfires and are vulnerable to damage
from earthquakes and wildfires. We are also vulnerable to damage from other types of disasters, including fire, floods, power loss, communications failures and similar events. If any disaster were to
occur, our ability to operate our business at our facilities would be seriously impaired. In addition, the unique nature of our research activities could cause significant delays in our programs and
make it difficult for us to recover from a disaster. The insurance we maintain may not be adequate to cover our losses resulting from disasters or other business interruptions. Accordingly, an
earthquake, wildfire or other disaster could materially and adversely harm our ability to conduct business.

ITEM 2.    PROPERTIES

We own no real property and have no plans to acquire any real property in the future. On January 28, 2005, we moved into new
headquarters of 22,867 square feet at 11494 Sorrento Valley Road in San Diego, California. This facility provides adequate space for our current research, manufacturing, and administrative operations.
This lease runs through February 28, 2010. The annual rent for this leased property is $433,901 in the first two years and $452,767 in year three and four of

42

---



Table of Contents

the
original lease term. The annual rent for the fifth and final year of the original lease term is $480,207. At the end of the original lease term, we have the option of renewing this lease for an
additional five-year lease term at an annual rate equal to the fair market rental value of the property, as defined in the lease agreement.

In
connection with this lease, we issued a warrant to purchase 50,000 shares of our common stock at $5.00 per share to the landlord of this leased facility in December 2004. This warrant
was immediately exercisable and expires five years from the date of issuance. This warrant was valued on the date of issuance using the Black-Scholes pricing model. The fair value of this warrant,
$120,913, is being recognized ratably over the five-year term of the lease as rent expense. As of December 31, 2008, this warrant had not been exercised.

In
January 2008, we entered into a new facility lease in Oslo, Norway to support our research and development activities conducted through our subsidiary Inovio AS. The term of the lease
is for three years and may be terminated with three months notice. Monthly rent is approximately $3,000 per month.

We
believe our current facilities will be adequate to meet our operating needs for the foreseeable future. Should we need additional space, we believe we will be able to secure
additional space at commercially reasonable rates.

ITEM 3.    LEGAL PROCEEDINGS

Pyrce v. Inovio Biomedical Corporation, Genetronics Biomedical Corporation, Genetronics, Inc., Inovio
AS, DOES 1 to 50, Superior Court of California, County of San Diego, Case No. 37-2007-000758899-CU-BC-CTL
(Hon. Ronald L. Styn). The plaintiff, a former consultant to Inovio AS, commenced this civil lawsuit against the Company and various subsidiaries in state court on September 28, 2007.

The
plaintiff seeks damages of approximately $780,000 he alleges to be due him under a consulting agreement he had with Inovio AS. Plaintiff further alleges the Company to be liable to
him by virtue of its acquisition of Inovio AS and resulting from a license executed with Wyeth Pharmaceuticals Inc.

Plaintiff's
original counsel withdrew from the case, and plaintiff was proceedingpro seuntil obtaining a new attorney who appeared in
September of 2008 and filed a nine-count amended complaint. The Court dismissed three of Plaintiff's counts and Plaintiff thereafter filed a nine-count second amended complaint
by which Plaintiff seeks approximately $780,000 in damages. The plaintiff has not yet served Inovio AS. The Company disputes the allegations, believes they are without merit and intends to vigorously
defend against them.

ITEM 4.    SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

No matters were submitted to a vote of security holders during the fourth quarter of fiscal 2008.

43

---





Table of Contents

PART II

ITEM 5.    MARKET FOR COMPANY'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER REPURCHASES OF EQUITY SECURITIES

Market Information

Our common stock is listed, and principally traded, on the NYSE Amex, a national securities exchange, under the symbol "INO." The
following table sets forth the quarterly high and low per share closing prices of our common stock for the two most recent fiscal years.

Year Ended December 31,2008

2007Period:

High

Low

High

LowFirst Quarter

$
1.45

$
0.83

$
3.46

$
2.82Second Quarter

$
1.30

$
0.78

$
4.17

$
2.20Third Quarter

$
1.13

$
0.60

$
2.94

$
1.16Fourth Quarter

$
0.80

$
0.16

$
1.51

$
0.85


As
of March 16, 2009, we had approximately 136 common stockholders of record. This figure does not include beneficial owners who hold shares in nominee name. The closing price per
share of our common stock on March 16, 2009 was $0.30, as reported on the NYSE Amex.

Dividends

The payment of any dividends on our common stock is within the discretion of our board of directors. However, we may not pay dividends
on our common stock without the consent of holders of a majority of each Series of our outstanding Preferred Stock. We have not paid cash dividends on our common stock and the board of directors does
not expect to declare cash dividends on the common stock in the foreseeable future.

The
holders of our Series A and B Preferred Stock were entitled to receive an annual dividend at the rate of 6%, payable quarterly, through September 30, 2006. These
dividends were payable in cash unless the closing price of our common shares for the 20 trading days immediately preceding the dividend payment date was equal to or greater than the conversion price
of such shares, in which event we may have elected to pay the dividends to the holders in common stock. There were no dividends paid to the former holders of our Series A and B Preferred Stock
during the years ended December 31, 2008 or 2007. We paid dividends to the holders of our Series A and B Preferred Stock through the issuance of 2,871 shares of our common stock valued
at $8,000 and in cash of $15,000 during the year ended December 31, 2006. As of December 31, 2008 and 2007 there were no shares of Series A or B Preferred Stock outstanding.

The
holders of our Series C Preferred Stock were entitled to receive an annual dividend at the rate of 6%, payable quarterly, through May 20, 2007. These dividends were
payable in cash unless the closing price of our common shares for the 20 trading days immediately preceding the dividend payment date was equal to or greater than the conversion price of such shares,
in which event we may have elected to pay the dividends to the holders in common stock. There were no dividends paid to the holders of our Series C Preferred Stock during the year ended
December 31, 2008. During the year ended December 31, 2007, we paid dividends to the holders of our Series C Preferred Stock in cash of $23,000. During the year ended
December 31, 2006, we paid dividends to the holders of our Series C Preferred Stock in cash of $117,000 and accrued dividends of $15,000 which were converted into common shares and
warrants as part of a private placement we completed in October 2006. As of December 31, 2008 and 2007, there were 71 shares of Series C Preferred Stock outstanding.

44

---



Table of Contents

Recent Sales of Unregistered Securities

There were no sales of unregistered securities during the fourth quarter of fiscal 2008.

Repurchases

We did not repurchase any of our equity securities during the fourth quarter of fiscal 2008.

Equity Compensation Plans

Our equity compensation plan information is provided as set forth in Part III, Item 11 herein.

Performance Graph

The graph below matches Inovio Biomedical Corporation's cumulative 5-year total shareholder return on common stock with the
cumulative total returns of the AMEX Composite index and the S & P SuperCap Biotechnology index. The graph assumes that the value of the investment in our common stock and in each of the
indexes (including reinvestment of dividends) was $100 on December 31, 2003 and tracks it through December 31, 2008.

COMPARISON OF 5 YEAR CUMULATIVE TOTAL RETURN*Among Inovio Biomedical Corporation, The AMEX Composite Index  And The S & P SuperCap Biotechnology Index

GRAPHIC

---

*$100
invested on 12/31/03 in stock & index-including reinvestment of dividends.

Fiscal
year ending December 31.

Copyright
© 2009 S&P, a division of The McGraw-Hill Companies Inc. All rights reserved.

12/03

12/04

12/05

12/06

12/07

12/08Inovio Biomedical Corporation


100.00


78.80


45.40


65.80


18.40


10.40AMEX Composite


100.00


124.13


155.00


184.30


217.52


132.72S & P SuperCap Biotechnology Index


100.00


114.09


138.97


139.43


130.94


142.49


The stock price performance included in this graph is not necessarily indicative of future stock price performance.

45

---



Table of Contents

ITEM 6.    SELECTED CONSOLIDATED FINANCIAL DATA

The following table sets forth our selected consolidated financial data for the periods indicated, derived from consolidated financial
statements prepared in accordance with U.S. generally accepted accounting principles.

Year Ended
December 31,
2008

Year Ended
December 31,
2007

Year Ended
December 31,
2006

Year Ended
December 31,
2005

Year Ended
December 31,
2004Operations Data:License fee and milestone payments

$
791,401

$
2,793,478

$
1,337,105

$
2,563,283

$
214,351Revenue under collaborative research & development arrangements


1,077,967


1,854,303


962,207


1,492,145


945,591Grants & miscellaneous revenue


228,264


159,948


1,168,866


1,411,825


7,157Total revenue


2,097,632


4,807,729


3,468,178


5,467,253


1,167,099Loss from continuing operations


(13,658,464
)

(15,898,420
)

(13,346,194
)

(15,506,970
)

(11,263,140
)Gain on disposal of assets














290,209Interest & other income


692,842


4,693,977


1,002,252


210,118


247,555Net loss


(12,965,622
)

(11,204,443
)

(12,343,942
)

(15,296,852
)

(10,972,931
)Imputed dividends common stock











(8,329,112
)

Imputed & declared dividends preferred stock





(23,335
)

(2,005,664
)

(2,736,658
)

(732,405
)Net loss attributable to common stockholders

$
(12,965,622
)
$
(11,227,778
)
$
(14,349,606
)
$
(26,362,622
)
$
(11,705,336
)Per common sharebasic & diluted:Net loss

$
(0.30
)
$
(0.27
)
$
(0.40
)
$
(0.81
)
$
(0.62
)Imputed dividends common stock











(0.44
)

Imputed & declared dividends preferred stock








(0.06
)

(0.14
)

(0.04
)Net loss attributable to common stockholders

$
(0.30
)
$
(0.27
)
$
(0.46
)
$
(1.39
)
$
(0.66
)Balance Sheet Data:Cash and equivalents

$
14,115,281

$
10,250,929

$
8,321,606

$
17,166,567

$
17,889,797Short-term investments





16,999,600


14,700,000





Long-term investments


9,169,471











Total assets


38,987,028


39,775,021


35,949,615


28,978,954


20,951,502Current liabilities


14,709,582


3,354,499


6,859,722


4,002,280


5,401,992Accumulated deficit


(152,812,948
)

(139,847,326
)

(128,619,548
)

(114,269,942
)

(87,907,320
)Total stockholders equity


19,106,147


31,034,754


18,151,864


23,470,748


15,549,510


ITEM 7.   MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

THIS ANNUAL REPORT ON FORM 10-K CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE RISKS AND
UNCERTAINTIES. SUCH STATEMENTS INCLUDE, BUT ARE NOT LIMITED TO, STATEMENTS CONTAINING THE WORDS "BELIEVES," "ANTICIPATES," "EXPECTS," "ESTIMATES" AND WORDS OF SIMILAR MEANING. OUR ACTUAL RESULTS COULD
DIFFER MATERIALLY FROM ANY FORWARD-LOOKING STATEMENTS, WHICH REFLECT MANAGEMENT'S OPINIONS ONLY AS OF THE DATE OF THIS REPORT, AS A RESULT OF SUCH RISKS AND UNCERTAINTIES. WE UNDERTAKE NO OBLIGATION
TO REVISE OR PUBLICLY RELEASE THE RESULTS OF ANY REVISIONS TO THESE FORWARD-LOOKING STATEMENTS. FACTORS THAT COULD CAUSE OR CONTRIBUTE TO SUCH DIFFERENCES INCLUDE, BUT ARE NOT LIMITED TO, THOSE FOUND
IN THIS ANNUAL REPORT ON FORM 10-K IN PART I, ITEM 1A "RISK FACTORS;" IN THIS PART II, ITEM 7, "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS;" AND
ADDITIONAL FACTORS DISCUSSED ELSEWHERE IN THIS ANNUAL REPORT AND IN OTHER DOCUMENTS WE FILE FROM TIME TO TIME WITH THE SECURITIES AND EXCHANGE COMMISSION, INCLUDING OUR QUARTERLY REPORTS ON FORM
10-Q. READERS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON ANY FORWARD-LOOKING STATEMENTS.

46

---



Table of Contents

The following discussion should be read in conjunction with the consolidated financial statements and notes thereto appearing elsewhere in
this Form 10-K. For a more comprehensive description of our business, see Part I. Item 1. Business.

Overview

Inovio Biomedical Corporation, or "Inovio," a Delaware corporation, organized in 2001, is a San Diego-based biomedical company focused
on the development of next-generation vaccines to prevent or treat cancers and chronic infectious diseases. Such vaccines, which could potentially protect millions of people from
debilitation or death from diseases without adequate treatments, may represent multi-billion dollar market opportunities. Historically, successful development of this new generation of
vaccinesDNA vaccineshas been hindered by the lack of safe, efficient and cost effective DNA delivery methods capable of enabling their potency. However, Inovio's
electroporation-based DNA delivery technology has shown potential in pre-clinical and clinical studies to play a pivotal role in facilitating delivery and enhancing the potency of
preventive and therapeutic vaccines.

Inovio
is a leader in developing DNA delivery solutions based on electroporation, which uses brief, controlled electrical pulses to create temporary pores in cell membranes and enable
increased cellular uptake of a useful biopharmaceutical. Once the DNA vaccine enters a cell, it can then "express" the proteins it was encoded to produce. These proteins, or antigens, are designed to
be uniquely associated with a targeted cancer or infectious disease, and may then stimulate a more powerful immune response if the immune system encounters the targeted disease at a subsequent time.

Inovio's
business strategy to realize value for the company and its stockholders is as follows:

First,
Inovio has leveraged its patented technologies through licensing and collaborations, such as its licensing arrangements with Merck & Co., Inc., or "Merck,"
Wyeth Pharmaceuticals, or "Wyeth" and Vical Inc., or "Vical," among other research-driven biopharmaceutical companies as well as government and non-government agencies. Inovio is
licensing the use of its electroporation-based DNA delivery systems for partners to use in conjunction with their proprietary DNA vaccines or DNA-based immunotherapies. These arrangements
provide Inovio with some combination of upfront payments, development fees, milestone payments, royalties and a supply agreement. These collaborators either have active programs that are pursuing
development of proprietary agents or researching the use of Inovio's technology or are currently evaluating such programs.

Second,
Inovio is pursuing proprietary vaccine development or co-development, resulting in whole or partial ownership in promising vaccines to prevent or treat cancers and
chronic infectious diseases.

Inovio's
technology is protected by an extensive patent portfolio covering in vivo electroporation. Inovio's patent portfolio encompasses a range of apparatuses, methodologies,
conditions, and applications including oncology, gene delivery, vascular, transdermal as well as ex vivo electroporation.

On
July 7, 2008, Inovio and VGX Pharmaceuticals, Inc. ("VGX"), a privately-held developer of DNA vaccines, executed a definitive merger agreement providing for
the issuance of Inovio shares in exchange for all of the outstanding securities of VGX and the merger of an acquisition subsidiary of Inovio with VGX (the "Merger"). Inovio and VGX subsequently
negotiated an amended and restated merger agreement (the "Amended Agreement"), which the parties executed on December 5, 2008. Completion of the Merger under the Amended Agreement remains
subject to registration with the SEC of the Inovio securities to be issued in the Merger, receipt of approval from both companies' stockholders, and other customary closing conditions.

As
of December 31, 2008, we had an accumulated deficit of $152.8 million. We expect to continue to incur substantial operating losses in the future due to our commitment to
our research and development programs, the funding of preclinical studies, clinical trials and regulatory activities and the costs of general and administrative activities.

47

---



Table of Contents

Critical Accounting Policies

The SEC defines critical accounting policies as those that are, in management's view, important to the portrayal of our financial
condition and results of operations and require management's judgment. Our discussion and analysis of our financial condition and results of operations is based on our audited consolidated financial
statements, which have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP"). The preparation of these financial statements requires us to make estimates
and judgments that affect the reported amounts of assets, liabilities, revenue and expenses. We base our estimates on experience and on various assumptions that we believe are reasonable under the
circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ
from those estimates. Our critical accounting policies include:

Revenue Recognition.

Revenue is recognized in accordance with Staff Accounting Bulletin ("SAB") No. 104,Revenue Recognition
in Financial Statements,and EITF Issue 00-21,Revenue Arrangements with Multiple Deliverables.

License
fees are comprised of initial fees and milestone payments derived from collaborative licensing arrangements. We continue to recognize non-refundable milestone
payments upon the achievement of specified milestones upon which we have earned the milestone payment, provided the milestone payment is substantive in nature and the achievement of the milestone was
not reasonably assured at the inception of the agreement. We defer payments for milestone events which are reasonably assured and recognize them ratably over the minimum remaining period of our
performance obligations. Payments for milestones which are not reasonably assured are treated as the culmination of a separate earnings process and are recognized as revenue when the milestones are
achieved.

We
have adopted a strategy of co-developing or licensing our gene delivery technology for specific genes or specific medical indications. Accordingly, we have entered into
collaborative research and development agreements and have received funding for pre-clinical
research and clinical trials. Payments under these agreements, which are non-refundable, are recorded as revenue as the related research expenditures are incurred pursuant to the terms of
the agreements and provided collectibility is reasonably assured.

We
receive non-refundable grants under available government programs. Government grants towards current expenditures are recorded as revenue when there is reasonable
assurance that we have complied with all conditions necessary to receive the grants, collectibility is reasonably assured, and as the expenditures are incurred.

Research and development expenses.Since our inception, virtually all of our activities have consisted of research and development
efforts related to
developing our electroporation technologies. Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits,
facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to operations as they are incurred. We review and
accrue clinical trials expense based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies and other events.

Valuation of Goodwill and Intangible Assets.Our business acquisitions typically result in goodwill and other intangible assets, and
the recorded
values of those assets may become impaired in the future. Acquired intangible assets are still being developed for the future economic viability contemplated at the time of acquisition. We are
concurrently conducting Phase I and pre-clinical trials using the

48

---



Table of Contents

acquired
intangibles, and we have entered into certain significant licensing agreements for use of these acquired intangibles.

We
record patents at cost and amortize these costs using the straight-line method over the expected useful lives of the patents or 17 years, whichever is less. Patent
cost consists of the consideration paid for patents and related legal costs. License costs are recorded based on the fair value of consideration paid and amortized using the straight-line
method over the shorter of the expected useful life of the underlying patents or the term of the related license agreement. As of December 31, 2008, our goodwill and intangible assets resulting
from acquisition costs of Inovio AS, and additional intangibles including patents and license costs, net of accumulated amortization, totaled $9.8 million.

The
determination of the value of such intangible assets requires management to make estimates and assumptions that affect our consolidated financial statements. We assess potential
impairments to intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. Our judgments regarding the
existence of impairment indicators and future cash flows related to intangible assets are based on operational performance of our acquired businesses, market conditions and other factors. If
impairment is indicated, we reduce the carrying value of the intangible asset to fair value. While our current and historical operating and cash flow losses are potential indicators of impairment, we
believe the future cash flows to be received from our intangible assets will exceed the intangible assets' carrying value, and accordingly, we have not recognized any impairment losses through
December 31, 2008.

Although
there are inherent uncertainties in this assessment process, the estimates and assumptions we use are consistent with our internal planning. If these estimates or their related
assumptions change in the future, we may be required to record an impairment charge on all or a portion of our goodwill and intangible assets. Furthermore, we cannot predict the occurrence of future
impairment-triggering events nor the impact such events might have on our reported asset values. Future events could cause us to conclude that impairment indicators exist and that goodwill or other
intangible assets associated with our acquired businesses are impaired. Any resulting impairment loss could have an adverse impact on our results of operations.

Stock-based Compensation.Stock-based compensation cost is estimated at the grant date based on the fair-value of the award and is
recognized as an expense ratably over the requisite service period of the award. Determining the appropriate fair-value model and calculating the fair value of stock-based awards at the
grant date requires considerable judgment, including estimating stock price volatility, expected option life and forfeiture rates. We develop our estimates based on historical data. If factors change
and we employ different assumptions in future periods, the compensation expense that we record may differ significantly from what we have recorded in the current period. A small change in the
estimates used may have a relatively large change in the estimated valuation. We use the Black-Scholes pricing model to value stock option awards. We recognize compensation expense using the
straight-line amortization method.

Auction Rate Securities and Auction Rate Securities Rights.We account for Auction Rate Securities ("ARS") under FAS 115,
Accounting for Certain Investments in Debt and Equity Securities, and FAS 157,Fair Value
Measurements. We account for ARS Rights in accordance with SFAS No. 159,The Fair Value Option for Financial Assets and Financial
LiabilitiesIncluding an amendment to FASB Statement No. 115. Our investments in ARS and our ARS Rights are recorded at their estimated fair value as there
is currently no liquid market which indicates value. We have used a discounted cash flow model to determine the estimated fair value of our investment in ARS and our ARS Rights as of
December 31, 2008. The assumptions used in preparing the discounted cash flow model include estimates for interest rates, timing and amount of cash flows and expected holding period of the ARS

49

---



Table of Contents

and
ARS Rights. Changes in the estimated fair value of the ARS and ARS Rights are reflected in the consolidated statement of operations as "Other income, net."

Registered Common Stock Warrants.We account for registered common stock warrants in accordance with EITF Issue 00-19, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company's Own Stock,on the understanding that in compliance
with applicable securities laws, the registered warrants require the issuance of registered securities upon exercise and do not sufficiently preclude an implied right to net cash settlement. We
classify registered warrants on the consolidated balance sheet as a current liability which is revalued at each balance sheet date subsequent to the initial issuance in October 2006 and August 2007.
Determining the appropriate fair-value model and calculating the fair value of registered warrants requires considerable judgment, including estimating stock price volatility and expected
warrant life. We develop our estimates based on historical data. A small change in the estimates used may have a relatively large change in the estimated valuation. We use the Black-Scholes pricing
model to value the registered warrants. Changes in the fair market value of the warrants are reflected in the consolidated statement of operations as "Other income, net."

Recent Accounting Pronouncements

Information regarding recent accounting pronouncements is contained in Note 3 to the Consolidated Financial Statements, included
elsewhere in this report.

Results of Operations

Comparison of Years Ended December 31, 2008 and 2007

The audited consolidated financial data for the years ended December 31, 2008 and December 31, 2007 is presented in the
following table and the results of these two periods are used in the discussion thereafter.

December 31,
2008

December 31,
2007

Increase/
(Decrease)
$

Increase/
(Decrease)
%Revenue:License fee and milestone payments

$
791,401

$
2,793,478

$
(2,002,077
)

(72
)%Revenue under collaborative research and development arrangements


1,077,967


1,854,303


(776,336
)

(42
)Grants and miscellaneous revenue


228,264


159,948


68,316


43Total revenue


2,097,632


4,807,729


(2,710,097
)

(56
)Operating expenses:Research and development


5,750,494


9,625,947


(3,875,453
)

(40
)General and administrative


10,005,602


11,080,202


(1,074,600
)

(10
)Total operating expenses


15,756,096


20,706,149


(4,950,053
)

(24
)Loss from operations


(13,658,464
)

(15,898,420
)

(2,239,956
)

(14
)Other income, net


49,006


3,421,580


(3,372,574
)

(99
)Interest income, net


643,836


1,272,397


(628,561
)

(49
)Net loss


(12,965,622
)

(11,204,443
)

(1,761,179
)

(16
)Imputed and declared dividends on preferred stock





(23,335
)

23,335


100Net loss attributable to common stockholders

$
(12,965,622
)
$
(11,227,778
)
$
(1,737,844
)

(15
)%


50

---



Table of Contents

Revenue

Our revenue consists of license fees, milestone payments, and amounts received from collaborative research and development arrangements
and grants.

Our
total revenue decreased $2.7 million or 56% for the year ended December 31, 2008, as compared to fiscal 2007 due to decreases in milestone payments and revenue under
collaborative research and development arrangements, offset partially by an increase in grants and other revenue.

The
$2.0 million decrease in license fees and milestone payments for the year ended December 31, 2008, as compared to fiscal 2007 was primarily due to the recognition of a
$2.0 million milestone payment during fiscal 2007, resulting from the achievement of a clinical milestone by Merck for the filing of an investigational new drug application for the second Merck
product in a major market. Under our agreement with Merck, we may receive additional future milestone payments linked to the successful development of a product. Revenue from other license agreements
remained consistent during the years ended December 31, 2008 and 2007.

The
$776,000 decrease in revenue under collaborative research and development arrangements during the year ended December 31, 2008, as compared to the 2007 fiscal year, was due to
an $368,000 decrease in Wyeth billings based on our collaborative agreement related to the commercialization of the Elgen device, and $408,000 in lower Merck collaborative research billings during
2008 as compared to 2007. Billings from research and development work performed pursuant to the Wyeth and Merck agreements are recorded as revenue as the related research expenditures are incurred.
Revenues from collaborative research and development arrangements are expected to decline in 2009, as Wyeth continues to evaluate internal strategic options prior to initiating further development of
electroporation-based infectious disease programs. Under our research and collaboration agreement with Merck, we have provided the majority of the required device development for use in their clinical
trials. Development activities for Merck will be limited until trial results are obtained.

The
$68,000 increase in grant and miscellaneous revenue was due to more revenue recognized from U.S. Army grants during fiscal 2008 as compared to fiscal 2007. On September 26,
2008, we received a new contract for $933,000 from the Department of Defense (U.S. Army) to continue research and development of DNA-based vaccines delivered via our proprietary
electroporation system. The contract, titled "Design and Engineering of the Elgen Gene Delivery System for Screening and Validation of Vaccine Candidates of Military Relevance," will run through May
2010. This project is focused on identifying DNA vaccine candidates with the potential to provide rapid, robust immunity to protect against bio-warfare and bioterror attacks.

During
the years ended December 31, 2008 and 2007, we recognized revenue of $135,000 and $159,000, respectively, attributable to the operations of our Norwegian subsidiary, Inovio
AS, which amounted to
approximately 6% and 3% of our total revenue. Inovio AS' revenue primarily consists of amounts received from grants and licensing revenue.

Research and Development Expenses

The $3.9 million decrease in research and development expenses for the year ended December 31, 2008, as compared to
fiscal 2007, was primarily due to a decrease in clinical trial expenses associated with patient enrollment, clinical site costs, data collection and monitoring costs related to the discontinued SECTA
clinical trials. Additional decreases are associated with reduced use of consulting and advisory services, offset by higher labor and other development costs associated with expansion of
in-house engineering and research expertise. Research and development expenses attributable to Inovio AS were $751,000 and $697,000 for the years ended December 31, 2008 and 2007,
respectively.

Our
research and development activities reflect our efforts to advance our products through the various stages of product development. The expenditures that will be necessary to execute
our

51

---



Table of Contents

development
plans are subject to numerous uncertainties, which may affect our research and development expenditures and capital resources. Even if earlier results are positive, we may obtain different
results in later stages of development, which could impact our development expenditures for a particular product. Although we spend a considerable amount of time planning our development activities,
we may be required to alter our plan based on new circumstances or events. Any deviation from our plan may require us to incur additional expenditures or accelerate or delay the timing of our
development spending.

General and Administrative Expenses

General and administrative expenses include business development expenses and the amortization of intangible assets. The
$1.1 million decrease in general and administrative expenses for the year ended December 31, 2008, as compared to fiscal 2007, was primarily due to a decrease in outside consulting and
advisory services related to partnering our SECTA therapy program as well as a decrease in personnel costs and employee stock-based compensation expense, offset by increased legal fees related to the
execution of the definitive merger agreement with VGX as well as other corporate matters. General and administrative costs attributable to Inovio AS were $150,000 and $84,000 for the years ended
December 31, 2008 and 2007, respectively.

Stock-based Compensation.

Stock-based compensation cost is measured at the grant date, based on the fair value of the award reduced by estimated forfeitures, and
is recognized as expense over the employee's requisite service period. Total compensation cost under SFAS No. 123(R) for our stock plans for the years ended December 31, 2008 and 2007
was $1.0 million and $1.6 million, of which $286,000 and $354,000 was included in research and development expenses and $746,000 and $1.2 million was included in general and
administrative expenses, respectively. At December 31, 2008, there was $752,000 of total unrecognized compensation cost, related to unvested stock options, which we expect to recognize over a
weighted-average period of one year, as compared to $1.3 million for the year ended December 31, 2007. Total stock-based compensation for options granted to non-employees for
the years ended December 31, 2008 and 2007 was $58,000 and $119,000, respectively.

Other Income/(Expense)

We recorded other income (expense) for the years ended December 31, 2008 and 2007 of $49,000 and $3.4 million,
respectively. The decrease in other income (expense) is primarily due to the revaluation of registered common stock warrants issued by us in October 2006 and August 2007. We are required to revalue
the warrants at each balance sheet date to fair value. If unexercised, the warrants will expire in October 2011 and August 2012, respectively.

Interest Income/(Expense)

Interest income (expense) for the years ended December 31, 2008 and 2007 was $644,000 and $1.3 million, respectively. The
decrease in interest and other income for fiscal 2008, as compared to fiscal 2007, was primarily due to a lower cash and investments balance and lower average interest rate.

Imputed and Declared Dividends on Preferred Stock

The holders of our Series C Preferred Stock were entitled to receive an annual dividend at a rate of 6%, in shares of common
stock or cash, payable quarterly, through May 20, 2007. As part of this dividend, we paid cash of $23,000 during fiscal 2007 to holders of our Series C Preferred Stock. No dividends were
paid to holders of our Series C Preferred Stock during the year ended December 31, 2008.

52

---



Table of Contents

Income Taxes

Since inception, we have incurred operating losses and accordingly have not recorded a provision for income taxes for any of the
periods presented. As of December 31, 2008, we had net operating loss carry forwards for federal and state income tax purposes of approximately $59.4 million and $58.0 million,
respectively. We also had federal and state research and development tax credits of approximately $1.2 million and $1.5 million, respectively. If not utilized, the net operating losses
and credits will begin to expire in 2013. Utilization of net operating losses and credits are subject to a substantial annual limitation due to ownership change limitations provided by the Internal
Revenue Code of 1986, as amended.

Comparison of Years Ended December 31, 2007 and 2006

The audited consolidated financial data for the years ended December 31, 2007 and December 31, 2006 is presented in the
following table and the results of these two periods are used in the discussion thereafter.

December 31,
2007

December 31,
2006

Increase/
(Decrease)
$

Increase/
(Decrease)
%Revenue:License fee and milestone payments

$
2,793,478

$
1,337,105

$
1,456,373


109
%Revenue under collaborative research and development arrangements


1,854,303


962,207


892,096


93Grants and miscellaneous revenue


159,948


1,168,866


(1,008,918
)

(86
)Total revenue


4,807,729


3,468,178


1,339,551


39Operating expenses:Research and development


9,625,947


8,509,785


1,116,162


13General and administrative


11,080,202


8,304,587


2,775,615


33Total operating expenses


20,706,149


16,814,372


3,891,777


23Loss from operations


(15,898,420
)

(13,346,194
)

2,552,226


19Other income, net


3,421,580


320,706


3,100,874


967Interest income, net


1,272,397


681,546


590,851


87Net loss


(11,204,443
)

(12,343,942
)

1,139,499


9Imputed and declared dividends on preferred stock


(23,335
)

(2,005,664
)

1,982,329


99Net loss attributable to common stockholders

$
(11,227,778
)
$
(14,349,606
)
$
3,121,828


22
%


Revenue

Our revenue consists of license fees, milestone payments, and amounts received from collaborative research and development arrangements
and grants.

Our
total revenue increased $1.3 million or 39% for the year ended December 31, 2007, as compared to fiscal 2006 due to significant increases in license fees, milestone
payments and revenue under
collaborative research and development arrangements, offset partially by a large decrease in grant revenue.

The
$1.5 million increase in license fees and milestone payments for the year ended December 31, 2007, as compared to fiscal 2006 was primarily due to the recognition of a
$2.0 million milestone payment during fiscal 2007, resulting from the achievement of a clinical milestone by Merck for the

53

---



Table of Contents

filing
of an investigational new drug application for the second Merck product in a major market. Under our agreement with Merck, we may receive additional future milestone payments linked to the
successful development of a product. We also recognized $175,000 in higher Wyeth license fee revenue in fiscal 2007 as compared to fiscal 2006, and acquired license agreements to our
GeneSwitch® technology resulting in increased revenue of $130,000 during fiscal 2007. These increases were partially offset by no Valentis license fee revenue during fiscal 2007 as
compared to $480,000 during fiscal 2006, and decreased revenue of $344,000 from the Merck licensing agreement in 2007 as this agreement was fully amortized in May 2007.

The
$892,000 increase in revenue under collaborative research and development arrangements during the year ended December 31, 2007, as compared to the 2006 fiscal year, was due to
an $814,000 increase in Wyeth billings based on our collaborative agreement related to the commercialization of the Elgen device, and $78,000 in higher Merck collaborative research billings during
2007 as compared to 2006. Billings from research and development work performed pursuant to the Wyeth and Merck agreements are recorded as revenue as the related research expenditures are incurred.

The
$1.0 million decrease in grant and miscellaneous revenue was due to minimal revenue recognized from U.S. Army grants during fiscal 2007 as compared to $899,000 during fiscal
2006 and a reduction in revenue recognized by Inovio AS from our European Union grant due to the timing of work performed.

During
the years ended December 31, 2007 and 2006, we recognized revenue of $159,000 and $1.1 million, respectively, attributable to the operations of Inovio AS, a
Norwegian company that we acquired in January 2005, which amounted to approximately 3% and 33% of our total revenue. Inovio AS' revenue primarily consists of amounts received from grants and licensing
revenue.

Research and Development Expenses

The $1.1 million increase in research and development expenses for the year ended December 31, 2007, as compared to
fiscal 2006, was primarily due to an increase in clinical trial expenses associated with patient enrollment, clinical site costs, data collection and monitoring costs, and increased costs related to
the use of Clinical Research Organization ("CROs") and Clinical Research Associates ("CRAs") related to our SECTA therapy program. Additional increases are associated with the expansion of our
in-house engineering and research expertise, increased consulting services, increased lab supplies related to our existing and next generation programs, increased outside lab testing
performed, and expensed inventory costs. These increases were partially offset by a $672,000 decrease in expenses attributable to Inovio AS totaling $697,000 and $1.4 million during the years
ended December 31, 2007 and 2006, respectively.

Our
research and development activities reflect our efforts to advance our products through the various stages of product development. The expenditures that will be necessary to execute
our development plans are subject to numerous uncertainties, which may affect our research and development expenditures and capital resources. Even if earlier results are positive, we may obtain
different results in later stages of development, which could impact our development expenditures for a particular product. Although we spend a considerable amount of time planning our development
activities, we may be required to alter our plan based on new circumstances or events. Any deviation from our plan may require us to incur additional expenditures or accelerate or delay the timing of
our development spending.

General and Administrative Expenses

General and administrative expenses include business development expenses and the amortization of intangible assets. The
$2.8 million increase in general and administrative expenses for the year ended December 31, 2007, as compared to fiscal 2006, was primarily due to an increase in outside consulting

54

---



Table of Contents

services
related to partnering our SECTA therapy program, an increase in investor relations services associated with expanding our DNA and gene therapy program, an increase in personnel expenses
associated with expanding our in-house expertise, increased legal fees associated with intellectual property and business development efforts, and increased legal, accounting and auditing
fees primarily attributable to matters related to correspondence with the SEC. In addition, we recorded a reduction of goodwill in 2007 related to the realization of foreign net operating loss
carryforwards. General and administrative costs attributable to Inovio AS were $84,000 for the year ended December 31, 2007 and were insignificant for the year ended December 31, 2006.

Stock-based Compensation.

Effective January 1, 2006, we adopted Statement of Financial Accounting Standards ("SFAS") No. 123(R), Stock-based Payment, and
elected to adopt the modified prospective application method. SFAS No. 123(R) requires us to use a
fair-value based method to account for stock-based compensation. Accordingly, stock-based compensation cost is measured at the grant date, based on the fair value of the award reduced by
estimated forfeitures, and is recognized as expense over the employee's requisite service period. Total compensation cost under SFAS No. 123(R) for our stock plans for the years ended
December 31, 2007 and 2006 was $1.6 million and $1.3 million, of which $354,000 and $423,000 was included in research and development expenses and $1.2 million and $921,000
was included in general and administrative expenses, respectively. At December 31, 2007, there was $1.3 million of total unrecognized compensation cost, related to unvested stock
options, which we expect to recognize over a weighted-average period of one year, as compared to $947,000 for the year ended December 31, 2006. Total stock-based compensation for options
granted to non-employees for the years ended December 31, 2007 and 2006 was $119,000 and $203,000, respectively.

Other Income/(Expense)

We recorded other income (expense) for the years ended December 31, 2007 and 2006 of $3.4 million and $321,000,
respectively. The increase in other income (expense) is primarily due to the revaluation of registered common stock warrants issued by us in October 2006 and August 2007. We are required to revalue
the warrants at each balance sheet date to fair value. If unexercised, the warrants will expire in October 2011 and August 2012, respectively.

Interest Income/(Expense)

Interest income (expense) for the years ended December 31, 2007 and 2006 was $1.3 million and $682,000, respectively. The
increase in interest income for fiscal 2007, as compared to fiscal 2006, was primarily due to a larger cash and short-term investments balance and higher average interest rate.

Imputed and Declared Dividends on Preferred Stock

The former holders of our Series A and B Preferred Stock received an annual dividend at a rate of 6%, in shares of common stock
or cash, payable quarterly through September 30, 2006. As a result, no dividends were paid to Series A or B Preferred Stock holders during the year ended December 31, 2007. We
paid cash of $345 and issued a total of 2,871 shares valued at $8,000 to the former holders of our Series A Preferred Stock, and we paid $15,000 in cash to the former holders of our
Series B Preferred Stock during fiscal 2006.

55

---





Table of Contents

The holders of our Series C Preferred Stock were entitled to receive an annual dividend at a rate of 6%, in shares of common stock or cash, payable
quarterly, through May 20, 2007. As part of this dividend, we paid cash of $23,000 during fiscal 2007 to holders of our Series C Preferred Stock. We paid cash $117,000 during fiscal 2006
to holders of our Series C Preferred Stock and accrued $15,000 for certain holders of our Series C Preferred Stock who participated in an equity financing we completed in October 2006.

During
2006, we recorded an imputed dividend charge of $1.9 million during the three months ended December 31, 2006, related to the investors who converted
$1.2 million of their Series C Preferred Stock investment into 473,744 shares of our common stock as part of our private placement closed in October 2006. This imputed dividend charge
was calculated using guidance contained in Emerging Issues Task Force ("EITF") Issue No. 00-27,Application of Issue No. 98-5 to Certain
Convertible Instruments. As part of this private placement, these investors received 304,450 additional shares of our common stock, as compared to the number of shares of our
common stock into which their existing Series C Preferred Stock could have been converted under the original terms of the Series C Preferred Stock. Under EITF Issue
No. 00-27, this incremental number of shares of our common stock was multiplied by the price of our common stock on the commitment date of the original Series C Preferred
Stock issuance, or $6.08 per share, to calculate the $1.9 million imputed dividend charge associated with this beneficial conversion.

Income Taxes

Since inception, we have incurred operating losses and accordingly have not recorded a provision for income taxes for any of the
periods presented. As of December 31, 2007, we had net operating loss carry forwards for federal and state income tax purposes of approximately $55.9 million and $50.8 million,
respectively. We also had federal and state research and development tax credits of approximately $714,000 and $989,000, respectively. If not utilized, the net operating losses and credits will begin
to expire in 2013. Utilization of net operating losses and credits are subject to a substantial annual limitation due to ownership change limitations provided by the Internal Revenue Code of 1986, as
amended

Liquidity and Capital Resources

Historically, our primary uses of cash have been to finance research and development activities including clinical trial activities in
the oncology, DNA vaccines and other immunotherapy areas of our business. Since inception, we have satisfied our cash requirements principally from proceeds from the sale of equity securities.

Recent Sales of Equity Securities

In May 2007, we completed a registered equity financing wherein we issued and sold 4,595,094 shares of our common stock for $3.52 per
share, resulting in aggregate cash proceeds of $16.2 million, prior to offering expenses of $110,000.

Working Capital and Liquidity

As of December 31, 2008, we had working capital of $554,000, as compared to $25.6 million as of December 31, 2007.
The decrease in working capital during the year ended December 31, 2008 was partly due to expenditures related to our research and development activities, as well as various general and
administrative expenses related to consultants, legal, accounting and audit, and corporate development. In addition, a substantive reduction in working capital was due to the reclassification of the
fair value of our auction rate securities, or ARS, from current to non-current investments in 2008, due to the illiquid state of these ARS. Management believes that Inovio's cash and cash
equivalents at

56

---



Table of Contents

December 31,
2008 are sufficient to meet its planned working capital needs through December 31, 2009. To continue its product development Inovio plans to raise additional working capital
through equity or debt financings.

Our
ARS are AAA-rated municipal debt obligations with a long-term maturity and an interest rate that is reset in short-term intervals through
auctions. Due to conditions in the global credit markets, in 2008, these securities, representing a par value of $13.6 million, had insufficient demand resulting in multiple failed auctions. As
a result, these affected securities are currently not liquid and the interest rates have been reset to predetermined higher rates.

In
December 2008, we, via our wholly-owned subsidiary Genetronics, Inc., or "Genetronics", which holds the ARS, accepted an offer of ARS Rights from UBS. The ARS Rights permit us
to require UBS to purchase our ARS at par value at any time during the period of June 30, 2010 through July 2, 2012. If we do not exercise our ARS Rights, the ARS will continue to accrue
interest as determined by the auction process or the terms of the ARS if the auction fails. If the ARS Rights are not exercised before July 2, 2012 they will expire and UBS will have no further
obligation to buy our ARS. UBS has the discretion to purchase or sell our ARS at any time without prior notice so long as we receive a payment at par upon any sale or disposition. UBS will only
exercise its discretion to purchase or sell our ARS for the purpose of restructurings, dispositions or other solutions that will provide us with par value for our ARS. As a condition to accepting the
offer of ARS Rights, we released UBS from all claims except claims for consequential damages relating to its marketing and sales of ARS. We also agreed not to serve as a class representative or
receive benefits under any class action settlement or investor fund.

In
conjunction with the acceptance of the ARS Rights, we also amended our existing loan agreement with UBS Bank USA, increasing the existing credit line up to $12.1 million, with
the ARS pledged as collateral. The loan will be treated as a "no net cost loan", as it will bear interest at a rate equal to the average rate of interest paid to Genetronics on the pledged ARS, and
the net interest cost to Genetronics will be zero. The Company fully drew down on the line of credit in December 2008.

Typically
the fair value of ARS approximates par value due to the frequent resets through the auction process. While we continue to earn interest on our ARS at the maximum contractual
rates, these investments are not currently trading and therefore do not currently have a readily determinable market value. Accordingly, the estimated fair value of the ARS no longer approximates par
value. We have used a discounted cash flow model to determine the estimated fair value of our investment in ARS and our ARS Rights as of December 31, 2008. The assumptions used in preparing the
discounted cash flow model include estimates for interest rates, timing and amount of cash flows and expected holding period of the ARS and ARS Rights.

We
elected to measure the ARS Rights under the fair value option of SFAS No. 159,The Fair Value Option for Financial Assets and Financial
LiabilitiesIncluding an amendment to FASB Statement No. 115,to mitigate volatility in reported earnings due to their linkage to the ARS, and recognized a
gain of approximately $4.3 million and recorded a corresponding long-term investment. Reflecting our intent to exercise the ARS Rights during the period of June 30, 2010
through July 2, 2012, we transferred our ARS from investments available-for-sale to trading securities. As a result of this transfer and as we no longer intend to hold
the ARS until the fair value recovers, we recognized an other-than-temporary impairment loss of approximately $4.4 million, representing a reversal of the related
temporary valuation allowance that was previously recorded in other comprehensive loss. We believe this loss is primarily attributable to the limited liquidity of these investments and have no reason
to believe that any of the underlying issuers are presently at risk of default. The recording of the fair value of the ARS Rights and the recognition of the
other-than-temporary impairment loss resulted in a net impact to the Consolidated Statement of Operations for the year ended December 31, 2008 of approximately $99,000,
which was recorded as other expense.

57

---



Table of Contents

As
of December 31, 2008, we had an accumulated deficit of $152.8 million. We have operated at a loss since 1994, and we expect this to continue for some time. The amount of
the accumulated deficit will continue to increase, as it will be expensive to continue research and development efforts. If these activities are successful and if we receive approval from the FDA to
market equipment, then even more funding will be required to market and sell the equipment. The outcome of the above matters cannot be predicted at this time. We are evaluating potential partnerships
as an additional way to fund operations. We will continue to rely on outside sources of financing to meet our capital needs beyond next year.

Our
long-term capital requirements will depend on numerous factors including:



The
ability to generate substantial funding to continue research and development activities, preclinical and clinical studies and clinical trials and manufacturing, scale-up,
and selling, general, and administrative activities is subject to a number of risks and uncertainties and will depend on numerous factors including:



The
global financial markets have recently experienced significant limits on available credit for companies of all sizes, and extreme volatility in market prices limiting the ability of
companies to raise capital at favorable prices, if at all. This lack of liquidity and the consistently changing market conditions are currently impacting our ARS as discussed above, as well as
creating significant fluctuations in the market price of our common stock. We cannot project how long such conditions will last in the global financial markets, and we cannot guarantee that additional
fundingwhether via incurrence of debt or equity saleswill be available when needed or on favorable terms. If it is not, we will be required to scale back our research and
development programs, preclinical studies and clinical trials, and selling, general, and administrative activities, or otherwise reduce or cease operations and our business and financial results and
condition would be materially adversely affected.

58

---



Table of Contents

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on
our financial condition, changes in financial condition, revenue, expenses, and results of operations, liquidity, capital expenditures or capital resources.

Contractual Obligations

On December 19, 2008, we amended our existing loan agreement with UBS Bank USA, increasing the existing credit line up to
$12.1 million, with our Auction Rate Securities pledged as collateral. We fully drew down on the line of credit on December 23, 2008. Advances under the Line of Credit bear interest at
LIBOR plus 1.00% (the "Spread Over LIBOR"). UBS may change the Spread Over LIBOR at its discretion when the Collateral consisting of ARS may be sold, exchanged or otherwise conveyed by the Company for
gross proceeds that are, in the aggregate, not less than the par value of such securities. The loan will be treated as a "no net cost loan", as it will bear interest at a rate equal to the average
rate of interest paid to the Company on the pledged ARS, and the net interest cost to the Company will be zero.

As
of December 31, 2008, we did not have any other material long-term debt or other known contractual obligations, except for the operating lease for our facility,
which expires in February 2010, and operating leases for copiers, which expire in 2009 through 2011.

We
are contractually obligated to make the following operating lease payments as of December 31, 2008:

Total

Less than
1 year

1 - 3 years

3 - 5 years

More than
5 yearsOperating lease obligations

$
683,617

$
539,825

$
143,792

$


$



ITEM 7A.    QUALITATIVE AND QUANTITATIVE DISCLOSURES ABOUT MARKET RISK

Interest Rate Risk

Market risk represents the risk of loss that may impact our consolidated financial position, results of operations or cash flows due to
adverse changes in financial and commodity market prices and rates. We are exposed to market risk primarily in the area of changes in United States interest rates and conditions in the credit markets,
and the recent and consistent fluctuations in interest rates and availability of funding in the credit markets primarily impacts the performance of our investments. We do not have any material foreign
currency or other derivative financial instruments. Under our current policies, we do not use interest rate derivative instruments to manage exposure to interest rate changes. We attempt to increase
the safety and preservation of our invested principal funds by limiting default risk, market risk and reinvestment risk. We mitigate default risk by investing in investment grade securities.

Fair Value Measurements

All of our investment securities are classified as trading securities and are reported on the consolidated balance sheet at market
value. Our investment securities consist of high-grade (AAA rated) auction rate securities ("ARS") issued primarily by municipalities, with a par value of approximately
$13.6 million. The negative conditions in the global credit markets have prevented some investors from liquidating their holdings, including their holdings of ARS. In early March 2008, we were
informed that there was insufficient demand at auction for all six of our high-grade ARS. As a result, these affected securities are currently not liquid, and we could be required to hold
them until they are redeemed by the issuer or to maturity. In the event we need to access the funds that are in an

59

---



Table of Contents

illiquid
state, we will not be able to do so without a loss of principal, until a future auction on these investments is successful, the securities are redeemed by the issuer or they mature.

In
December 2008, we, via our wholly-owned subsidiary Genetronics, Inc., or "Genetronics", which holds the ARS, accepted an offer of ARS Rights from our investment advisor, UBS
Financial Services, Inc., a subsidiary of UBS AG, or UBS. The ARS Rights permit us to require UBS to purchase our ARS at par value at any time during the period of June 30, 2010 through
July 2, 2012. If we do not exercise our ARS Rights, the ARS will continue to accrue interest as determined by the auction process or the terms of the ARS if the auction fails. If the ARS Rights
are not exercised before July 2, 2012 they will expire and UBS will have no further obligation to buy our ARS. UBS has the discretion to purchase or sell our ARS at any time without prior
notice so long as we receive a payment at par upon any sale or disposition. UBS will only exercise its discretion to purchase or sell our ARS for the purpose of restructurings, dispositions or other
solutions that will provide us with par value for our ARS. As a condition to accepting the offer of ARS Rights, we released UBS from all claims except claims for consequential damages relating to its
marketing and sales of ARS. We also agreed not to serve as a class representative or receive benefits under any class action settlement or investor fund.

In
conjunction with the acceptance of the ARS Rights, we also amended our existing loan agreement with UBS Bank USA, increasing the existing credit line up to $12.1 million, with
the ARS pledged as collateral. The loan will be treated as a "no net cost loan", as it will bear interest at a rate equal to the average rate of interest paid to us on the pledged ARS, and our net
interest cost will be zero. We fully drew down on the line of credit in December 2008.

In
the event we need to access the funds that are in an illiquid state, we will not be able to do so without the possible loss of principal, until a future auction for these investments
is successful or they are redeemed by the issuer or they mature.

Foreign Currency Risk

We have operated primarily in the United States and most transactions during the year ended December 31, 2008, have been made in
U.S. dollars. Accordingly, we have not had any material exposure to foreign currency rate fluctuations, nor do we have any foreign currency hedging instruments in place.

We
have conducted clinical trials in Europe in conjunction with several Clinical Research Organizations ("CRO's"), where we have clinical sites being monitored by Clinical Research
Associates ("CRA's"). While invoices relating to these clinical trials are generally denominated in U.S. dollars, our financial results could be affected by factors such as inflation in foreign
currencies, in relation to the U.S. dollar, in markets where these vendors have assisted us in conducting these clinical trials.

Certain
transactions related to our Company and our subsidiaries Inovio AS and Inovio Asia Pte. Ltd. ("IAPL"), are denominated primarily in foreign currencies,
including Euros, British Pounds, Canadian Dollars, Norwegian Kroner, Swedish Krona, and Singapore Dollars. As a result, our financial results could be affected by factors such as changes in foreign
currency exchange rates or weak economic conditions in foreign markets where Inovio conducts business, including the impact of the existing crisis in the global financial markets in such countries and
the impact on both the U.S. dollar and the noted foreign currencies.

We
do not use derivative financial instruments for speculative purposes. We do not engage in exchange rate hedging or hold or issue foreign exchange contracts for trading purposes.
Currently, we do not expect the impact of fluctuations in the relative fair value of other currencies to be material in 2009.

60

---



Table of Contents

ITEM 8.    FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

The information required by this Item 8 is incorporated by reference to our Consolidated Financial Statements and the Report of
Independent Registered Public Accounting Firm beginning at page F-1 of this report.

ITEM 9.    CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.

ITEM 9A.    CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

As of December 31, 2008, an evaluation was carried out by the company, with the participation of our Chief Executive Officer and
Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934). Based upon that
evaluation, our Chief Executive Officer and Chief Financial Officer concluded that these disclosure controls and procedures were effective as of the end of the period covered by this report.

Internal Control Over Financial Reporting

Management's Annual Report on Internal Control Over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in
Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934. Our internal control over financial reporting is a process designed under the supervision of our
Chief Executive Officer and Chief Financial Officer to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our financial statements for external
purposes in accordance with U.S. generally accepted accounting principles.

As
of December 31, 2008, management, with the participation of the Chief Executive Officer and Chief Financial Officer, assessed the effectiveness of our internal control over
financial reporting based on the criteria for effective internal control over financial reporting established in "Internal ControlIntegrated Framework," issued by the Committee of
Sponsoring Organizations ("COSO") of the Treadway Commission. Based on the assessment, management determined that we maintained effective internal control over financial reporting as of
December 31, 2008.

Attestation Report of the Registered Public Accounting Firm

This annual report does not include an attestation report of the company's registered public accounting firm regarding internal control
over financial reporting. Management's report was not subject to attestation by the company's registered public accounting firm pursuant to temporary rules of the Securities and Exchange Commission
that permit the company to provide only management's report in this annual report.

Changes in Internal Control over Financial Reporting

There have not been any changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and
15d-15(f) under the Securities Exchange Act of 1934) that occurred during the fourth quarter of our fiscal year ended December 31, 2008, that have materially affected, or are
reasonably likely to materially affect, our internal control over financial reporting.

ITEM 9B.    OTHER INFORMATION

None.

61

---



Table of Contents

PART III

ITEM 10.    DIRECTORS AND EXECUTIVE OFFICERS OF THE COMPANY

DIRECTORS AND EXECUTIVE OFFICERS

Our executive officers and directors, and their ages and positions are as follows:

Name

Age

PositionAvtar Dhillon, M.D.


48

Director, and President and Chief Executive OfficerJames L. Heppell, LLB(1)(2)


52

Director, and Chairman of the BoardSimon X. Benito(1)(2)(3)


63

DirectorTazdin Esmail(1)(2)(3)


59

DirectorRiaz Bandali(2)(3)


39

DirectorRobert W. Rieder(1)(2)


61

DirectorStephen Rietiker, M.D(3)


51

DirectorPatrick Gan


50

DirectorPeter D. Kies


45

Chief Financial Officer and HR ManagerMichael Fons, Ph.D.


48

Vice President, Corporate DevelopmentPunit Dhillon.


28

Vice President, Finance and Operations


---

AVTAR DHILLON, M.D.joined Inovio as the President and Chief Executive Officer, and as a director, in October 2001. Prior to joining
Inovio, Dr. Dhillon was engaged by MDS Capital Corp. (now Lumira Capital Corp.), one of North America's leading healthcare venture capital organizations, as a consultant in July 1998, and
subsequently became Investment Manager in August 1999 and Vice President in 2000. In July 1989, Dr. Dhillon started a medical clinic and subsequently practiced family medicine for over
12 years. From March 1997 to July 1998, Dr. Dhillon served as consultant to Cardiome Pharmaceuticals., a biotechnology company listed on NASDAQ National Market and the Toronto Stock
Exchange. Dr. Dhillon has a Bachelor of Science, honors degree in physiology and M.D. degree from the University of British Columbia. Dr. Dhillon is also a director of Protox
Therapeutics, a publicly traded specialty pharmaceutical company and Auricle Biomedical, a capital pool company.

JAMES L. HEPPELL, L.L.B.has been a director of Inovio since September 1994, Interim Chairman of the Board from September 1999 to March
2001, and Chairman of the Board since March 2001. Mr. Heppell is President and Fund Manager of BC Advantage Funds (VCC) Ltd., a venture fund that invests in early stage life science and
technology companies located in British Columbia. Mr. Heppell is a director of Protox Therapeutics and Urodynamix Technologies, and a director of a number of private life science companies. In
addition to his L.L.B., Mr. Heppell has a Bachelor of Science degree in Microbiology from the University of British Columbia. After joining the Bar, Mr. Heppell was seconded to the
British Columbia Securities Commission to work as a Filings Analyst for six months. He has been a member of the Securities Policy Advisory Committee to the Commission and Chairman of the Securities
Section of the Canadian Bar Association (British Columbia Branch).

SIMON X. BENITOhas been a director of Inovio since December 2003. Prior to his retirement, Mr. Benito had a successful and
extensive career serving several health care companies in senior executive positions, including 25 years at Merck & Co, Inc. His most recent positions included Senior Vice
President, Merck Vaccine Division; Executive Vice President, Merck-Medco Managed Care; and Executive Director and Vice President, Merck Human Health, Japan. In addition, Mr. Benito was a Fellow
of the Institute of Chartered Accountants in England and Wales for over thirty years until his

62

---



Table of Contents

retirement
in 1999. Since April 2005, Mr. Benito has served as a director of DURECT Corporation, a publicly traded specialty pharmaceutical company.

TAZDIN ESMAILhas been a director of Inovio since August 2000. Mr. Esmail is the co-founder, former director, President
and Chief Executive Officer of Protox Therapeutics Inc., a company that is developing targeted proteins for the treatment of cancer. Mr. Esmail also served as a director of BC Advantage
Funds (VCC) Ltd., a venture fund that invests in early stage life science and technology companies located in British Columbia. He is also the Founder, and former Chairman of the Board,
Director, President and Chief Executive Officer of Forbes Medi-Tech Inc., a company listed on the Toronto Stock Exchange and the NASDAQ National Market. Mr. Esmail is a
former Vice-President of operations of QLT Inc., a Toronto Stock Exchange and the NASDAQ National Market listed biotechnology company, and a former Director of Pharmaceutical
Operations for the American Home Products division of American Cyanamid (now Wyeth), where he also managed the company's oncology and hospital products division.

RIAZ BANDALIhas served as a director of Inovio since August 2004. Mr. Bandali currently serves as Senior Vice President, Strategy
and Business Development for MDS Analytical Technologies, a division of MDS Inc., a company listed on the New York and Toronto Stock Exchanges. Prior to joining MDS Analytical Technologies, he
spent four years as Senior Vice-President, Business Development and Operations, at MDS Sciex, another division of MDS Inc. Prior to joining MDS Sciex, he served as
Vice-President and Venture Partner with MDS Capital, which he joined in late 1994. Mr. Bandali has also served on the boards of several health and life sciences companies in the
United States and Canada. Prior to joining MDS Capital, he served as Chief Financial Officer and Senior Vice-President, Business Development for Apoptogen Inc., and Transplantation
Technologies Inc. During the early 1990s, he was a managing principal at a computer network consulting firm. Mr. Bandali has a Bachelor of Science from the University of British Columbia
in Vancouver, where he majored in Microbiology, and a Masters of Business Administration from McGill University in Montreal.

ROBERT W. RIEDERhas served as a director of Inovio since May 2007. Mr. Rieder is currently the Chief Executive Officer and
Chairman of the Board of Directors of Cardiome Pharma Corp. (NASDAQ: CRME). Mr. Rieder has had a successful and extensive career in venture capital and in operational management. Prior to
joining Cardiome, Mr. Rieder was vice-president at MDS Ventures Pacific Inc., an affiliate of MDS Capital Corp., and has served as a director for multiple public and private
technology companies. Mr. Rieder received his Masters of Business Administration from the University of Western Ontario.

STEPHEN RIETIKER, M.D., has served as a director of Inovio since February 2008. Dr. Rietiker has management and board experience in
both publicly held and privately held healthcare companies. Since 2007, Dr. Rietiker has served as Chairman of AurigaVision AG and has served as a senior advisor to Brown Brothers
Harriman & Co.'s corporate finance team since 2004. From 2004 to 2006, Dr. Rietiker served as Executive Director and CEO for IMI Intelligent Medical Implants AG, and served from
2003 to 2004 as CEO and a director of Pendragon Medical Ltd. He has held positions with Roche, Boehringer Mannheim, Schering Plough, Covance and Sulzer Medica AG (later Centerpulse AG). Since
2003, he has been actively involved as executive director and investor in various start-ups. He is also a director of Prospero Minerals Corporation and Contract Farming India AG. In 2007,
he founded AurigaVision AG based in Zug, Switzerland, which serves as a platform with the ultimate goal to turn visions and technologies into successful businesses.

PATRICK GAN,was appointed a director of Inovio in May 2008. Mr. Gan is currently Managing Partner of ATP Capital Pte Ltd, a
Singapore based institutional fund, which is one of Inovio's stockholders. Mr. Gan has over 23 years of working experience in the healthcare sector where he held a number of positions in
senior management, sales, marketing and project management. Prior to joining ATP in October 2005, Mr. Gan was Chief Executive Officer of Tiger Airways since January 2004. From January through
December 2003, Mr. Gan invested personally with various small business

63

---



Table of Contents

ventures.
From January 2001 to December 2002, Mr. Gan served as the Area Director for the Asia Pacific region for Novartis, and served from 1998 to 2000 as Managing Director of Asia Pacific
region of Glaxo Wellcome and subsequently as Director of Integration based in Singapore for the merger with Smith Kline in the Asia Pacific region. In previous positions, Mr. Gan was with Roche
Pharmaceuticals & Chemicals, first in Singapore, and subsequently in Switzerland (the company's headquarters) and China, where he was responsible for a number of different areas, from marketing
the implementation of the company's MedNet IT system to developing longer-term business plans for the different markets. Mr. Gan holds a B.Sc. in Pharmacy from the National
University of Singapore and received his Masters of Business Administration from the University of Warwick.

PETER KIEShas been employed by Inovio as Chief Financial Officer since June 2002. For the 15 years prior to joining Inovio,
Mr. Kies acquired broad expertise in the functional and strategic management of biotechnology and high technology companies across the full spectrum of corporate growth, from Initial Public
Offering to profitability. From May 1996 until joining Inovio, he served as Chief Financial Officer for Newgen Results Corporation, and prior to that served as Controller for Cytel Corporation and as
an auditor for Ernst & Young LLP. Mr. Kies holds a B.S. in Business Administration from United States International University in San Diego, California.

MICHAEL FONS, PhD,was promoted by Inovio to Vice President of Corporate Development in August 2007. Dr. Fons joined Inovio as
Executive Director of Corporate Development in June 2004. In such capacity, he has been instrumental in defining Inovio's corporate strategy relating to DNA vaccines and DNA delivery, including
assisting in securing DNA-related license agreements, acquiring valuable intellectual property assets, and establishing a strong standard for the management of Inovio's corporate
relationships. Prior to joining Inovio, Dr. Fons held business development roles with Vical, GeneMedicine, and Valentis. He is an Adjunct Associate Professor of Microbiology and Immunology with
the University of Texas Medical Branch. Dr. Fons is a published author of 24 papers in scientific journals and numerous book chapters.

PUNIT DHILLONwas promoted by Inovio to Vice President, Finance and Operations in January 2008. Mr. Dhillon joined Inovio in
September 2003 and has played a vital role in various corporate finance projects, including management of financing transactions, as well as day-to-day management of
operational functions. Mr. Dhillon was most recently Executive Director of Finance and Operations. Prior to joining Inovio, he worked for a corporate finance law firm as a law clerk. He
previously worked with MDS Capital Corp. (now Lumira) and was a consultant to several early stage health and life-science companies where he
acquired broad experience in corporate management, finance and capital markets. Mr. Dhillon has a Bachelor of Arts, Honors, in Political Science and a minor in Business Administration from
Simon Fraser University. Mr. Dhillon is also a director of Auricle Biomedical, a capital pool company.

Certain Legal Proceedings

No directors, nominees or executive officers have been involved in the certain legal proceedings listed in Item 401 of
Regulation S-K.

Family Relationships

No family relationships exist between any of the directors or executive officers of Inovio except for that of Mr. Punit Dhillon,
Vice President Finance and Operations, who is the nephew of Inovio's Chief Executive Officer and director, Dr. Avtar Dhillon. Neither Mr. Dhillon nor Dr. Dhillon have been party
to any transaction requiring disclosure pursuant to Item 404(a) of Regulation S-K.

Committees of the Board of Directors and Attendance at Board Meetings

During the year ended December 31, 2008, the Board of Directors met ten times, the Audit Committee met six times, the Nomination
and Corporate Governance Committee met seven times and

64

---



Table of Contents

the
Compensation Committee met seven times. Each director attended at least 75% of the aggregate number of meetings held by (i) the Board of Directors and (ii) those committees of the
Board of Directors on which he served.



The functions of the Audit Committee include retaining our independent registered public accounting firm, reviewing its independence,
reviewing and approving the planned scope of our annual audit, reviewing and approving any fee arrangements with our independent registered public accounting firm, overseeing its audit work, reviewing
and pre-approving any non-audit services that may be performed by it, reviewing the adequacy of accounting and financial controls, reviewing our critical accounting policies
and reviewing and approving any related party transactions. The Board of Directors amended the charter for the Audit Committee on March 6, 2008, to better reflect the practices and
responsibilities of the Audit Committee. The Audit Committee's charter, a component of our corporate governance policy, is available separately on our website
at:http://media.corporate-ir.net/media_files/irol/10/105128/corpGov/AuditCommittee.pdf

The
members of the Audit Committee are Simon Benito (Chair), Riaz Bandali, Tazdin Esmail and Steven Rietiker. Each member of the Audit Committee is independent under the NYSE Amex
listing standards. The Board has determined that Mr. Benito is an "audit committee financial expert" as defined under Item 407(d)(5)(ii) of Regulation S-K under the
Securities Act of 1933, as amended (the "Securities Act").



The Compensation Committee determines the salary of the executive officers of Inovio, grants stock options under the 2007 Omnibus
Incentive Plan and performs such other functions regarding compensation as the Board of Directors may delegate. The Board of Directors amended the charter for the Compensation Committee on
March 27, 2008. The Compensation Committee's charter, a component of our corporate governance policy, is available separately on our website at: http://media.corporate-ir.net/media_files/irol/10/105128/corpGov/CompCommit.pdf.

The
members of the Compensation Committee are James L. Heppell (Chair), Simon Benito, Tazdin Esmail and Robert W. Rieder. Each member of the Compensation Committee is independent under
the NYSE Amex listing standards.



The Nomination and Corporate Governance Committee identifies and recommends candidates for election to the Board of Directors. It
advises the Board of Directors on all matters relating to directorship practices, including the criteria for selecting directors, policies relating to tenure and retirement of directors and
compensation and benefit programs for non-employee directors. While the Nomination and Corporate Governance Committee has not established any minimum criteria for serving as a director,
the Committee focuses on selecting individuals that have skill sets that augment the skill sets of the current directors and are most likely to assist in the building and success of Inovio. In
addition, the Committee believes it appropriate for at least one member of the Board of Directors to meet the criteria for an "audit committee financial expert," as defined by Securities and Exchange
Commission rules, that independent members of the board who serve on the audit committee are able to read and understand fundamental financial statements, including a balance sheet, income statement,
and cash flow statement and that at least a majority of the members of the Board of Directors meet the definition of "independent" under NYSE Amex rules.

The
Nomination and Corporate Governance Committee also makes recommendations relating to the duties and membership of committees of the Board of Directors, recommends processes to
evaluate the performance and contributions of individual directors and the Board of Directors as a whole,

65

---



Table of Contents

approves
procedures designed to provide that adequate orientation and training are provided to new members of the Board of Directors, consults with the Chief Executive Officer in the process of
recruiting new directors and assists in locating senior management personnel and selecting members for the scientific advisory board.

The
Nomination and Corporate Governance Committee has developed a policy to govern Inovio's approach to corporate governance issues and provides a forum for concerns of individual
directors about matters not easily or readily discussed in a full board meeting (e.g., the performance of management). Individual directors are entitled to engage outside advisors at the
expense of Inovio, with the prior approval of the Nomination and Corporate Governance Committee, and with the full knowledge of management. The Board of Directors amended the charter for the
Nomination and Corporate Governance Committee on March 27, 2008. The Nomination and Corporate Governance Committee's charter, a component of our corporate governance policy, is available
separately on our website at:http://media.corporate-ir.net/media_files/irol/10/105128/corpGov/NomandCorpGov.pdf

The
members of the Nomination and Corporate Governance Committee are Tazdin Esmail (Chair), Riaz Bandali, Simon Benito, James L. Heppell, and Robert W. Rieder. Each member of the
Nomination and Corporate Governance Committee is independent under the NYSE Amex listing standards.

Corporate Governance

Inovio's Corporate Governance policy, which includes the charters of the committees of the Board of Directors, is available on our
website,www.inovio.com. The Board of Directors has implicitly and explicitly acknowledged its responsibility for the stewardship of Inovio in the
following ways:



Management prepares an annual business plan for Inovio and presents the plan to the Inovio Board of Directors for its review and
comments. In connection therewith, the Board of Directors discusses various strategic matters with management and identifies business risks associated with Inovio's activities.



The board of directors takes responsibility for appointing those members of senior management who become Inovio's officers. Currently,
the members of senior management of Inovio are: Dr. Avtar Dhillon, President and Chief Executive Officer; Peter Kies, Chief Financial Officer and Human Resources Manager; Dr. Michael
Fons, Vice President, Corporate Development; and Punit Dhillon, Vice President, Finance and Operations.



The board of directors has procedures in place to ensure effective communication between Inovio, its stockholders, prospective
investors, and the public, including the dissemination of information on a regular and timely basis. Historically, the Chairman of the Board of
Directors, the Chief Executive Officer, the Chief Financial Officer and the Vice President, Finance and Operations, along with various other Inovio employees and consultants, devoted a portion of
their time to dealing with stockholders and prospective investors. Stockholders who want to communicate with the board or any individual director can write to Inovio's Secretary at the following
address: 11494 Sorrento Valley Road, San Diego, CA 92121-1318; such correspondence should indicate that status as an Inovio stockholder. Depending on the subject matter, management
will:



66

---



Table of Contents



Along with management, the board of directors is responsible for Inovio's internal control and management information systems. The
Audit Committee of the Board of Directors meets with Inovio's independent registered public accounting firm quarterly to review Inovio's financial statements and to review Inovio's financial reporting
procedures.



To ensure that the board of directors functions independently of management, Inovio has separated the office of chairman of the Board
from that of Chief Executive Officer. Further the independent directors meet on a regular basis as often as necessary to fulfill their responsibilities, including at least annually in executive
session without the presence of non-independent directors and management. James L. Heppell, Simon Benito, Tazdin Esmail, Riaz Bandali, Robert Rieder and Stephen Rietiker are each
independent under the NYSE Amex listing standards.



On December 5, 2008, the Inovio Board of Directors, upon recommendation from its Nomination and Corporate Governance Committee
adopted a Modified Plurality Voting Policy as an addition to its Corporate Governance Policy. The Modified Plurality Voting Policy provides that any nominee for director in an uncontested election who
receives (a) a greater number of votes "withheld" from his or her election than votes "for" his or her election and (b) votes "withheld" from his or her election that constitute
thirty-five percent (35%) or more of the outstanding shares of Inovio common stock, must promptly tender his or her written resignation following the certification of the stockholder vote.
The Inovio board of directors, in accordance with the procedures set out in the policy and upon a recommendation from the Nomination and Corporate Governance Committee, shall either accept such
resignation or defer its acceptance for no more than thirty days to enable the Inovio board to maintain compliance with applicable rules and regulations. Inovio shall promptly disclose such
determination on any pending resignation via a Current Report on Form 8-K. A copy of the Modified Plurality Voting Policy is posted to Inovio's website as part of Inovio's overall
Corporate Governance Policy.



Inovio has adopted a Code of Ethics, which applies to all directors, officers and employees, including the principal executive officer,
principal financial and accounting officer and controller. The purpose of the Code of Ethics is to promote honest and ethical conduct. The Code of Ethics was previously filed with our Annual Report on
Form 10-K for the year ended December 31, 2004 as Exhibit 14.1 and is incorporated by reference as Exhibit 14.1 to this report. The Code of Ethics is also
available on Inovio's website and available in print, without charge, upon written request to the Secretary at 11494 Sorrento Valley Road, San Diego, CA 92121-1318. Any amendments to or
waivers of the Code of Ethics will be promptly
posted on the Inovio's website atwww.inovio.comor in a report on Form 8-K, as required by applicable laws.

67

---





Table of Contents

COMPLIANCE WITH SECTION 16(a) OF THE SECURITIES EXCHANGE ACT OF 1934

Section 16(a) of the Exchange Act requires Inovio's officers, directors and persons who beneficially own more than ten percent
of our common stock to file with the Securities and Exchange Commission initial reports of ownership and reports of changes in beneficial ownership of our common stock. Officers, directors and 10% or
greater stockholders are required by the SEC regulations to furnish us with copies of all Section 16(a) forms they file.

Based
solely on Inovio's review of the copies of such reports furnished to Inovio's management believes that all officers, directors and greater than ten percent stockholders complied
with the filing requirements of Section 16(a) for the year ended December 31, 2008.

ITEM 11.    EXECUTIVE COMPENSATION

2008 Summary Compensation Table

The following table sets forth compensation information for 2008 and 2007 for our President and Chief Executive Officer, the Chief
Financial Officer and HR Manager, the two other executive officers serving at December 31, 2008, one former executive officer who served during 2008, and the Managing Director of Inovio AS
(collectively, the "Named Executive Officers"), whose salary and bonus exceeded $100,000 for 2008.

Name and Principal Position

Year

Salary
(1)

Bonus
(2)

Stock
Awards
(3)

Option
Awards
(4)

All Other
Compensation

Total(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)Dr. Avtar Dhillon,


2008

$
369,417




$
102,218

$
178,332

$
18,725
(5)
$
656,025President and Chief Executive Officer


2007

$
357,503

$
116,375

$
69,188

$
391,394

$
5,342

$
939,802Peter Kies,


2008

$
220,784







$
98,931




$
319,715Chief Financial Officer and HR Manager


2007

$
206,966

$
26,000




$
128,244




$
361,810Michael Fons,


2008

$
197,061







$
59,833

$
3,220

$
260,114Vice President, Corporate Development


2007

$
188,180

$
16,625




$
81,877

$
3,324

$
290,006Punit Dhillon,


2008

$
171,876







$
85,517

$
3,900

$
261,293Vice President, Operations and Finance(6)


2007

$
145,736

$
13,300




$
94,025

$
3,900

$
256,961Dietmar Rabussay,


2008

$
69,506







$
15,488

$
114,723

$
199,717Vice President, Research and Development(7)


2007

$
185,391







$
63,927

$
5,200

$
254,518Iacob Mathiesen,


2008

$
188,556




$
63,420

$
51,543




$
303,519Managing Director, Inovio AS(8)


2007

$
179,449




$
166,050

$
62,985




$
408,484


68

---



Table of Contents



Grants of Plan Based Awards

The following table sets forth certain information with respect to stock and option awards and other plan-based awards
granted to our named executive officers during 2008. Amounts representing Estimated Future Payouts Under Non-Equity Incentive Awards (i.e. thresholds, targets and minimums), and
Estimated Future Payouts Under Equity Incentive Plan Awards (i.e. thresholds, targets and

69

---



Table of Contents

minimums)
have not been reported in the following table as they are not applicable to our compensation program during 2008.

Name

Grant
Date

All Other
Stock
Awards:
Number of
Shares of
Stock (#)(1)

All Other
Option
Awards:
Number of
Securities
Underlying
Options (#)

Exercise or
Base Price
of Option
Awards
($/Share)

Grant Date
Fair Value
of Stock
and Option
Awards ($)(a)

(b)

(c)

(d)

(e)

(f)Avtar Dhillon,


2/1/2008





75,000

$
0.87

$
35,010President and Chief Executive Officer


2/1/2008


75,000







$
68,25012/9/2008





100,000

$
0.50

$
32,360Peter Kies,


2/1/2008





30,000

$
0.87

$
14,004Chief Financial Officer and


7/9/2008





60,000

$
1.06

$
34,230HR Manager


12/9/2008





40,000

$
0.50

$
12,944Michael Fons,


2/1/2008





20,000

$
0.87

$
34,230Vice President, Corporate


7/9/2008





60,000

$
1.06

$
9,336Development


12/9/2008





20,000

$
0.50

$
6,472Punit Dhillon,


2/1/2008





50,000

$
0.87

$
23,340Vice President, Finance and


7/9/2008





60,000

$
1.06

$
34,230Operations


12/9/2008





70,000

$
0.50

$
22,652Iacob Mathiesen,


7/9/2008





50,000

$
1.06

$
28,525Managing Director, Inovio AS


Options Exercised

There were no options exercised by our named executive officers during 2008.

70

---





Table of Contents

Outstanding Equity Awards at Fiscal Year-End Table

The following tables set forth certain information with respect to outstanding equity awards to the named executive officers under our
equity incentive plans during 2008.

OPTION AWARDSName

Number of
Securities
Underlying
Unexercised
Options (#)
Exercisable

Number of
Securities
Underlying
Unexercised
Options (#)
Unexercisable

Option
Exercise
Price ($)

Option
Expiration
Date(a)

(b)

(c)

(d)

(e)Avtar Dhillon


100,000





2.08


10/09/2011President and CEO


25,000





1.64


04/28/2012124,999





1.96


06/27/201212,499





1.00


10/24/201262,500





1.08


01/09/201381,249





2.52


08/07/201337,499





5.00


11/06/2013125,000





5.00


12/31/2013150,000





3.82


01/14/201556,250


18,750


2.89


03/06/2016112,500


112,500


3.16


03/07/201718,750


56,250


0.87


02/01/201825,000


75,000


0.50


12/09/2018931,246


262,500Peter Kies


37,500





1.96


06/27/2012CFO and HR Manager


7,500





1.00


10/24/201212,500





1.24


03/24/201314,375





2.52


08/07/201320,000





4.46


02/24/201533,750


11,250


2.89


03/06/201637,500


37,500


3.16


03/07/20177,500


22,500


0.87


02/01/201815,000


45,000


1.06


07/09/201810,000


30,000


0.50


12/09/2018195,625


146,250Michael Fons


37,500





5.32


06/16/2014VP, Corporate Development


15,000


5,000


2.45


03/22/201610,000


10,000


3.16


03/08/201712,500


12,500


3.75


05/03/20175,000


15,000


0.87


02/01/201815,000


45,000


1.06


07/09/20185,000


15,000


0.50


12/09/2018100,000


102,500


71

---



Table of Contents

OPTION AWARDSName

Number of
Securities
Underlying
Unexercised
Options (#)
Exercisable

Number of
Securities
Underlying
Unexercised
Options (#)
Unexercisable

Option
Exercise
Price ($)

Option
Expiration
Date(a)

(b)

(c)

(d)

(e)Dietmar Rabussay(1)


3,750





16.52


02/06/2010VP, Research and Development


500





6.00


08/24/20106,250





6.28


05/16/20117,500





1.80


10/23/20117,500





1.64


04/28/20127,500





1.00


10/24/201212,500





1.24


03/24/201319,937





2.52


08/07/201310,000





4.46


02/24/201533,750


11,250


2.89


03/06/201612,500


12,500


3.16


03/07/2017121,687


23,750Punit Dhillon


25,000





2.76


06/30/2013VP, Finance and Operations


6,250





2.52


08/07/201315,000





4.33


02/24/201526,250


8,750


2.45


03/22/201620,000


20,000


3.16


03/08/20177,500


7,500


3.75


05/03/201712,500


37,500


0.87


02/01/201815,000


45,000


1.06


07/09/201817,500


52,500


0.50


12/09/2018145,000


171,250Iacob Mathiesen


15,000


5,000


2.45


03/22/2016Managing Director, Inovio AS


10,000


10,000


3.16


03/08/201712,500


12,500


3.75


05/03/201712,500


37,500


1.06


07/09/201850,000


65,000


STOCK AWARDSName

Number of
Unvested
Shares (#)(1)

Fair Market
Value ($)(a)

(b)

(c)Avtar Dhillon
President & CEO


93,750


187,313Iacob Mathiesen
Managing Director, Inovio AS


45,000


166,050138,750


353,363




72

---



Table of Contents



Compensation Committee Interlocks and Insider Participation

In 2008, the Compensation Committee consisted of James L. Heppell (Chair), Simon Benito, Tazdin Esmail and Robert W. Rieder, each of
whom is an independent director under the NYSE Amex listing standards. Other than James L. Heppell, who is a former officer of Inovio, no member of the Compensation Committee is a former or current
officer or employee of Inovio.

During
2008, Avtar Dhillon, our Chief Executive Officer, served as a director of BC Advantage (VCC) Funds, Inc. James L. Heppell, a member of our Compensation Committee, serves as
President and Fund Manager of BC Advantage (VCC) Funds, Inc.

No
other persons who were members of the Compensation Committee during 2008 had any relationships requiring disclosure.

Compensation of Directors

During 2008, Inovio paid each non-employee director of Inovio (other than the Chairman of the Board) an annual retainer fee
of $19,000 and paid the Chairman of the Board an annual retainer fee of $35,000. We pay or reimburse all reasonable expenses associated with directors' attendance at and participation in board and
committee meetings and other company business which a director attends. For 2008, Inovio also paid an additional $9,000 to the Compensation Committee chairman as compensation for services as that
committee's chairman, an additional $14,000 to the Audit Committee chairman as compensation for services as that committee's chairman, and an additional $5,000 to the Nomination and Corporate
Governance Committee chairman as compensation for services as that committee's chair. Inovio also pays each non-employee director $1,500 for attendance at each Board meeting conducted in
person and $750 for each Board meeting conducted telephonically.

Inovio
does not pay director fees to its directors who are also Inovio employees. Thus, Dr. Dhillon does not receive director fees.

Non-employee
directors are eligible to receive, from time to time, grants of options to purchase shares of common stock under the Plan as determined by the full Board of
Directors. During the year ended December 31, 2008, Inovio granted 10-year options to purchase a total of 225,000 shares of its common stock to its non-employee
directors. Mssrs. Bandali, Benito, Esmail, Heppell, Rieder and Rietiker received 15,000 shares each, at an exercise price of $0.89. Mr. Rietiker and Mr. Gan also received 30,000 shares
each upon joining the Board of Directors in 2008, exercisable at $1.05 and $0.89, respectively. In August 2008, Mr. Heppell also received options to purchase 75,000 shares of common stock,
exercisable at $1.03 per share. In December 2008, Mr. Chong also received options to purchase 15,000 shares of common stock, exercisable at $0.50 per share, which were disclaimed in conjunction
with his resignation from the Board of Directors as reported on Form 8-K on February 6, 2009.

Director Compensation Table

The following table sets forth certain information with respect to director compensation during 2008. Amounts representing Stock
Awards, Non-equity Incentive Plan Compensation and All Other

73

---



Table of Contents

Compensation
are not included in the following table as they are not applicable to our compensation program during 2008.

Name

Fees
Earned or
Paid in
Cash
($)

Option
Awards
($)(2)

Total
($)(a)

(b)

(c)

(d)James Heppell


58,250


42,144


100,394Simon Benito


48,000


26,379


74,379Tazdin Esmail


39,000


26,379


65,379Riaz Bandali


28,000


26,379


54,379Robert Rieder


31,750


33,607


65,357Stephen Rietiker


23,250


12,693


35,943Patrick Gan


15,500


3,182


18,682Chin Cheong Chong(1)















Employment Contracts, Termination of Employment and Change-in-Control Arrangements

Inovio has written employment agreements with each of its Executive Officers which have been filed as exhibits in filings with the
Securities and Exchange Commission on Form 8-K filed on April 3, 2006 for Dr. Avtar Dhillon and Mr. Peter Kies; on August 21, 2007 for Dr. Michael
Fons; and on March 12, 2008 for Mr. Punit Dhillon.

Under
the employment agreement with Dr. Avtar Dhillon dated October 10, 2001, Dr. Dhillon serves as our President and Chief Executive Officer. Dr. Dhillon's
employment agreement provided for an initial annual salary of $200,000 and periodic increases, as determined by the Board from time to time, but no less than an annual increase at least equal to the
percentage increase in the cost of living in the San Diego Area over the previous year. Dr. Dhillon is also entitled to an annual bonus and stock option awards if certain milestone objectives
agreed to between the Board and Dr. Dhillon each year are met, as determined by the Board, and four weeks of paid vacation each year. The term of Dr. Dhillon's employment agreement is
for 10 years ending October 9, 2011, unless sooner terminated by Dr. Dhillon or by Inovio. If Dr. Dhillon's employment agreement is terminated by Inovio other than for
cause as set forth in the agreement or as a consequence of Dr. Dhillon becoming permanently disabled, or if the employment agreement is terminated by Dr. Dhillon within 180 days
after a "change of control" of Inovio as defined in the agreement, or by Dr. Dhillon for a breach by Inovio, Dr. Dhillon is entitled to receive a lump sum severance payment equal to two
times his annual salary and bonus at the time of termination, plus the continuation of his health benefits (or payment of the amount necessary to secure the same) for one year after termination. If
Dr. Dhillon's employment agreement is terminated by Inovio as a consequence of Dr. Dhillon becoming permanently disabled, Dr. Dhillon is entitled to receive a lump sum severance
payment equal to his annual salary at the time

74

---



Table of Contents

of
termination and his bonus based on the amount of such bonus most recently paid to him, pro rated from January 1 of the year of termination through date of termination.

Under
the employment agreement with Peter Kies, dated December 15, 2003, Mr. Kies serves as our Chief Financial Officer. Mr. Kies' employment agreement provided for
an initial annual salary of $180,000 to be periodically increased by such amounts as determined by the Board from time to time. Mr. Kies is also entitled to an annual bonus (which may consist
of cash, stock or stock options) if certain milestone objectives agreed to between the Board and Mr. Kies each year are met, three weeks of paid vacation each year and such stock options as may
be approved by the Board. The term of Mr. Kies employment agreement is for 10 years ending December 14, 2013, unless sooner terminated by Mr. Kies or by Inovio. If
Mr. Kies's employment agreement is terminated by Inovio other than for cause as set forth in the agreement or as a consequence of Mr. Kies becoming permanently disabled, or if the
employment agreement is terminated by Mr. Kies for a breach by Inovio, including termination of employment following a change of control, Mr. Kies is entitled to receive a severance
payment, payable in such regular intervals as may determined by Inovio, equal to (a) one-half of his annual salary for the year prior to the date of termination, and (b) his
bonus based on the amount of such bonus most recently paid to him, pro rated from January 1 of the year of termination through date of termination.

Under
the employment contract with Dr. Michael Fons, dated August 31, 2007, Mr. Fons serves as our Vice President, Corporate Development. Dr. Fon's employment
agreement provides for an initial annual salary of $195,050 to be periodically increased by such amounts as determined by the Board from time to time. Dr. Fons is also entitled to an annual
bonus (which may consist of cash, stock or stock options) if certain milestone objectives agreed to between the Board and Dr. Fons each year are met, three weeks of paid vacation each year, and
such stock options as may be approved by the Board. The term of Dr. Fons employment agreement is for 10 years ending August 30, 2017, unless sooner terminated by Dr. Fons
or by Inovio. If Dr. Fons' employment agreement is terminated by Inovio other than for cause as set forth in the agreement or as a consequence of Dr. Fons becoming permanently disabled,
or if the
employment agreement is terminated by Dr. Fons for a breach by Inovio, including termination of employment following a change of control, Dr. Fons is entitled to receive a severance
payment, payable in such regular intervals as may determined by Inovio, equal to (a) one-half of his annual salary for the year prior to the date of termination, and (b) his
bonus based on the amount of such bonus most recently paid to him, pro rated from January 1 of the year of termination through date of termination.

Under
the employment contract with Punit Dhillon, dated March 12, 2008, Mr. Dhillon serves as our Vice President, Finance and Operation. Mr. Dhillon's employment
agreement provides for an initial annual salary of $176,000 to be periodically increased by such amounts as determined by the Board from time to time. Mr. Dhillon is also entitled to an annual
bonus (which may consist of cash, stock or stock options) if certain milestone objectives agreed to between the Board and Mr. Dhillon each year are met, three weeks of paid vacation each year,
and such stock options as may be approved by the Board. The term of Mr. Dhillon's employment agreement is for 10 years ending March 12, 2018, unless sooner terminated by
Mr. Dhillon or by Inovio. If Mr. Dhillon's employment agreement is terminated by Inovio other than for cause as set forth in the agreement or as a consequence of Mr. Dhillon
becoming permanently disabled, or if the employment agreement is terminated by Mr. Dhillon for a breach by Inovio, including termination of employment following a change of control,
Mr. Dhillon is entitled to receive a severance payment, payable in such regular intervals as may determined by Inovio, equal to (a) one-half of his annual salary for the year
prior to the date of termination, and (b) his bonus based on the amount of such bonus most recently paid to him, pro rated from January 1 of the year of termination through date of
termination.

75

---



Table of Contents

Our
executive officers participate, while they are employees, in all employee benefits maintained by Inovio, including any group disability plan, insurance plan, medical and dental
plans, and are entitled to reimbursement of all reasonable out-of-pocket Inovio-related expenses.

Equity Compensation Plan Information

The following table sets forth the Company's equity compensation plan information as of December 31, 2008:

Plan

Number of
securities to be
issued upon
exercise of
outstanding
options

Weighted-
average
exercise
price of
outstanding
options

Number of securities
remaining available
for future issuance
under equity
compensation plansEquity compensation plans approved by security holders:2007 Omnibus Incentive Plan


1,465,812

$
0.90


42,938Amended 2000 Stock Option Plan


3,136,152


3.06


1997 Stock Option Plan


14,750


15.59


4,616,714

$
2.42


42,938


2007 Omnibus Incentive Plan

The following summary of the Inovio Biomedical Corporation 2007 Omnibus Incentive Plan (the "Plan"), for which option awards were
granted during 2008 is qualified in its entirety by the specific language of the Plan, a copy of which is incorporated by reference to Exhibit 4.2 of our Registration Statement on
Form S-8 filed on May 24, 2007, and available to any stockholder upon request to Peter Kies, by phone at (858) 597-6006, fax at
(858) 597-0451, email atpkies@Inovio.com, or mail at 11494 Sorrento Valley Rd., San Diego, CA 92121-1318.

General.The Plan provides for the grant of Incentive Stock Options ("ISOs") and Nonstatutory Stock Options ("NSOs"). As of
March 2, 2009, we
had outstanding options under the Plan to purchase an aggregate of 1,392,062 shares of our common stock at per share exercise prices ranging from $0.25 to $3.75.

Shares subject to the Plan.In the event of any stock dividend, stock split, reverse stock split, recapitalization, combination,
reclassification, or
similar change in the capital structure of Inovio, appropriate adjustments will be made to the shares subject to the Plan, and to outstanding options. To the extent any outstanding option under the
Plan expires or terminates prior to exercise in full or if Inovio repurchases shares issued upon exercise of an option, the shares of common stock for which that option is not exercised or the
repurchased shares are returned to the Plan and will again be available for issuance under the Plan.

Administration.The Compensation Committee of the Board administers the Plan. All option grants are approved by the Compensation
Committee, except
that our Chief Executive Officer and/or Chairman of the Board of Directors may approve option grants to persons below the level of Vice President of Inovio to a maximum individual grant of 50,000
options. With respect to the participation of individuals whose transactions in Inovio's equity securities are subject to Section 16 of the Securities Exchange Act of 1934, the Plan must be
administered in compliance with the requirements, if any, of Rule 16b-3 under the Exchange Act. Subject to the provisions of the Plan, the Compensation Committee determines the
persons to whom options are to be granted, the number of shares to be covered by each option, whether an option is to be an ISO or a NSO, the terms of vesting and exercisability of each option,
including the effect thereon of an optionee's termination of service, the type of consideration to be paid to Inovio upon exercise of an option, the duration of each option, and

76

---



Table of Contents

all
other terms and conditions of the options. Accordingly, future grants under the Plan are not yet determinable.

Eligibility.Generally, all employees, directors and consultants of Inovio or of any present or future parent or subsidiary
corporations of Inovio
are eligible to participate in the Plan. In addition, the Plan also permits the grant of options to prospective employees, consultants and directors in connection with written offers of employment or
engagement. Any person eligible under the Plan may be granted a NSO. However, only employees may be granted ISOs.

Terms and conditions of options.Each option granted under the Plan is evidenced by a written agreement between Inovio and the
optionee specifying
the number of shares subject to the option and the other terms and conditions of the option, consistent with the requirements of the Plan. The exercise price per share must equal at least the fair
market value of a share of Inovio's common stock on the date of grant of the stock option. The exercise price of any ISO granted to a person who at the time of grant owns stock possessing more than
10% of the total combined voting power of all classes of stock of Inovio or any parent or subsidiary corporation of Inovio, referred to as a 10% Stockholder, must be at least 110% of the fair market
value of a share of Inovio's common stock on the date of grant.

Generally,
the exercise price may be paid in cash, by check, or in cash equivalent, by tender of shares of Inovio's common stock owned by the optionee having a fair market value not less
than the exercise price, by the assignment of the proceeds of a sale or a loan with respect to some or all of the shares of common stock being acquired upon the exercise of the option, by means of a
promissory note, by any lawful method approved by the board or by any combination of these. The Compensation Committee may nevertheless restrict the forms of payment permitted in connection with any
option grant.

The
Compensation Committee will specify when options granted under the Plan will become exercisable and vested. Shares subject to options generally vest and become exercisable in
installments, subject to the optionee's continued employment or service or achievement of specified milestones.

Change in control.Upon a change in control, as defined in the Plan, the Compensation Committee may arrange for the acquiring or
successor
corporation to assume or substitute new options for the options outstanding under the Plan. To the extent that the options outstanding under the Plan are not assumed, substituted for, or exercised
prior to such event, generally, they will terminate.

Termination or amendment.Unless sooner terminated, no ISOs may be granted under the Plan after July 30, 2010. The Board may
terminate or
amend the Plan at any time, but, no amendment may adversely affect an outstanding option without the consent of the optionee, unless the amendment is required to preserve the option's status as an ISO
or is necessary to comply with any applicable law.

Federal Income Tax Consequences of the 2007 Omnibus Incentive Plan

The following summary is intended only as a general guide as to the United States federal income tax consequences under current law of
participation in the Plan and does not attempt to describe all possible federal or other tax consequences of such participation or tax consequences based on particular circumstances.

ISOs.An optionee recognizes no taxable income for regular income tax purposes as the result of the grant or exercise of an ISO
qualifying under
Section 422 of the Internal Revenue Code of 1986, as amended (the "Code"). Optionees who do not dispose of their shares for two years following the date the option was granted or within one
year following the exercise of the option will normally recognize a long-term capital gain or loss equal to the difference, if any, between the sale price and the purchase price of the
shares. If an optionee satisfies such holding periods upon a sale of the shares, Inovio will

77

---



Table of Contents

not
be entitled to any deduction for federal income tax purposes. If an optionee disposes of shares within two years after the date of grant or within one year from the date of exercise, referred to
as a disqualifying disposition, the difference between the fair market value of the shares on the exercise date, and the option exercise price, not to exceed the gain realized on the sale if the
disposition is a transaction with respect to which a loss, if sustained, would be recognized, will be taxed as ordinary income at the time of disposition. Any gain in excess of that amount will be a
capital gain. If a loss is recognized, there will be no ordinary income, and such loss will be a capital loss. A capital gain or loss will be long-term if the optionee's holding period is
more than 12 months. Generally, for federal income tax purposes, Inovio should be able to deduct any ordinary income recognized by the optionee upon the disqualifying disposition of the shares,
except to the extent the deduction is limited by applicable provisions of the Code or the regulations thereunder.

The
difference between the option exercise price and the fair market value of the shares on the exercise date of an ISO is an adjustment in computing the optionee's alternative minimum
taxable income and may be subject to an alternative minimum tax which is paid if the tax exceeds the regular tax for the year. Special rules may apply with respect to certain subsequent sales of the
shares in a disqualifying disposition, certain basis adjustments for purposes of computing the alternative minimum taxable income on a subsequent sale of the shares and certain tax credits that may
arise with respect to optionees subject to the alternative minimum tax.

NSOs.Options not designated or qualifying as ISOs will be NSOs. NSOs have no special tax status. An optionee generally
recognizes no taxable income
as the result of the grant of such an option. Upon exercise of a NSO, the optionee normally recognizes ordinary income in an amount equal to the difference between the option exercise price and the
fair market value of the shares on the exercise date. If the optionee is an employee, the ordinary income generally is subject to withholding of income and employment taxes. Upon the sale of stock
acquired by the exercise of a NSO, any gain or loss, based on the difference between the sale price and the fair market value on the exercise date, will be taxed as capital gain or loss. A capital
gain or loss will be long-term if the optionee's holding period is more than 12 months. No tax deduction is available to Inovio with respect to the grant of a NSO or the sale of the
stock acquired pursuant to that grant. Inovio generally should be entitled to a deduction equal to the amount of ordinary income recognized by the optionee as a result of the exercise of a NSO, except
to the extent the deduction is limited by applicable provisions of the Code or the regulations thereunder.

401(k) Plan

Inovio has in place a contributory retirement plan (the "401(k) Plan") for all full time employees age 21 and older with at least
12 months of service, which is designed to be a tax deferred plan in accordance with the provisions of Section 401(k) of the Code. The 401(k) Plan provides that each participant may
contribute up to 15% of his or her salary and Inovio may make a contribution equal to a percentage of salary contributed by the participant to his or her plan account at the end of each plan year.
Under the 401(k) Plan, employees may elect to enroll on January 1, April 1, July 1 and October 1 of any plan year, provided that they have been employed by Inovio for at
least three months. Subject to the rules for maintaining the tax status of the 401(k) Plan, an additional contribution by Inovio may be made at Inovio's discretion.

ITEM 12.    SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth information as of March 16, 2009, with respect to the beneficial ownership of Inovio's common
stock by (i) each person known to Inovio to be the beneficial owners of more than 5% of its common stock, (ii) each of Inovio's directors and nominees for director, (iii) each of
Inovio's executive officers, and (iv) all of Inovio's directors and executive officers as a group.

78

---



Table of Contents

Beneficial
ownership is determined in accordance with the rules of the SEC. In computing the number of shares beneficially owned by a stockholder and the percentage of ownership of that
stockholder, shares of common stock underlying shares of convertible preferred stock, options or warrants held by that stockholder that are convertible or exercisable, as the case may be, within
60 days of March 16, 2009 are included. Those shares, however, are not deemed outstanding for the purpose of computing the percentage ownership of any other person. Each stockholder's
percentage of ownership in the following table is based upon 44,041,800 shares of Inovio common stock outstanding as of March 16, 2009.

Beneficial Owner of Shares of Common Stock(1)(2)

Amount and Nature of
Beneficial Ownership of
Shares of Common Stock

Percent of Class of
Shares of Common Stock5% Stockholders:(3)NoneDirectors, Director Nominees and Executive Officers:Avtar Dhillon(4)


1,164,357


2.58
%James L. Heppell(5)


226,519


*Riaz Bandali(6)


86,655


*Simon X. Benito(7)


99,983


*Tazdin Esmail(8)


150,723


*Robert W. Rieder(9)


34,999


*Stephen Rietiker(10)


330,000


*Patrick Gan(11)


9,999


*Peter Kies(12)


235,201


*Michael Fons(13)


121,275


*Punit Dhillon(14)


181,214


*All executive officers and directors as a group(15) (11 persons)


2,640,925


5.93
%


---

79

---



Table of Contents

ITEM 13.    CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

Procedures for Approval of Related Party Transactions

Our executive officers, directors and principal stockholders, including their immediate family members and affiliates, are prohibited
from entering into a related party transaction with us without the prior consent of our Board of Directors. We have an unwritten policy that any request for us to enter into a transaction with an
executive officer, director, principal stockholder or any of such persons' immediate family members or affiliates in which the amount involved exceeds $120,000 must first be presented to our Board of
Directors for review, consideration and approval. In approving or rejecting the proposed agreement, our Board of Directors will consider the relevant facts and circumstances available and deemed
relevant, including, but not limited to, the risks, costs, and benefits to the Company, the terms of the transactions, the availability of other sources for comparable services or products, and, if
applicable, the impact on director independence. Our Board of Directors shall only approve those agreements that, in light of known circumstances, are in, or are not inconsistent with, our best
interests, as determined in good faith by the Board. We currently have no related party transactions requiring such approval.

Director Independence

See Item 10 "Directors, Executive Officers and Corporate Governance" for a discussion of board member independence.

80

---





Table of Contents

ITEM 14.    PRINCIPAL ACCOUNTANT FEES AND SERVICES

PRINCIPAL ACCOUNTING FIRM FEES

During the years ended December 31, 2008 and 2007, Inovio retained Ernst & Young LLP to provide services as
follows:

Year

Audit Fees

Tax Fees

Total Fees2008

$
568,532

$
51,830

$
620,3622007

$
583,722

$
98,200

$
681,922


Audit Fees.Audit fees include fees for the audit of Inovio's annual consolidated financial statements and fees for the review
of Inovio's interim
financial statements. Audit fees also include other services that generally only the independent auditor can reasonably provide, including comfort letters, statutory audits, attest services, and
consents and assistance with and review of documents filed with the SEC.

Tax Fees.Tax fees include fees for services performed by the professional staff in the tax department of Ernst &
Young LLP except for
those tax services that could be classified as audit or audit-related services. These include tax compliance and various tax consultation fees.

None
of the fees listed above were approved by the Audit Committee in reliance on a waiver from pre-approval under Rule 2-01(c)(7)(i)(C) of
Regulation S-X.

Audit Committee Pre-Approval Policies and Procedures

The Audit Committee on an annual basis reviews audit and non-audit services performed by the independent registered public
accounting firm for such services. The Audit Committee may also pre-approve particular services on a case-by-case basis. All audit and non-audit
services are pre-approved by the Audit Committee, which considers, among other things, the possible effect of the performance of such services on the accounting firm's independence. The
Audit Committee has considered the role of Ernst & Young LLP in providing services to Inovio for the year ended December 31, 2008 and has concluded that such services are
compatible with Ernst & Young LLP's independence as Inovio's independent registered public accounting firm.

The
Audit Committee will only approve those services that would not impair the independence of the independent registered public accounting firm and which are consistent with the rules
of the Securities and Exchange Commission.

Under
this policy, the Audit Committee meets at least annually to review and where appropriate approve the audit and non-audit services to be performed by Inovio's
independent registered public accounting firm. Any subsequent requests to have the independent registered public accounting firm perform any additional services must be submitted in writing to the
Audit Committee by the Chief Financial Officer, together with the independent registered public accounting firm, which written request must include an affirmation from each that the requested services
are consistent with the Securities and Exchange Commission and Public Company Accounting Oversight Board's rules on auditor independence.

PART IV

ITEM 15.    EXHIBITS AND FINANCIAL STATEMENT SCHEDULES



81

---



Table of Contents

Schedules
not listed herein have been omitted because the information required to be set forth therein is not applicable or is included in the Financial Statements or notes thereto.

The
following exhibits are filed as part of this annual report on Form 10-K:

Exhibit
Number

Description of Document2.1
#
Amended and Restated Agreement and Plan of Merger By and Among Inovio Biomedical Corporation, Inovio Acquisition, LLC, and VGX Pharmaceuticals, Inc. dated December 5, 2008 (included asAnnex Ato the registrant's Registration Statement on Form S-4). (File No. 333-156035), filed on January 23, 2009).3.1
(a)
Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 of the registrant's Registration Statement on Form S-3 (File No. 333-108752) filed on September 12,
2003).(b)
Certificate of Amendment to Amended and Restated Certificate of Incorporation as filed with the Delaware Secretary of State on September 10, 2004 (incorporated by reference to Exhibit 3.1 of the registrant's
Current Report on Form 8-K filed September 16, 2004).(c)
Certificate of Amendment to the Amended and Restated Certificate of Incorporation as filed with the Delaware Secretary of State on March 31, 2005 (incorporated by reference to Exhibit 3.1 of the registrant's
Current Report on Form 8-K filed on April 4, 2005).3.2
(a)
Certificate of Incorporation of Inovio Acquisition Corporation dated June 23, 2008 (incorporated by reference to Exhibit 3.2(a) of registrant's initial registration statement on Form S-4 (File
No. 333-156035) on December 10, 2008).(b)
Certificate of Conversion of Inovio Acquisition Corporation to Inovio Acquisition, LLC dated October 31, 2008 (incorporated by reference to Exhibit 3.2(b) of registrant's initial registration statement
on Form S-4 (File No. 333-156035) on December 10, 2008).(c)
Certificate of Formation of Inovio Acquisition, LLC dated October 31, 2008 (incorporated by reference to Exhibit 3.2(c) of registrant's initial registration statement on Form S-4 (File
No. 333-156035) on December 10, 2008).3.3
(a)
Certificate of Designations, Rights and Preferences of Series C Convertible Preferred Stock of Registrant (incorporated by reference to Exhibit 3.3 of the registrant's Registration Statement on Form S-3
filed on June 21, 2004).(b)
Certificate of Decrease of Shares of Series C Cumulative Convertible Preferred Stock of Registrant (incorporated by reference to Exhibit 3.4 of the registrant's Registration Statement on Form S-3 filed
on June 21, 2004).3.4

Amended and Restated Bylaws of Inovio Biomedical Corporation, as amended through November 30, 2007 (incorporated by reference to Exhibit 3.2 of the registrant's Form 8-K filed on December 6,
2007).3.5

Operating Agreement of Inovio Acquisition, LLC, dated October 31, 2008 (incorporated by reference to Exhibit 3.5 of registrant's initial registration statement on Form S-4 (File No. 333-156035)
 on December 10, 2008).


82

---



Table of Contents

Exhibit
Number

Description of Document4.1

Amended 2000 Stock Option Plan, as amended by the Board of Directors through March 6, 2006 with approvals by Stockholders through May 5, 2006 (incorporated by reference to Exhibit 4.1 of the registrant's
Registration Statement on Form S-8 filed on July 28, 2006).4.2
+
Forms of Incentive and Nonstatutory Stock Option Agreements used in connection with the 2000 Stock Option Plan (incorporated by reference to Exhibit 10.7 of the registrant's Registration Statement on
Form S-4/A (File No. 333-58168) filed on April 5, 2001).4.3

Warrant to Purchase Common Stock, dated September 15, 2000 by and between the Registrant and the University of South Florida Research Foundation (incorporated by reference to Exhibit 10.6 of the registrant's
Form 10-Q filed on November 9, 2000).4.4

Warrant to Purchase Common Stock, dated September 15, 2000 by and between the Registrant and Dr. Richard Gilbert (incorporated by reference to Exhibit 10.7 of the registrant's Form 10-Q filed on
November 9, 2000).4.5

Warrant to Purchase Common Stock, dated September 15, 2000 by and between the Registrant and Dr. Richard Heller (incorporated by reference to Exhibit 10.8 of the registrant's Form 10-Q filed on
November 9, 2000).4.6

Warrant to Purchase Common Stock, dated September 15, 2000 by and between the Registrant and Dr. Mark Jaroszeski (incorporated by reference to Exhibit 10.9 of the registrant's Form 10-Q filed on
November 9, 2000).4.7

Investors Rights Agreement, dated July 14, 2003, between the Registrant and the Purchasers listed on Schedule 1 thereto (incorporated by reference to Exhibit 4.2 of the registrant's Registration
Statement on Form S-3 (File No. 333-108752) filed on September 12, 2003).4.8

Specimen Common Stock certificate (incorporated by reference to Exhibit 4.8 of the registrant's Registration Statement on Form S-3 (File No. 333-108752) filed on September 12, 2003).4.9

Investor Rights Agreement dated as of May 10, 2004 by and between the registrant and the purchasers indicated on the schedule thereto (incorporated by reference to Exhibit 4.2 of the registrant's
Registration Statement on Form S-3 filed on June 21, 2004).4.10

Form of Series C Common Stock Purchase Warrant dated as of May 10, 2004 by and between the registrant and the purchasers indicated on the schedule thereto (incorporated by reference to Exhibit 4.3 of
the registrant's Registration Statement on Form S-3 filed on June 21, 2004).4.11

Registration Rights Agreement dated December 30, 2005, by and among the registrant and the investors named on the signature pages thereto (incorporated by reference to Exhibit 99.3 to registrant's
Form 8-K filed with the Securities and Exchange Commission on January 6, 2006).4.12

Form of Common Stock Purchase Warrant dated as of September 15, 2006 by and between the registrant and each of the purchasers listed on Schedule 1 to the Securities Purchase Agreement (Exhibit 10.23
herein) (incorporated by reference to Exhibit 4.3 of the registrant's Current Report on Form 8-K filed on September 20, 2006).4.13

Registration Rights Agreement dated as of September 15, 2006 by and among registrant and certain investors indicated on a schedule thereto (incorporated by reference to Exhibit 10.5 of the registrant's
Quarterly Report on Form 10-Q filed on November 9, 2006).


83

---



Table of Contents

Exhibit
Number

Description of Document4.14

Form of Common Stock Purchase Warrant to be used by and between the registrant and each of the purchasers listed on Schedule 1 to the Securities Purchase and Exchange Agreement (Exhibit 10.25 herein)
(incorporated by reference to Exhibit 4.24 of the registrant's Annual Report on Form 10-K filed on March 16, 2007).4.15
+
First Amended and Restated Inovio Biomedical Corporation 2007 Omnibus Incentive Plan (incorporated by reference to Exhibit 4.2 of the registrant's Registration Statement on Form S-8 filed on May 9,
2008).4.16
+
Form of Restricted Stock Award Grants under the 2007 Omnibus Stock Incentive Plan (incorporated by reference to Exhibit 4.3 to the Registrant's Registration Statement on Form S-8 filed on May 14,
2007).4.17
+
Form of Incentive and Non-Qualified Stock Option Grants under the 2007 Omnibus Stock Incentive Plan (incorporated by reference to Exhibit 4.4 to the Registrant's Registration Statement on Form S-8 filed with
the Securities and Exchange Commission on May 14, 2007).10.1

Lease Agreement by and between the registrant and Nexus Sorrento Glen LLC dated August 26, 1999 (incorporated by reference to Exhibit 10.15 of the registrant's Registration Statement on Form S-1,
as amended (File No. 333-88427), filed on October 5, 1999).10.2

License Agreement dated September 20, 2000 by and between the registrant and the University of South Florida Research Foundation, Inc. (incorporated by reference to Exhibit 10.5 of the registrant's
Form 10-Q filed on November 9, 2000).10.3

Asset Purchase Agreement by and among the Registrant, Genetronics, Inc., a subsidiary of the Registrant, and Harvard Bioscience, Inc. dated December 24, 2002 (incorporated by reference to Exhibit A
to the registrant's Definitive Proxy Statement filed on January 7, 2003).10.4

Preferred Stock and Warrant Purchase Agreement dated as of May 10, 2004 by and between the registrant and the purchasers indicated on the schedule thereto (incorporated by reference to Exhibit 4.1 of the
registrant's Registration Statement on Form S-3 filed on June 21, 2004).10.5

Non-Exclusive License and Research Collaboration Agreement dated as of May 21, 2004 by and among the registrant and Merck & Co., Inc. and Genetronics, Inc., a subsidiary of the registrant
(incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q filed on August 13, 2004).10.6

Lease Agreement by and between the registrant and Sorrento Centre Tenancy in Common dated November 29, 2004 (incorporated by reference to Exhibit 10.16 of the registrant's Annual Report of Form 10-K for
the year ended December 31, 2004, filed on March 15, 2005).10.7

Lease Amendment #3 by and between the registrant and Nexus Sorrento Glen LLC dated January 21, 2005 (incorporated by reference to Exhibit 10.17 of the registrant's Annual Report of Form 10-K for
the year ended December 31, 2004, filed on March 15, 2005).10.8

Stock Purchase Agreement dated January 25, 2005 by and among the registrant, Inovio AS and the Shareholders of Inovio AS (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K
filed on January 31, 2005).


84

---



Table of Contents

Exhibit
Number

Description of Document10.9

Securities Purchase Agreement dated as of December 16, 2005, among registrant and each purchaser identified on the signature pages thereto (incorporated by reference to Exhibit 99.1 of the registrant's Report of
Form 8-K, filed on January 6, 2006).10.10

License Agreement dated September 15, 2006 between registrant and Inovio Asia Pte. Ltd. (incorporated by referenced to Exhibit 10.1 to registrant's Quarterly Report on Form 10-Q filed on
November 9, 2006).10.11

Securities Purchase Agreement dated September 15, 2006 between registrant and purchasers named therein (incorporated by reference to Exhibit 4.1 of the registrant's Current Report on Form 8-K filed on
September 20, 2006).10.12

Amendment to Securities Purchase Agreement, amending the Securities Purchase Agreement filed as Exhibit 10.27 (incorporated by reference to Exhibit 4.3 of the registrant's Current Report on Form 8-K
filed on October 16, 2006).10.13

Securities Purchase and Exchange Agreement between registrant and Inovio Asia Pte. Ltd. and the purchasers named therein, dated September 15, 2006 (incorporated by referenced to Exhibit 10.2 to
registrant's Quarterly Report on Form 10-Q filed on November 9, 2006).10.14

Preferred Exchange Agreement dated September 15, 2006 between registrant and certain holders of Series C Preferred Stock (incorporated by referenced to Exhibit 4.4 of the registrant's Registration
Statement on Form S-3, filed January 19, 2007).10.15

Securities Purchase Agreement dated May 14, 2007 relating to the Direct Financing between registrant and purchasers named therein (incorporated by reference to Exhibit 4.1 of the registrant's Current Report
on Form 8-K, filed May 16, 2007).10.16

Letter Agreement Dated August 3, 2007 between Registrant and Asia Life Sciences Venture Consulting Inc. (incorporated by reference to Exhibit 4.1 of the registrant's Current Report on Form 8-K
filed August 6, 2007).10.17

Form of Warrant to Purchase Common Stock (incorporated by reference to Exhibit 4.2 of the registrant's Current Report on Form 8-K filed August 6, 2007).10.18
+
Employment Agreement dated August 31, 2007 by and between the registrant and Dr. Michael Fons (incorporated by reference to Exhibit 99.2 of the registrant's Current Report on Form 8-K/A filed
September 10, 2007).10.19
+
Employment Agreement for Punit Dhillon dated March 12, 2008 (incorporated by reference to Exhibit 99.2 of the registrant's Current Report on Form 8-K/A, filed March 14, 2008).10.20
+
Consulting Agreement dated May 3, 2008 by and between Dietmar Rabussay and Genetronics, Inc. (incorporated by reference to Exhibit 10.1 of the registrant's Current Report on Form 8-K, filed
May 7, 2008).10.21
+
Addendum to P. Kies Employment Agreement, dated July 2, 2008 (incorporated by reference to Exhibit 10.1 of the registrant's Current Report on Form 8-K, filed July 8, 2008).10.22
+
Form of Employment Agreement by and between the registrant and Dr. Michael Fons, for use effective only upon closing of the Merger (incorporated by reference to Exhibit 10.22 as filed with the registrant's
registration statement on Form S-4 (File No. 333-156035) on December 10, 2008).


85

---



Table of Contents

Exhibit
Number

Description of Document10.23
+
Form of Employment Agreement by and between the registrant and Punit Dhillon, for use effective only upon closing of the Merger (incorporated by reference to Exhibit 10.23 as filed with the registrant's registration
statement on Form S-4 (File No. 333-156035) on December 10, 2008).10.24
+
Form of Employment Agreement by and between the registrant and Peter Kies, effective only upon closing of the Merger (incorporated by reference to Exhibit 10.24 as filed with the registrant's registration
statement on Form S-4 (File No. 333-156035) on December 10, 2008).10.25
+
Form of Employment Agreement by and between the registrant and Dr. Avtar Dhillon, for use effective only upon closing of the Merger (incorporated by reference to Exhibit 10.25 as filed with the registrant's
registration statement on Form S-4 (File No. 333-156035) on December 10, 2008).14.1

Inovio Biomedical Corporation Code of Ethics for Senior Officers (incorporated by reference to Exhibit 14.1 of the registrant's Annual Report on Form 10-K for the year ended December 31, 2004, filed on
March 15, 2005).21.1

Subsidiaries of the registrant.23.1

Consent of Independent Registered Public Accounting Firm.24.1

Power of Attorney (included on signature page).31.1

Certification of the Chief Executive Officer pursuant Securities Exchange Act Rule 13a-14(a).31.2

Certification of the Chief Financial Officer pursuant Securities Exchange Act Rule 13a-14(a).32.1

Certification pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.


---

86

---





Table of Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this
report to be signed on its behalf by the undersigned, thereunto duly authorized on March 31, 2009.

Inovio Biomedical CorporationBy:

/s/ AVTAR DHILLON Avtar Dhillon President and Chief Executive Officer


POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Avtar Dhillon and Peter
Kies, and each of them severally, his or her true and lawful attorney-in-fact with power of substitution and resubstitution to sign in his or her name, place and stead, in any
and all capacities, to do any and all things and execute any and all instruments that such attorney may deem necessary or advisable under the Securities Exchange Act of 1934 and any rules, regulations
and requirements of the U.S. Securities and Exchange Commission in connection with the Annual Report on Form 10-K and any and all amendments hereto, as fully for all intents and
purposes as he or she might or could do in person, and hereby ratifies and confirms all said attorneys-in-fact and agents, each acting alone, and his or her substitute or
substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on
the dates indicated.

Signature

Title

Date/s/ AVTAR DHILLON Avtar Dhillon

President, Chief Executive Officer
(Principal Executive Officer), Director

March 31, 2009/s/ PETER KIES Peter Kies

Chief Financial Officer
(Principal Accounting Officer and
Principal Financial Officer)

March 31, 2009/s/ JAMES L. HEPPELL James L. Heppell

Director

March 31, 2009/s/ RIAZ BANDALI Riaz Bandali

Director

March 31, 2009/s/ TAZDIN ESMAIL Tazdin Esmail

Director

March 31, 2009


87

---



Table of Contents

Signature

Title

Date/s/ SIMON X. BENITO Simon X. Benito

Director

March 31, 2009/s/ ROBERT W. RIEDER Robert W. Rieder

Director

March 31, 2009/s/ STEPHEN RIETIKER Stephen Rietiker

Director

March 31, 2009/s/ PATRICK GAN Patrick Gan

Director

March 31, 2009


88

---





Table of Contents

INOVIO BIOMEDICAL CORPORATION        Index to Consolidated Financial Statements



PageReport of Independent Registered Public Accounting Firm

F-2Consolidated Balance Sheets as of December 31, 2008 and December 31, 2007

F-3Consolidated Statements of Operations for each of the years ended December 31, 2008, 2007 and
2006

F-4Consolidated Statements of Stockholders' Equity for each of the years ended December 31, 2008, 2007 and
2006

F-5Consolidated Statements of Cash Flows for each of the years ended December 31, 2008, 2007 and
2006

F-7Notes to Consolidated Financial Statements

F-8


F-1

---





Table of Contents

Report of Independent Registered Public Accounting Firm

The
Board of Directors and Stockholders
Inovio Biomedical Corporation

We
have audited the accompanying consolidated balance sheets of Inovio Biomedical Corporation as of December 31, 2008 and 2007 and the related consolidated statements of
operations, stockholders' equity and cash flows for each of the three years in the period ended December 31, 2008. These financial statements are the responsibility of the Company's management.
Our responsibility is to express an opinion on these financial statements based on our audits.

We
conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to
obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in
the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement
presentation. We believe that our audits provide a reasonable basis for our opinion.

In
our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of Inovio Biomedical Corporation at
December 31, 2008 and 2007 and the consolidated results of its operations and its cash flows for each of the three years in the period ended December 31, 2008, in conformity with U.S.
generally accepted accounting principles.

|                                     |  |                      
|------------------------------------ |  | ---------------------
|                                     |  | /s/ Ernst & Young LLP
|San Diego, California
March 27, 2009 |  |                      

F-2

---





Table of Contents

Inovio Biomedical Corporation        CONSOLIDATED BALANCE SHEETS

As of December 31,2008

2007ASSETSCurrent assets:Cash and equivalents

$
14,115,281

$
10,250,929Short-term investments





16,999,600Accounts receivable


671,187


1,139,966Prepaid expenses and other current assets


477,285


613,656Total current assets


15,263,753


29,004,151Long-term investments


9,169,471


Auction rate security rights


4,281,494


Fixed assets, net


353,807


401,727Intangible assets, net


5,850,540


6,186,430Goodwill


3,900,713


3,900,713Other assets


167,250


282,000Total assets

$
38,987,028

$
39,775,021LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable and accrued expenses

$
1,367,300

$
1,807,305Accrued clinical trial expenses


399,919


573,767Line of credit


12,109,423


Common stock warrants


224,582


367,071Deferred revenue


523,544


544,410Deferred rent


84,814


61,946Total current liabilities


14,709,582


3,354,499Deferred revenue, net of current portion


4,269,151


4,335,806Deferred rent, net of current portion


14,898


99,712Deferred tax liabilities


887,250


950,250Total liabilities


19,880,881


8,740,267Commitments and contingenciesStockholders' equity:Preferred stockpar value $0.001; Authorized shares: 10,000,000, issued and outstanding: 71 and 113,382 at December 31, 2008 and December 31,
 2007, respectively





113Common stockpar value $0.001; Authorized shares: 300,000,000, issued and outstanding: 44,116,800 and 44,023,050 at December 31, 2008 and
43,870,989 and 43,814,739 at December 31, 2007, respectively


44,022


43,815Additional paid-in capital


171,868,914


170,730,621Receivables from stockholders





(50,000
)Accumulated deficit


(152,812,948
)

(139,847,326
)Accumulated other comprehensive income


6,159


157,531Total stockholders' equity


19,106,147


31,034,754Total liabilities and stockholders' equity

$
38,987,028

$
39,775,021


The accompanying notes are an integral part of these consolidated financial statements.

F-3

---





Table of Contents

Inovio Biomedical Corporation        CONSOLIDATED STATEMENTS OF OPERATIONS

Year ended December 31,2008

2007

2006Revenue:License fee and milestone payments

$
791,401

$
2,793,478

$
1,337,105Revenue under collaborative research and development arrangements


1,077,967


1,854,303


962,207Grants and miscellaneous revenue


228,264


159,948


1,168,866Total revenue


2,097,632


4,807,729


3,468,178Operating expenses:Research and development


5,750,494


9,625,947


8,509,785General and administrative


10,005,602


11,080,202


8,304,587Total operating expenses


15,756,096


20,706,149


16,814,372Loss from operations


(13,658,464
)

(15,898,420
)

(13,346,194
)Other income, net


49,006


3,421,580


320,706Interest income, net


643,836


1,272,397


681,546Net loss


(12,965,622
)

(11,204,443
)

(12,343,942
)Imputed and declared dividends on preferred stock





(23,335
)

(2,005,664
)Net loss attributable to common stockholders

$
(12,965,622
)
$
(11,227,778
)
$
(14,349,606
)Amounts per common sharebasic and diluted:Net loss

$
(0.30
)
$
(0.27
)
$
(0.40
)Imputed and declared dividends on preferred stock








(0.06
)Net loss attributable to common stockholders

$
(0.30
)
$
(0.27
)
$
(0.46
)Weighted average number of common shares outstandingbasic and diluted


43,914,004


41,493,412


31,511,683


The
accompanying notes are an integral part of these consolidated financial statements.

F-4

---





Table of Contents

Inovio Biomedical Corporation        CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

Preferred stock

Common stockAccumulated
other
Comprehensive
(loss) incomeNumber
of shares

Amount

Number
of shares

Amount

Additional
paid-in
capital

Receivables
From
stockholders

Accumulated
deficit

Total
stockholders'
equityBalance at December 31, 2005


1,562,424


1,562


29,468,756


29,469


137,739,954





(114,269,942
)

(30,295
)

23,470,748Exercise of stock options for cash








148,629


148


251,280











251,428Issuance of common stock for patents and other assets








86,956


87


128,835











128,922Issuance of stockholder note receivable














86,030


(86,030
)







Issuance of common stock for cash, net of issuance costs of $1,161,070








4,074,067


4,074


5,058,931











5,063,005Issuance of common stock for consulting services








49,261


49


99,951











100,000Conversions of preferred stock to common stock


(534,355
)

(534
)

1,763,981


1,764


(1,230
)










Stock-based compensation








45,000


45


1,546,662











1,546,707Imputed and declared dividends








2,871


3


1,873,317











1,873,320Comprehensive loss:Net loss attributable to common stockholders




















(14,349,606
)




(14,349,606
)Foreign currency translation gain























67,340


67,340Total comprehensive loss


























(14,282,266
)Balance at December 31, 2006


1,028,069

$
1,028


35,639,521

$
35,639

$
146,783,730

$
(86,030
)
$
(128,619,548
)
$
37,045

$
18,151,864Exercise of stock options for cash








94,563


94


218,407











218,501Exercise of warrants for cash








3,082


3


7,394











7,397Cashless exercise of warrants








38,097


38


(38
)










Conversions of preferred stock to common stock


(914,687
)

(915
)

960,238


961


(46
)










Conversions of ordinary shares to common stock








2,201,644


2,202


5,347,793











5,349,995Cash receipt towards stockholder notes receivable

















36,030








36,030Issuance of common stock for consulting services








263,750


264


610,762











611,026Issuance of common stock for cash, net of issuance costs of $110,313








4,595,094


4,595


16,059,829











16,064,424Stock-based compensation








18,750


19


1,702,790











1,702,809Comprehensive loss:Net loss attributable to common stockholders




















(11,227,778
)




(11,227,778
)Unrealized gain on investments























9,945


9,945Foreign currency translation gain























110,541


110,541Total comprehensive loss


























(11,107,292
)Balance at December 31, 2007


113,382

$
113


43,814,739

$
43,815

$
170,730,621

$
(50,000
)
$
(139,847,326
)
$
157,531

$
31,034,754


The accompanying notes are an integral part of these consolidated financial statements.

F-5

---



Table of Contents

Inovio Biomedical Corporation

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Continued)

Preferred stock

Common stockAccumulated
other
Comprehensive
(loss) incomeNumber
of shares

Amount

Number
of shares

Amount

Additional
paid-in
capital

Receivables
From
stockholders

Accumulated
deficit

Total
stockholders'
equityBalance at December 31, 2007


113,382

$
113


43,814,739

$
43,815

$
170,730,621

$
(50,000
)
$
(139,847,326
)
$
157,531

$
31,034,754Exercise of stock options for cash








1,250


1


1,087











1,088Conversions of preferred stock to common stock


(113,311
)

(113
)

113,311


113














Reserve for stockholder note receivable

















50,000








50,000Issuance of common stock for consulting services








56,250


55


46,520











46,575Stock-based compensation








37,500


38


1,090,686











1,090,724Comprehensive loss:Net loss attributable to common stockholders




















(12,965,622
)




(12,965,622
)Unrealized loss on investments























(9,945
)

(9,945
)Foreign currency translation loss























(141,427
)

(141,427
)Total comprehensive loss


























(13,116,994
)Balance at December 31, 2008


71





44,023,050

$
44,022

$
171,868,914




$
(152,812,948
)
$
6,159

$
19,106,147


The accompanying notes are an integral part of these consolidated financial statements.

F-6

---





Table of Contents

Inovio Biomedical Corporation        CONSOLIDATED STATEMENTS OF CASH FLOWS

Year ended December 31,2008

2007

2006Cash flows from operating activities:Net loss

$
(12,965,622
)
$
(11,204,443
)
$
(12,343,942
)Adjustments to reconcile net loss to net cash used in operating activities:Depreciation


195,285


185,683


206,743Amortization of intangible assets


797,742


831,958


767,900Change in value of common stock warrants


(142,489
)

(3,173,621
)

(135,182
)Unrealized loss on trading securities


4,380,529





Recognition of auction rate securities rights


(4,281,494
)




Stock-based compensation


1,090,724


1,702,809


1,546,707Compensation for services paid in common stock


46,575


611,026


100,000Amortization of deferred tax liabilities


(63,000
)

(63,000
)

(63,000
)Deferred rent


(61,946
)

(66,832
)

(57,385
)Impairment of long term investments


114,750





Loss on disposal of fixed assets


9,792





Realization of loss carryforwards





389,881


Revenue from conversion of note payable








(10,810
)Accretion of discount on available-for-sale securities


(60,345
)

(86,670
)

Changes in operating assets and liabilities:Accounts receivable


464,825


(726,884
)

(57,631
)Prepaid expenses and other current assets


19,518


507,230


(400,417
)Accounts payable and accrued expenses


(583,841
)

(321,080
)

(233,894
)Deferred revenue


(87,521
)

(99,806
)

3,637,763Net cash used in operating activities


(11,126,518
)

(11,513,749
)

(7,043,148
)Cash flows from investing activities:Purchases of long-term investments


(4,500,000
)

(18,602,985
)

(24,000,000
)Proceeds from long-term investments


8,000,000


16,400,000


9,300,000Purchases of capital assets


(121,946
)

(141,635
)

(46,744
)Capitalization of patents and other assets


(461,852
)

(504,095
)

(1,318,431
)Net cash provided by (used in) investing activities


2,916,202


(2,848,715
)

(16,065,175
)Cash flows from financing activities:Proceeds from issuance of common stock, net of issuance costs


1,088


16,290,322


8,975,735Proceeds from line of credit


12,220,494





Repayment of line of credit


(111,071
)




Reserve for stockholder note receivable


50,000





Repayment of stockholder note receivable





36,030


Proceeds from issuance of shares to minority interest








5,349,995Payment of preferred stock cash dividend





(23,335
)

(132,343
)Net cash provided by financing activities


12,160,511


16,303,017


14,193,387Effect of exchange rate changes on cash


(85,843
)

(11,230
)

69,975Increase (decrease) in cash and cash equivalents


3,864,352


1,929,323


(8,844,961
)Cash and cash equivalents, beginning of period


10,250,929


8,321,606


17,166,567Cash and cash equivalents, end of period

$
14,115,281

$
10,250,929

$
8,321,606


The accompanying notes are an integral part of these consolidated financial statements.

F-7

---





Table of Contents

INOVIO BIOMEDICAL CORPORATION        NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

1. The Company

Inovio Biomedical Corporation, or "Inovio," a Delaware corporation, organized in 2001, is a San Diego-based biomedical company focused on the development of next-generation
vaccines to prevent or treat cancers and chronic infectious diseases. Such vaccines, which could potentially protect millions of people from debilitation or death from diseases without adequate
treatments, may represent multi-billion dollar market opportunities. Historically, successful development of this new generation of vaccinesDNA vaccineshas been hindered by
the lack of safe, efficient and cost effective DNA delivery methods capable of enabling their potency. However, Inovio's electroporation-based DNA delivery technology has shown potential in
pre-clinical and clinical studies to play a pivotal role in facilitating delivery and enhancing the potency of preventive and therapeutic vaccines.

On
July 7, 2008, Inovio and VGX Pharmaceuticals, Inc. ("VGX"), a privately-held developer of DNA vaccines, executed a definitive merger agreement providing for
the issuance of Inovio shares in exchange for all of the outstanding securities of VGX and the merger of an acquisition subsidiary of Inovio with VGX (the "Merger"). Inovio and VGX subsequently
negotiated an amended merger agreement (the "Amended Agreement"), which the parties executed on December 5, 2008. Completion of the Merger under the Amended Agreement is subject to registration
with the SEC of the Inovio securities to be issued in the Merger, receipt of approval from both companies' stockholders, and other customary closing conditions.

2. Summary of Significant Accounting Policies

Basis of Presentation

Inovio incurred a net loss attributable to common stockholders of $13.0 million for the year ended December 31, 2008 and had an
accumulated deficit of $152.8 million as of December 31, 2008. Management believes that Inovio's cash and equivalents of $14.1 million at December 31, 2008 are sufficient to meet its planned working
capital needs through December 31, 2009. To continue its product development Inovio plans to raise additional working capital through equity or debt financing. There can be no assurance that
additional sources of capital will be available at favorable terms, if at all. If Inovio is not able to secure additional funding, Inovio will be required to scale back its research and development
programs, preclinical studies and clinical trials, and general and administrative activities and may not be able to continue in business. These consolidated financial statements do not include any
adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue in business. Inovio's consolidated financial statements
as of and for the year ended December 31, 2008 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal
course of business for the foreseeable future.

Consolidation

The accompanying consolidated financial statements include the accounts of Inovio Biomedical Corporation and its domestic and foreign
subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

Use of estimates

The preparation of consolidated financial statements in accordance with U.S. generally accepted accounting principles requires us to
make estimates and judgments that affect the reported amounts of

F-8

---



Table of Contents

INOVIO BIOMEDICAL CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

2. Summary of Significant Accounting Policies (Continued)

assets,
liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. Inovio bases its estimates on historical experience and on various other assumptions that are
believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other
sources. Actual results may differ from these estimates under different assumptions or conditions. On an ongoing basis, Inovio reviews its estimates to ensure that these estimates appropriately
reflect changes in the business or as new information becomes available.

Cash and equivalents

Equivalents are highly liquid investments purchased with original maturities of three months or less and are stated at cost, which
approximates market value. At December 31, 2008 there were no cash equivalents held in money market funds. At December 31, 2007, cash equivalents included $3.7 million in money
market funds.

Accounts receivable

Trade accounts receivable are recorded at invoiced amounts and do not bear interest. Inovio performs ongoing credit evaluations of our
customers' financial condition. Credit is extended to customers as deemed necessary and generally does not require collateral. Management believes that the risk of loss is significantly reduced due to
the quality and financial position of our customers. No allowance for doubtful accounts was deemed necessary at December 31, 2008 and 2007.

Long-term investments

Inovio's investments consist of auction rate securities ("ARS") which are on deposit with a major financial institution and are stated
at fair market value. All of Inovio's investments are classified as municipal debt securities as of December 31, 2008 and 2007, and are ARS which have contractual maturities in excess of ten
years and reset to par on a monthly basis. See Note 3 for further discussion of the Company's long-term investments.

Auction Rate Securities Rights

Auction Rate Security Rights ("ARS Rights") consist of the right to sell ARS held by the Company back to the financial institution
which sold them to the Company, at par, at its sole discretion, any time during the period from June 30, 2010 through July 2, 2012, and gives the financial institution the right to
purchase these ARS or sell them on the Company's behalf at par anytime through July 2, 2012. See Note 3 for further discussion of the Company's ARS Rights.

Fixed assets

Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful life of
the assets, generally three to five years. Leasehold improvements are amortized over the shorter of the remaining term of the related leases or the estimated economic useful lives of the improvements.
Repairs and maintenance are expensed as incurred.

F-9

---



Table of Contents

INOVIO BIOMEDICAL CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

2. Summary of Significant Accounting Policies (Continued)

Cost method investments

Investments in corporate entities with less than a 20% voting interest are accounted for under the cost method. Inovio monitors these
investments for impairment and makes appropriate reductions in carrying values if it is determined that an impairment charge is required, based primarily on the financial condition and
near-term prospects of these companies.

The
Company's cost method investments consist of investments in two non-public companies of $25,000 and $10,250 for the year ended December 31, 2008, as compared to
$25,000 and $125,000, for the year ended December 31, 2007, respectively. During the year ended December 31, 2008 the Company recorded an $114,750 impairment charge on one of its cost
method investments due to certain events indicating a decline in the non-public company's fair value.

Goodwill

Goodwill represents costs which were in excess of the fair value in our acquisition of Inovio AS.

In
accordance with Statement of Financial Accounting Standards ("SFAS") No. 142,Goodwill and Other Intangible Assets, goodwill and
intangible assets with indefinite lives are not amortized but instead are measured for impairment annually, or when events indicate that impairment exists. Our accounting policy with respect to
reviewing goodwill for impairment is a two step process. The first step of the impairment test compares the fair value of our reporting unit with its carrying value including allocated goodwill. If
the carrying value of our reporting unit exceeds its fair value, then the second step of the impairment test is performed to measure the impairment loss, if any. We test goodwill for impairment at the
entity level which is considered our reporting unit. Our estimate of fair value is determined using both the Discounted Cash Flow method of the Income Approach and the Guideline Public Company method
of the Market Approach. The Discounted Cash Flow method estimates future cash flows of our business for a certain discrete period and then discounts them to their present value. The Guideline Public
Company method computes value indicators ("multiples") from the operating data of the selected publicly traded guideline companies. After these multiples were evaluated, appropriate value indicators
were selected and applied to the operating statistics of the reporting unit to arrive at indications of value. Specifically, we relied upon the application of Total Invested Capital based valuation
multiples for each guideline company. In applying the Income and Market Approaches, premiums and discounts were determined and applied to estimate the fair values of the reporting unit. To arrive at
the indicated value of equity under each approach, we then assigned a relative weighting to the resulting values from each approach to determine whether the carrying value of the reporting unit
exceeds its fair value, thus requiring step 2 of the impairment test.

We
conduct the impairment test annually on November 30th for each fiscal year for which goodwill is evaluated for impairment. We are also aware of the requirement to
evaluate goodwill for impairment at other times should circumstances arise pursuant to the guidance provided in SFAS 142, paragraph 26. To date, we have concluded that the fair value of
the reporting unit significantly exceeded the carrying value and therefore, step 2 of the impairment test has never been performed.

Intangible Assets

Intangible assets acquired as part of the Inovio AS acquisition are amortized using the straight-line method over their
estimated period of contractual and cash flow benefit, which is 18 years.

F-10

---



Table of Contents

INOVIO BIOMEDICAL CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

2. Summary of Significant Accounting Policies (Continued)

Patents
are recorded at cost and amortized using the straight-line method over the expected useful lives of the patents or 17 years, whichever is less. Cost is
comprised of the consideration paid for patents and related legal costs. If management determines that development of products to which patent costs relate is not reasonably certain or that costs
exceed recoverable value, such costs are charged to operations.

License
costs are recorded based on the fair value of consideration paid and amortized using the straight-line method over the shorter of the expected useful life of the
underlying patents or the term of the related license agreement.

Intangible
assets subject to amortization and long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of
an asset may not be recoverable in accordance with SFAS No. 144 discussed below. Additional factors we consider include the operational performance of our acquired businesses, estimates of
future cash flows, market conditions, and other qualitative factors. Any estimates and assumptions we use for reviewing potential impairments are consistent with our internal planning. See
Notes 7 and 18 for further discussion of the Company's goodwill and intangible assets.

Income taxes

Inovio accounts for income taxes using the liability method of tax allocation. Future income taxes are recognized for the future income
tax consequences attributable to differences between the carrying values of assets and liabilities and their respective income tax bases. Future income tax assets and liabilities are measured using
enacted income tax rates expected to apply to taxable income in the years in which temporary differences are expected to be recovered or settled. The effect on future income tax assets and liabilities
of a change in rates is included in earnings in the period that includes the enactment date. Future income tax assets are recorded in the consolidated financial statements if realization is considered
more likely than not.

Revenue recognition

Revenue is recognized in accordance with SAB No. 104,Revenue Recognition in Financial
Statements,and EITF Issue 00-21,Revenue Arrangements with Multiple Deliverables.

License
fees are comprised of initial fees and milestone payments derived from collaborative licensing arrangements. Inovio continues to recognize non-refundable milestone
payments upon the achievement of specified milestones, provided the milestone payment is substantive in nature and the achievement of the milestone was not reasonably assured at the inception of the
agreement. Inovio defers payments for milestone events which are reasonably assured and recognizes them ratably over the minimum remaining period of the performance obligations. Payments for
milestones which are not reasonably assured are treated as the culmination of a separate earnings process and are recognized as revenue when the milestones are achieved.

Inovio
has adopted a strategy of co-developing or licensing our gene delivery technology for specific genes or specific medical indications. Accordingly, Inovio has entered
into collaborative research and development agreements and has received funding for pre-clinical research and clinical trials. Payments under these agreements, which are
non-refundable, are recorded as revenue as the

F-11

---



Table of Contents

INOVIO BIOMEDICAL CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

2. Summary of Significant Accounting Policies (Continued)

related
research expenditures are incurred pursuant to the terms of the agreements and provided collectibility is reasonably assured.

Inovio
receives non-refundable grants under available government programs. Inovio records government grants applicable towards current expenditures as revenue when there is
reasonable assurance that the Company has complied with all conditions necessary to receive the grants, collectibility is reasonably assured, and the related expenditures have been incurred.

Research and development expenses

Since Inovio's inception, virtually all of the Company's activities have consisted of research and development efforts related to
developing electroporation technologies. Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits, facilities
and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to operations as they are incurred. Inovio reviews and accrues
clinical trials expense based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies and other events.

Net loss per share

Net loss per share is calculated in accordance with SFAS No. 128,Earnings Per
Share. Basic loss per share is computed by dividing the net loss for the year by the weighted average number of common shares outstanding during the year. Diluted loss per
share is calculated in accordance with the treasury stock method and reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted
to common stock. Since the effect of the assumed exercise of common stock options and other convertible securities was anti-dilutive for all periods presented, basic and diluted loss per
share are the same.

The
following table summarizes potential common shares that were excluded from historical basic and diluted net loss per share calculation because of their anti-dilutive
effect:

Common stock equivalents

As of
December 31,
2008

As of
December 31,
2007

As of
December 31,
2006Options to purchase common stock


4,616,714


3,465,462


2,798,900Warrants to purchase common stock


6,890,448


8,892,000


8,663,700Convertible preferred stock


104,409


217,720


1,177,959Non-vested restricted common stock


138,750


101,250


Total


11,750,321


12,676,432


12,640,559


Leases

Leases are classified as either capital or operating leases. Leases which transfer substantially all of the benefits and risks
incidental to the ownership of assets are accounted for as if there was an acquisition of an asset and incurrence of an obligation at the inception of the lease. All other leases are accounted for as
operating leases. Inovio's San Diego headquarters facility lease, which has escalating payments, is expensed on a straight-line basis over the term of five years. At the end of the
original

F-12

---



Table of Contents

INOVIO BIOMEDICAL CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

2. Summary of Significant Accounting Policies (Continued)

lease
term, Inovio has the option of renewing this lease for an additional five-year lease term at an annual rate equal to the fair market rental value of the property, as defined in the
lease agreement. This lease represents the primary expense and commitment as indicated in Note 11 "Commitments" below. Other leases exist for the Norway facility and for office machinery, such
as copiers, wherein lease expense is recorded as incurred.

Stock-based compensation

Inovio accounts for stock-based compensation in accordance with SFAS No. 123(R),Share-Based
Payment. Inovio estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in
estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions,
including the expected stock price volatility and expected option life. Inovio amortizes the fair value of the awards on a straight-line basis. All options grants are amortized over the
requisite service period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free
interest rate is based on the U.S. Treasury yield in effect at the time of grant. The forfeiture rate is based on historical data and Inovio records stock-based compensation expense only for those
awards that are expected to vest. The dividend yield is based on the fact that no dividends have been paid on common stock historically, and none are currently expected to be paid.

Assumptions
used in the Black-Scholes model are presented below:

Year Ended December 31,2008

2007

2006Risk-free interest rate


1.38% - 3.18%


4.07% - 4.67%


4.68% - 4.96%Expected volatility


69% - 91%


93% - 98%


98% - 109%Expected life in years


4


6


6Dividend yield











Other Accumulated Comprehensive Loss

Components of comprehensive loss are reported in the consolidated financial statements in the period in which they are recognized. The
components of comprehensive loss for us include net loss, unrealized gains and losses on investments and foreign currency translation adjustments. The components of accumulated other comprehensive
loss are indicated on the Consolidated Statements of Stockholder's Equity.

Pending Adoption of Recent Accounting Pronouncements

In November 2007, the EITF issued EITF Issue No. 07-1,Accounting for Collaborative
Arrangements Related to the Development and Commercialization of Intellectual Property.Companies may enter into arrangements with other companies to jointly develop,
manufacture, distribute, and market a product. Often the activities associated with these arrangements are conducted by the collaborators without the creation of a separate legal entity (that is, the
arrangement is operated as a "virtual joint venture"). The arrangements generally provide that the collaborators will share, based on contractually defined calculations, the profits or losses from the
associated activities. Periodically, the collaborators

F-13

---



Table of Contents

INOVIO BIOMEDICAL CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

2. Summary of Significant Accounting Policies (Continued)

share
financial information related to product revenues generated (if any) and costs incurred that may trigger a sharing payment for the combined profits or losses. The consensus requires
collaborators in such an arrangement to present the result of activities for which they act as the principal on a gross basis and report any payments received from (made to) other collaborators based
on other applicable GAAP or, in the absence of other applicable GAAP, based on analogy to authoritative accounting
literature or a reasonable, rational, and consistently applied accounting policy election. EITF Issue No. 07-1 is effective for collaborative arrangements in place at the beginning
of the annual period beginning after December 15, 2008. The Company does not expect the adoption of EITF Issue No. 07-1 to have a material impact on its consolidated
financial statements.

In
December 2007, the FASB issued SFAS No. 141(R),Business Combinations. SFAS No. 141(R) changes the requirements for an
acquirer's recognition and measurement of the assets acquired and liabilities assumed in a business combination, including the treatment of contingent consideration, pre-acquisition
contingencies, transaction costs, in-process research and development and restructuring costs. In addition, under SFAS No. 141(R), changes in an acquired entity's deferred tax
assets and uncertain tax positions after the measurement period will impact income tax expense. This statement is effective for the Company with respect to business combination transactions for which
the acquisition date is after December 31, 2008. The Company is currently evaluating the impact that SFAS No. 141(R) will have on its consolidated financial statements, including
specifically evaluating the impact upon consummation of the proposed Merger with VGX, if completed. The impact of adopting SFAS No. 141(R) on the Company's consolidated financial statements
depends on the terms of any future business combination transactions.

In
December 2007, the FASB issued SFAS No. 160,Noncontrolling Interests in Consolidated Financial Statements (an amendment of Accounting Research
Bulletin, or ARB, No. 51).SFAS No. 160 requires that noncontrolling (minority) interests be reported as a component of equity, that net income attributable to
the parent and to the noncontrolling interest be separately identified in the income statement, that changes in a parent's ownership interest while the parent retains its controlling interest be
accounted for as equity transactions, and that any retained noncontrolling equity investment upon the deconsolidation of a subsidiary be initially measured at fair value. This statement is effective
for fiscal years beginning after December 31, 2008, and shall be applied prospectively. However, the presentation and disclosure requirements of SFAS No. 160 are required to be applied
retrospectively for all periods presented. The retrospective presentation and disclosure requirements of this statement will be applied to any prior periods presented in financial statements for the
fiscal year ending December 31, 2009, and later periods during which the Company has a consolidated subsidiary with a noncontrolling interest. As of December 31, 2008, the Company does
not have any consolidated subsidiaries in which there is a noncontrolling interest.

In
April 2008, the FASB issued Staff Position No. 142-3,Determination of the Useful Life of Intangible Assets("FSP
No. 142-3"). FSP No. 142-3 amends the factors to be considered in assumptions used to determine the useful lives of recognized intangible assets recognized under
SFAS No. 142. The new guidance applies to intangible assets with contractual lives that are acquired individually or with a group of assets as well as those assets acquired in a business
combination. The new guidance is effective for fiscal years beginning after December 15, 2008 and interim periods. The Company will adopt the statement on January 1, 2009 and is
currently evaluating the impact FSP No. 142-3 will have on its consolidated financial statements.

F-14

---



Table of Contents

INOVIO BIOMEDICAL CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

2. Summary of Significant Accounting Policies (Continued)

In
November 2008, FASB ratified EITF Issue No. 08-7,Accounting for Defensive Intangible Assets.
EITF 08-7 applies to defensive intangible assets, which are acquired intangible assets that the acquirer does not intend to actively use but intends to hold to prevent its
competitors from obtaining access to them. As these assets are separately identifiable, EITF 08-7 requires an acquiring entity to account for defensive intangible assets as a
separate unit of accounting which should be amortized to expense over the period the asset diminished in value. Defensive intangible assets must be recognized at fair value in accordance with
SFAS 141R and SFAS 157. EITF 08-7 is effective for financial statements issued for fiscal years beginning after December 15, 2008. The Company will adopt
EITF 08-7 on January 1, 2009 and is currently evaluating the potential impact of EITF 08-7 on its consolidated financial statements when implemented.

Adoption of Recent Accounting Pronouncements

In September 2006, the Financial Accounting Standards Board, or FASB, issued SFAS No. 157,Fair Value
Measurements. SFAS No. 157 establishes a framework for measuring fair value in accordance with GAAP, clarifies the definition of fair value within that framework, and
expands disclosures about the use of fair value measurements. It also responds to investors' requests for expanded information about the extent to which companies measure assets and liabilities at
fair value, the information used to measure fair value and the effect of fair value measurements on earnings. SFAS No. 157 applies whenever other standards require (or permit) assets or
liabilities to be measured at fair value, and does not expand the use of fair value in any new circumstances. SFAS No. 157 was effective for the Company on January 1, 2008. The adoption
of SFAS No. 157 did not have a material impact on the Company's consolidated financial statements.

In
February 2007, the FASB issued SFAS No. 159,The Fair Value Option for Financial Assets and Financial LiabilitiesIncluding an amendment to
FASB Statement No. 115. SFAS No. 159 allows certain financial assets and liabilities to be recognized, at the Company's election, at fair market value, with any
gains or losses for the period recorded in the statement of operations. SFAS No. 159 includes available-for-sale securities in the assets eligible for this treatment.
Currently, the Company records the unrealized gains or losses for the period in comprehensive income (loss) and in the equity section of the balance sheet. SFAS No. 159 was effective for the
Company on January 1, 2008. The Company did not elect to adopt the fair value option under SFAS No. 159 on any assets or liabilities not previously carried at fair value, except for the
Auction Rate Securities Rights ("ARS Rights") that were recorded in connection with the Company's acceptance of the offer of ARS Rights from UBS as more fully described in Note 3.

In
June 2007, the EITF issued EITF Issue No. 07-3,Accounting for Nonrefundable Advance Payments for Goods or Services to be Used in Future
Research and Development Activities. The consensus requires companies to defer and capitalize prepaid, nonrefundable research and development payments to third parties over the
period that the research and development activities are performed or the services are provided, subject to an assessment of recoverability. EITF Issue No. 07-3 is effective for new
contracts entered into beginning on January 1, 2008. The adoption of EITF Issue No. 07-3 did not have a material impact on the Company's consolidated financial statements.

F-15

---



Table of Contents

INOVIO BIOMEDICAL CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

3. Investment Securities and Fair Value Measurements

Currently, the Company records the unrealized gains or losses on available-for-sale securities for the period in comprehensive income (loss) and in the equity
section of the balance sheet. SFAS No. 159 was effective for the Company on January 1, 2008. The Company did not elect to adopt the fair value option under SFAS No. 159 on any
assets or liabilities not previously carried at fair value, except for the Auction Rate Securities Rights ("ARS Rights") that were recorded in connection with the Company's acceptance of the offer of
ARS Rights from its investment provider, UBS Financial Services, Inc., a subsidiary of UBS AG ("UBS"), as more fully described below.

SFAS
No. 157 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as
observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and
Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.

The
Company's financial assets measured at fair value on a recurring basis subject to the disclosure requirements of SFAS No. 157 at December 31, 2008 are as follows:

Fair Value Measurements at
Reporting Date UsingTotal

Significant
Unobservable
Inputs
(Level 3)Auction rate securities, long-term

$
9,169,471

$
9,169,471Auction rate securities rights, long-term


4,281,494


4,281,494Total

$
13,450,965

$
13,450,965


The
Company has determined that no items meet the criteria for definition within the level 1 or 2 hierarchies. Level 3 assets held as of December 31, 2008 include
municipal debt obligations with an auction rate reset mechanism issued by municipalities. These auction rate securities ("ARS") are AAA-rated debt instruments with long-term
maturities and interest rates that are reset at short-term intervals through auctions. Due to conditions in the global credit markets, in 2008, these securities, representing a par value
of $13.6 million, had insufficient demand resulting in multiple failed auctions. As a result, these effected securities are currently not liquid and the interest rates have been reset to
predetermined higher rates. Due to the illiquid state of these investments, the Company has classified the balance of its ARS as long-term investments in the balance sheet as of
December 31, 2008.

In
December 2008, the Company, via its wholly-owned subsidiary Genetronics, Inc., or "Genetronics", which holds the ARS, accepted an offer of ARS Rights from UBS. The ARS Rights
permit the Company to require UBS to purchase the Company's ARS at par value at any time during the period of June 30, 2010 through July 2, 2012. If the Company does not exercise its ARS
Rights, the ARS will continue to accrue interest as determined by the auction process or the terms of the ARS if the auction fails. If the ARS Rights are not exercised before July 2, 2012 they
will expire and UBS will have no further obligation to buy the Company's ARS. UBS has the discretion to purchase or sell the Company's ARS at any time without prior notice so long as the Company
receives a payment at par upon any sale or disposition. UBS will only exercise its discretion to purchase or sell the Company's ARS for the purpose of restructurings, dispositions or other solutions
that will provide the Company

F-16

---



Table of Contents

INOVIO BIOMEDICAL CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

3. Investment Securities and Fair Value Measurements (Continued)

with
par value for its ARS. As a condition to accepting the offer of ARS Rights, the Company released UBS from all claims except claims for consequential damages relating to its marketing and sales of
ARS. The Company also agreed not to serve as a class representative or receive benefits under any class action settlement or investor fund.

In
conjunction with the acceptance of the ARS Rights, Genetronics also amended its existing loan agreement with UBS Bank USA, increasing the existing credit line up to
$12.1 million, with the ARS pledged as collateral. Genetronics fully drew down on the credit line in December 2008 (See Note 4).

Typically
the fair value of ARS approximates par value due to the frequent resets through the auction process. While the Company continues to earn interest on its ARS at the maximum
contractual rates, these investments are not currently trading and therefore do not currently have a readily determinable market value. Accordingly, the estimated fair value of the ARS no longer
approximates par value. The Company has used a discounted cash flow model to determine the estimated fair value of its investment in ARS and its ARS Rights as of December 31, 2008. The
assumptions used in preparing the discounted cash flow model include estimates for interest rates, timing and amount of cash flows and expected holding period of the ARS and ARS Rights.

The
Company elected to measure the ARS Rights under the fair value option of SFAS No. 159 to mitigate volatility in reported earnings due to their linkage to the ARS, and
recognized a gain of approximately $4.3 million and recorded a corresponding long-term investment. Reflecting management's intent to exercise its ARS Rights during the period of
June 30, 2010 through July 2, 2012, the Company transferred its ARS from investments available-for-sale to trading securities. As a result of this transfer and as
the Company no longer intends to hold the ARS until the fair value recovers, the Company recognized an other-than-temporary impairment loss of approximately
$4.4 million, representing a reversal of the related temporary valuation allowance that was previously recorded in other comprehensive loss. Management believes this loss is primarily
attributable to the limited liquidity of these investments and has no reason to believe that any of the underlying issuers are presently at risk of default. The recording of the fair value of the ARS
Rights and the recognition of the other-than-temporary impairment loss resulted in a net impact to the Consolidated Statement of Operations for the year ended
December 31, 2008 of approximately $99,000, which was recorded as other expense. The ARS Rights will continue to be measured at fair value utilizing Level 3 inputs until the earlier of
their maturity or exercise.

F-17

---



Table of Contents

INOVIO BIOMEDICAL CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

3. Investment Securities and Fair Value Measurements (Continued)

The
following table provides a summary of changes in fair value of the Company's Level 3 financial assets as of December 31, 2008:

Auction Rate
SecuritiesBalance at January 1, 2008

$
Transfers in to Level 3


14,050,000Total unrealized losses included in other expense


(4,380,529
)Recognition of ARS Rights


4,281,494Purchases and settlements (net)


(500,000
)Balance at December 31, 2008

$
13,450,965Total loss included in other expense in the consolidated statement of operations relating to assets held at December 31, 2008

$
(99,035
)


4. Line of Credit

On August 26, 2008, the Company received notice from UBS Bank USA ("UBS") that the Company's application had been approved for a $5.0 million uncommitted demand revolving
line of credit ("Line of Credit") secured by ARS held by the Company in an account with UBS Financial Services, Inc. (the "Collateral Account"), to provide additional working capital. On
December 19, 2008, the Company amended its existing loan agreement with UBS Bank USA, increasing the existing credit line up to $12.1 million, with the ARS pledged as collateral. The
Company fully drew down on the line of credit on December 23, 2008. Advances under the Line of Credit bear interest at LIBOR plus 1.00% (the "Spread Over LIBOR"). UBS may change the Spread Over
LIBOR at its discretion when the Collateral consisting of ARS may be sold, exchanged or otherwise conveyed by the Company for gross proceeds that are, in the aggregate, not less than the par value of
such securities. The loan will be treated as a "no net cost loan", as it will bear interest at a rate equal to the average rate of interest paid to the Company on the pledged ARS, and the net interest
cost to the Company will be zero.

5. Major Customers and Concentration of Credit Risk

Customer

2008

% of Total
Revenue

2007

% of Total
Revenue

2006

% of Total
RevenueMerck

$
631,549


30
%
$
3,268,884


68
%
$
1,535,540


44
%Wyeth


846,693


40


1,118,023


23





Valentis














655,123


19U.S Army grant


92,954


4


21,423





898,932


26All other


526,436


26


399,399


9


378,583


11Total Revenue

$
2,097,632


100
%
$
4,807,729


100
%
$
3,468,178


100
%


During
the years ended December 31, 2008 and 2007, we recognized revenue from our collaboration and licensing agreements with Merck and Wyeth, which were executed in May 2004 and
November 2006, respectively. As of December 31, 2008, $397,000 or 59%, and $221,000 or 33%, of our total accounts receivable balance of $671,000, was attributable to Merck and Wyeth,
respectively. As of December 31, 2007, $240,000 or 21%, and $889,000 or 78%, of our total accounts receivable balance of $1.1 million, was attributable to Merck and Wyeth, respectively.

F-18

---



Table of Contents

INOVIO BIOMEDICAL CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

5. Major Customers and Concentration of Credit Risk (Continued)

There is minimal credit risk with these customers based upon collection history, their size and financial condition. Accordingly, we do not consider it necessary to record a reserve for
uncollectible accounts receivable.

6. Fixed Assets

Fixed assets at December 31, 2008 and 2007 consist of the following:

Cost

Accumulated
depreciation
and
amortization

Net book
valueAs of December 31, 2008Machinery, equipment and office furniture

$
1,397,829

$
(1,205,536
)
$
192,293Leasehold improvements


341,133


(179,619
)

161,514$
1,738,962

$
(1,385,155
)
$
353,807As of December 31, 2007Machinery, equipment and office furniture

$
2,026,992

$
(1,836,966
)
$
190,026Leasehold improvements


734,317


(522,616
)

211,701$
2,761,309

$
(2,359,582
)
$
401,727


Depreciation
expense for the years ending December 31, 2008, 2007 and 2006 was $195,000, $186,000 and $207,000, respectively. In accordance with SFAS No. 144, the company
determined that the carrying value of these long-lived assets was not impaired for the periods presented.

7. Goodwill and Intangible Assets

In accordance with SFAS No. 142,Goodwill and Other Intangible Assets, the Company's goodwill is not amortized, but is subject to
an annual impairment test. The following sets forth the intangible assets by major asset class:

December 31, 2008

December 31, 2007Useful
Life (Yrs)

Gross

Accumulated
Amortization

Net Book
Value

Gross

Accumulated
Amortization

Net Book
ValueNon-Amortizing:Goodwill(a)




$
3,900,713

$


$
3,900,713

$
3,900,713

$


$
3,900,713Amortizing:Patents


8 - 17


5,685,961


(3,255,231
)

2,430,730


5,224,109


(2,775,713
)

2,448,396Licenses


8 - 17


1,198,781


(947,721
)

251,060


1,198,781


(854,497
)

344,284Other(b)


18


4,050,000


(881,250
)

3,168,750


4,050,000


(656,250
)

3,393,750Total Intangible assets





10,934,742


(5,084,202
)

5,850,540


10,472,890


(4,286,460
)

6,186,430Total goodwill and intangible assets





14,835,455


(5,084,202
)

9,751,253

$
14,373,603

$
(4,286,460
)
$
10,087,143


---

F-19

---



Table of Contents

INOVIO BIOMEDICAL CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

7. Goodwill and Intangible Assets (Continued)

Aggregate amortization expense on intangible assets was $798,000, $832,000 and $768,000 for the years ended December 31, 2008, 2007 and
2006, respectively. Amortization expense related to intangible assets at December 31, 2008 for each of the next five fiscal years and beyond is expected to be incurred as follows:

2009

$
703,5432010


652,8242011


603,1482012


554,8012013


504,164Thereafter


2,832,060$
5,850,540


In
accordance with SFAS No. 142, the Company has completed its annual impairment tests and fair value analysis for goodwill and other non-amortizing intangible assets,
respectively, held throughout the year. The Company conducts the impairment test annually on November 30th for each fiscal year for which goodwill is evaluated for
impairment. There were no impairments or impairment indicators present and no loss was recorded during the year ended December 31, 2008.

8. Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses at December 31, 2008 and 2007 consist of the following:

As of
December 31,
2008

As of
December 31,
2007Trade accounts payable

$
377,332

$
394,786Accrued compensation


372,015


559,685Other accrued expenses


617,953


852,834$
1,367,300

$
1,807,305


9. Deferred Revenue

We defer revenue recognition of cash receipts from licensing and other agreements and recognize them ratably over the minimum remaining period of our performance obligations. The
combined

F-20

---



Table of Contents

INOVIO BIOMEDICAL CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

9. Deferred Revenue (Continued)

current
and long-term deferred revenue balance of $4.8 million consists primarily of an unrecognized balance of $3.9 million arising from the $4.5 million payment
received from Wyeth in November 2006 for the 15 year collaborative and licensing agreement.

10. Stockholders' Equity

Preferred Stock

Outstanding as of
December 31,Authorized

Issued

2008

2007Series A Preferred Stock, par $0.001


1,000


817





Series B Preferred Stock, par $0.001


1,000


750





Series C Preferred Stock, par $0.001


1,091


1,091


71


71Series D Preferred Stock, par $0.001


1,966,292


1,966,292





113,311


The
following is a summary of changes in the number of outstanding shares of our preferred stock for the years ended December 31, 2006, 2007 and 2008:

Series A

Series B

Series C

Series DShares Outstanding as of January 1, 2006


52


100


337


1,561,935Preferred Shares converted


(52
)

(100
)

(235
)

(533,968
)Shares Outstanding as of December 31, 2006








102


1,027,967Preferred Shares converted








(31
)

(914,656
)Shares Outstanding as of December 31, 2007








71


113,311Preferred Shares converted











(113,311
)Shares Outstanding as of December 31, 2008








71





The
shares of the Company's outstanding Series C Preferred Stock have the following pertinent rights and privileges, as set forth in the Company's Amended and Restated Certificate
of Incorporation and its Certificates of Designations, Rights and Preferences related to the various series of preferred stock.

Dividend Preferences

The holders of all series of the Company's preferred stock are entitled to receive dividends on a pari passu basis with the holders of
common stock, when, if and as declared by the Company's Board of Directors.

In
addition, the holders of the Series C Preferred Stock received a mandatory dividend rate of 6% per annum per outstanding share of Series C Preferred Stock, payable
quarterly, based on the $10,000 Liquidation Preference of such share through the period ending on May 20, 2007. These dividends were paid in cash or common stock equal to the equivalent cash
amount divided by the 20 day preceding average closing price. The Company could only elect to pay the dividends in shares of common stock if the average closing price of the shares of common
stock for the 20 days immediately preceding the dividend payment date was equal to or greater than the conversion price of either of the relevant series of Preferred Stock. All dividends were
paid to outstanding Series C Preferred Stockholders on each quarter-end payment date. No dividends were paid to holders of our Series C

F-21

---



Table of Contents

INOVIO BIOMEDICAL CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

10. Stockholders' Equity (Continued)

Preferred
Stock during the year ended December 31, 2008. We paid cash dividends to holders of our Series C Preferred Stock of $23,000 during the year ended December 31, 2007.

Rights on Liquidation

In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company (a "liquidation event"), before any
distribution of assets of the Company shall be made to or set apart for the holders of common stock, the holders of Series C Preferred Stock, pari passu, are entitled to receive payment of such
assets of the Company in an amount equal to $10,000 per share of such series of preferred stock, plus any accumulated and unpaid dividends thereon (whether or not earned or declared).

If
the assets of the Company available for distribution to stockholders exceed the aggregate amount of the liquidation preferences payable with respect to all shares of each series of
preferred stock then outstanding, then, after the payment of such preferences is made or irrevocably set aside, the holders of the Company's common stock are entitled to receive a pro rata portion of
such assets based on the aggregate number of shares of common stock held by each such holder. The holders of the Company's outstanding preferred stock shall participate in such a distribution on a
pro-rata basis, computed based on the number of shares of common stock which would be held by such preferred holders if immediately prior to the liquidation event all of the outstanding
shares of the preferred stock
had been converted into shares of common stock at the then current conversion value applicable to each series.

A
Change of Control of the Company (as defined in the Certificates of Designations, Rights and Preferences) is not a liquidation event triggering the preferences described above, and is
instead addressed by separate terms in the Series C Certificates of Designations, Rights, and Preferences.

Although
the liquidation preferences are in excess of the par value of $0.001 per share of the Company's preferred stock, these preferences are equal to or less than the stated value of
such shares based on their original purchase price.

Voting Rights

The holders of all series of the Company's preferred stock outstanding have full voting rights and powers equal to the voting rights
and powers of holders of the Company's common stock and are entitled to notice of any stockholders' meeting in accordance with the Company's Bylaws. Holders of the Company's preferred stock are
entitled to vote on any matter upon which holders of the Company's common stock have the right to vote, including, without limitation, the right to vote for the election of directors together with the
holders of common stock as one class.

Actions Requiring the Consent of Holders of Convertible Preferred Stock

As long as a certain number of shares of each series of the Company's preferred stock issued on the respective "Date of Original Issue"
for such series are outstanding, the consent of at least a majority of the shares of that series of preferred stock outstanding are necessary to approve:



F-22

---



Table of Contents

INOVIO BIOMEDICAL CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

10. Stockholders' Equity (Continued)



These
specific voting rights are applicable for the Series C Preferred Stock as long as at least 35% of the number of shares of Series C Preferred Stock issued on the Date
of Original Issue remain outstanding, and the same threshold applies to the Series D Preferred Stock. As of December 31, 2008, there were no voting rights remaining.

Participation Rights

Holders of the Series C Preferred Stock have the right to participate with respect to the Company's issuance of any equity or
equity-linked securities or debt convertible into equity or in which there is an equity component ("Additional Securities") on the same terms and conditions as offered by the Company to the other
purchasers of such Additional Securities. However securities issued or issuable upon any of the following are not deemed "Additional Securities": (A) the conversion of outstanding preferred
stock or exercise of related warrants, or the issuance of shares of common stock as payment of dividends to holders of preferred stock, (B) the exercise of any warrants or options outstanding
prior to the authorization or issuance of the series of preferred stock in question (C) the issuance (at issuance or exercise prices at or above fair market value) of common stock, stock awards
or options under, or the exercise of any options granted pursuant to, any Board-approved employee stock option or similar plan for the issuance of options or capital stock of the Company,
(D) the issuance of shares of common stock pursuant to a stock split, combination or subdivision of the outstanding shares of common stock, and (E) for evaluation of the rights of the
Series C Preferred Stock
only, in connection with a bona fide joint venture or development agreement or strategic partnership, the primary purpose of which is not to raise equity capital.

Each
time the Company proposes to offer any Additional Securities, it is obligated to provide each holder of shares of the Series C Preferred Stock notice of such intention
including the terms of such

F-23

---



Table of Contents

INOVIO BIOMEDICAL CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

10. Stockholders' Equity (Continued)

intended
offering (including size and pricing) and the anticipated closing date of the sale. These preferred stockholders then have a specified period in which to respond to the Company to elect to
purchase or obtain, at the price and on the terms specified in the Company's notice, up to that number of such Additional Securities which equals such holder's Pro Rata Amount. The "Pro Rata Amount"
for any given holder of shares of the Series C Preferred Stock equals that portion of the Additional Securities offered by the Company which equals the proportion that the number of shares of
common stock that such preferred stockholder owns or has the right to acquire to the total number of shares of common stock then outstanding (assuming in each case the full conversion and exercise of
all convertible and exercisable securities then outstanding).

The
holders of the Series C Preferred Stock have the right to pay the consideration for the Additional Securities purchasable upon such participation with shares of such series of
Preferred Stock, which will be valued for such purpose at the applicable series' Liquidation Preference plus any accrued and unpaid dividends for such purpose. However, when shares of such preferred
stock are used as participation consideration, then such holder's Pro Rata Amount is increased (but not decreased) to the extent necessary to equal that number of Additional Securities as are
convertible into or exchangeable for such number of shares of Common Stock as is obtained by dividing (a) the Liquidation Preference attributable to such holder's shares of the applicable
series of Preferred Stock plus any accrued and unpaid dividends on such Preferred Stock by (b) the Conversion Value then in effect for such shares, and in such event the Company shall be
obligated to sell such number of Additional Securities to each such holder, even if the aggregate Pro Rata Amount for all such holders exceeds the aggregate amount of Additional Securities that the
Company had initially proposed to offer. To the extent that not all holders of a particular series of preferred stock elect to participate up to their full Pro Rata Amounts, the participating holders
of that series of preferred stock have the right to increase their participation accordingly.

The
participation rights of the holders of the Series C Preferred Stock may not be assigned or transferred, other than assignment to any wholly-owned subsidiary or parent of, or
to any corporation or entity that is, within the meaning of the Securities Act, controlling, controlled by or under common control with, any such holder. As a result of transfers, the holders of the
Series C Preferred Stock outstanding as of December 31, 2008 no longer had such participation rights.

During
our October 2006, December 2005 and January 2005 common stock offerings, we informed holders of our outstanding Series A, B, and C Cumulative Convertible Preferred Stock
with participation rights, of their ability to participate in the respective offering based upon the pricing of the transaction and the applicable liquidation preference for the series of preferred
share participating.
These participating stockholders obtained incremental shares of common stock as a result of exercising their participation rights, thereby converting their outstanding shares of Cumulative Convertible
Preferred Stock at a lower offering price compared to their current conversion price. The right to participate was available only for a limited period time in relation to the specific transaction and
the exercise of the existing participation right did not reflect or create a lasting change in the holders' conversion privileges. Some of the participating stockholders had previously converted a
portion of their shares of the Company's preferred stock pursuant to their optional conversion rights, and most of the participating stockholders wholly converted their remaining shares of the
Company's preferred stock through exercise of their participation rights in the noted offerings.

F-24

---



Table of Contents

INOVIO BIOMEDICAL CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

10. Stockholders' Equity (Continued)

Conversion Rights

The Series C Preferred Stock each provide the holder of such shares an optional conversion right and provide a mandatory
conversion upon certain triggering events.

Right to ConvertThe holder of any share or shares of Series C Preferred Stock has the right at any time, at such holder's option,
to convert
all or any lesser portion of such holder's shares of the Preferred Stock into such number of fully paid and non-assessable shares of Common Stock as is determined by dividing
(i) the aggregate Liquidation Preference applicable to the particular series of preferred shares, plus accrued and unpaid dividends thereon by (ii) the applicable Conversion Value (as
defined in the relevant series' Certificate of Designations, Rights and Preferences) then in effect for such series of preferred shares. The Company is not obligated to issue any fractional shares or
scrip representing fractional shares upon such conversion and instead shall pay the holder an amount in cash equal to such fraction multiplied by the current market price per share of the Company's
common stock.

Mandatory ConversionThe Company has the option upon thirty (30) days prior written notice, to convert all of the outstanding
shares of the
Series C Preferred Stock into such number of fully paid and non-assessable shares of common stock as is determined by dividing (i) the aggregate Liquidation Preference of the
shares of the relevant series of preferred stock to be converted plus accrued and unpaid dividends thereon by (ii) the applicable Conversion Value (as defined in the relevant series'
Certificate of Designations, Rights and Preferences) then in effect, if at any time after
twelve months following the Original Issue Date of each such series of preferred stock all of the following triggering events occur:



As
of December 31, 2008, our outstanding shares of the Series C Preferred Stock were convertible into 104,409 shares of our common stock at a conversion price of $6.80 per
share, and the applicable Daily Market Price of the common stock for triggering mandatory conversion equaled $18.00 per share. As of December 31, 2008 there were no shares of Series D
Preferred Stock outstanding.

Imputed and Declared Dividends on Preferred Stock

The holders of our Series A and B Preferred Stock were entitled to receive an annual dividend at the rate of 6%, payable
quarterly, through September 30, 2006. These dividends were payable in cash unless the closing price of our common shares for the 20 trading days immediately preceding the

F-25

---



Table of Contents

INOVIO BIOMEDICAL CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

10. Stockholders' Equity (Continued)

dividend
payment date was equal to or greater than the conversion price of such shares, in which event we may have elected to pay the dividends to the holders in common stock. As part of this dividend
to holders of Series A and B Preferred Stock, we issued a total of 2,871 common shares valued at $8,000, and paid $15,000 in cash during 2006. There were no shares of Series A or B
Preferred Stock outstanding on December 31, 2008, 2007 or 2006, respectively.

The
holders of our Series C Preferred Stock are entitled to receive an annual dividend at the rate of 6%, payable quarterly, through May 20, 2007. These dividends are
payable in cash unless the closing price of our common shares for the 20 trading days immediately preceding the dividend payment date is equal to or greater than the conversion price of such shares,
in which event we may elect to pay the dividends to the holders in common stock. As part of this dividend, we paid cash of $23,000 during fiscal 2007 to holders of our Series C Preferred Stock.
We paid cash $117,000 during fiscal 2006 to holders of our Series C Preferred Stock and accrued $15,000 for certain holders of our Series C Preferred Stock who participated in our
October 2006 equity financing, during fiscal 2006. No dividends were paid to holders of our Series C Preferred Stock during the year ended December 31, 2008.

During
2006, we recorded an imputed dividend charge of $1.9 million during the three months ended December 31, 2006, related to the investors who converted
$1.2 million of their Series C Preferred Stock investment into 473,744 shares of our common stock as part of our October 2006 private placement. This imputed dividend charge was
calculated using guidance contained in Emerging Issues Task Force ("EITF") Issue No. 00-27,Application of Issue No. 98-5 to Certain
Convertible Instruments. As part of this private placement, these investors received 304,450 additional shares of our common stock, as compared to the number of shares of our
common stock into which their existing Series C Preferred Stock could have been converted under the original terms of the Series C Preferred Stock. Under EITF Issue
No. 00-27, this incremental number of shares of our common stock was multiplied by the price of our common stock on the commitment date of the original Series C Preferred
Stock issuance, or $6.08 per share, to calculate the $1.9 million imputed dividend charge associated with this beneficial conversion.

Common Stock

In August 2007, we entered into an agreement with an outside consulting advisor pursuant to which we issued 230,000 registered shares
of common stock and registered warrants to purchase 150,000 shares of common stock, as payment of a non-refundable retainer in connection with the engagement of its services. The warrants
issued have an exercise price of $3.00 per share, and are exercisable through August 6, 2012. As of December 31, 2008, none of these warrants have been exercised.

In
May 2007, we completed a registered equity financing, whereby we sold 4,595,094 shares of our common stock resulting in gross aggregate cash proceeds of $16.2 million.

In
March 2007, we entered into an agreement in which we agreed to issue a total of 90,000 restricted shares of our common stock in equal quarterly installments in exchange for consulting
services. As of December 31, 2008, we had issued all 90,000 restricted common shares.

In
January 2007, we exchanged for 2,201,644 restricted shares of our common stock and warrants to purchase up to 770,573 restricted shares of our common stock for 2,201,644 ordinary
shares of our Singapore subsidiary Inovio Asia Pte. Ltd. (IAPL), pursuant to the terms of the Securities Purchase

F-26

---



Table of Contents

INOVIO BIOMEDICAL CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

10. Stockholders' Equity (Continued)

and
Exchange Agreement under which the ordinary shares were originally issued by IAPL in October 2006 for $5.3 million. The warrants issued have an exercise price of $2.87 per share and are
exercisable through October 13, 2011. As of December 31, 2008, none of these warrants have been exercised.

In
March 2007, we terminated our exclusive royalty-free license to IAPL allowing our subsidiary to use certain of our intellectual property, which had been issued in October
2006 prior to the ordinary share financing described above, in exchange for 6,584,365 ordinary shares of IAPL. Upon termination we retained the IAPL ordinary shares received in the license
transaction.

In
October 2006, we completed a registered offering with foreign investors, whereby we sold 4,074,067 shares of our common stock and issued warrants to purchase 1,425,919 shares of our
common stock which resulted in gross aggregate cash proceeds of $9.9 million. As part of this offering, we informed holders of our then outstanding Series C Preferred Stock who held
participation rights, of their ability to participate in the respective offering based upon the pricing of the transaction and the applicable liquidation preference for their series of preferred
shares with such rights. Some of these participating stockholders had previously converted a portion of their shares of preferred stock pursuant to their optional conversion rights, and most of these
participating stockholders wholly converted their remaining shares of the Company's preferred stock through exercise of their participation rights in this offering. By electing to participate in this
offering, these participating preferred stockholders converted 115.12 shares of previously issued Series C Preferred Stock and $14,571 of accrued dividends into 479,722 restricted shares of our
common stock and warrants to purchase 167,902 restricted shares of our common stock. These participating stockholders received 304,450 additional restricted shares of our common stock as compared to
the number of shares of our common stock into which their existing Series C Preferred Stock could have been converted under the original terms of the Series C Preferred Stock. As a
result, we recorded an imputed dividend charge of $1.9 million related to the participating stockholders who converted $1.2 million of their previous Series C Preferred Stock
investment. We calculated this imputed dividend charge pursuant to the guidance contained in Emerging Issues Task Force ("EITF") Issue No. 00-27,Application
of Issue No. 98-5 to Certain Convertible Instruments, where the incremental number of shares of our common stock which was received by our participating
Series C Preferred Stockholders was multiplied by the price of our common stock on the commitment date of the original Series C Preferred Stock issuance, or $6.08 per share, to calculate
the imputed dividend charge associated with this beneficial conversion. All warrants issued in connection with our 2006 registered offering have an exercise price of $2.87 per share and are
exercisable through October 13, 2011. As of December 31, 2008, none of these warrants have been exercised.

In
July and October 2006, we issued 25,000 and 24,261 shares of our common stock, respectively, to an outside consulting company in payment of a non-refundable retainer in
connection with the engagement of its services.

In
June 2006, we issued 86,956 common shares to a licensing company in exchange for various patents and other assets and a $50,000 shareholder note receivable.

Warrants

In addition to warrants granted as discussed above, the Company has issued the following additional warrants.

F-27

---



Table of Contents

INOVIO BIOMEDICAL CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

10. Stockholders' Equity (Continued)

Participants
in our December 2005 private placement were issued five-year warrants to purchase an aggregate of 3,462,451 shares of our common stock with an exercise price of
$2.93 per share, exercisable through December 30, 2010. As of December 31, 2008, none of these warrants have been exercised.

In
connection with the leasing of our new corporate headquarters, the Company issued a warrant to purchase 50,000 shares of our common stock at $5.00 per share to the landlord of this
leased facility in December 2004. This warrant is immediately exercisable and expires on December 6, 2009, five years from the date of issuance. This warrant was valued on the date of issuance
using the Black-Scholes pricing model. The fair value of this warrant, $121,000, will be recognized ratably over the five-year term of the lease as rent expense. As of December 31,
2008, none of these warrants have been exercised.

Participants
in our Series C Preferred Stock offering in May 2004 were issued five-year warrants to purchase 561,084 shares of our common stock at an exercise price of
$8.80 per share, exercisable through May 10, 2009. The placement agents for the Series C Preferred Stock offering were also issued five-year warrants to purchase 152,519
shares of our common stock at an exercise price of $6.80 per share, exercisable through May 10, 2009. As of December 31, 2008, none of these warrants have been exercised.

On
September 15, 2000, we entered into an exclusive license agreement with the University of South Florida Research Foundation, Inc. (USF), whereby USF granted us an
exclusive, worldwide license to USF's rights in patents and patent applications generally related to needle electrodes ("License Agreement"). Pursuant to the License Agreement, we granted USF and its
designees warrants to
acquire 150,000 common shares for $9.00 per share until September 14, 2010. Of the total warrants granted, 75,000 vested at the date of grant and the remainder will vest upon the achievement of
certain milestones. The 75,000 non-forfeitable vested warrants were valued at $554,000 using the Black- Scholes pricing model and were recorded as other assets with a credit to additional
paid-in capital. The remaining 75,000 warrants are forfeitable and will be valued at the fair value on the date of vesting using the Black- Scholes pricing model. As of December 31,
2008, no warrants issued in connection with this licensing agreement had been exercised.

In
July 2008, warrants to purchase 2,001,552 shares of our common stock expired, issued in connection with our Series A and B Preferred Stock offerings.

Stock options

The Company has one active stock and cash-based incentive plan, our 2007 Omnibus Incentive Plan (the "Incentive Plan"),
pursuant to which we have granted stock options and restricted stock awards to executive officers, directors and employees. The plan was adopted on March 31, 2007, approved by the stockholders
on May 4, 2007, and approved by the stockholders as amended on May 2, 2008. The Incentive Plan reserves 1,750,000 shares of our common stock for issuance as or upon exercise of incentive
awards granted and to be granted at future dates. At December 31, 2008, we had 42,938 shares of common stock available for future grant and had outstanding 138,750 shares of unvested restricted
common stock, 101,250 shares of vested restricted stock, and options to purchase 1,465,812 shares of common stock. The awards granted and available for future grant under the Incentive Plan generally
have a term of ten years and generally vest over a period of three years. The Incentive Plan terminates by its terms on March 31, 2017.

F-28

---



Table of Contents

INOVIO BIOMEDICAL CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

10. Stockholders' Equity (Continued)

The Incentive Plan supersedes all of our previous stock option plans, which include our 1997 Stock Option Plan, under which we had options to purchase 14,750 shares of common stock
outstanding and our Amended 2000 Stock Option Plan, under which we had options to purchase 3,136,152 shares of common stock outstanding at December 31, 2008. The terms and conditions of the
options outstanding under these plans remain unchanged.

Total
compensation cost under SFAS No. 123(R) for our stock plans for the years ended December 31, 2008, 2007 and 2006 was $1.0 million, $1.6 million, and
$1.3 million of which $286,000, $354,000 and $423,000 was included in research and development expenses and $746,000, $1.2 million and $921,000 was included in general and administrative
expenses, respectively.

At
December 31, 2008 and 2007, there was $752,000 and $1.3 million of total unrecognized compensation cost, respectively, related to unvested stock options, which is
expected to be recognized over a weighted-average period of one year.

The
Company accounts for options granted to non-employees in accordance with Emerging Issues Task Force ("EITF") No. 96-18, Accounting for Equity Instruments That Are Issued to Other Than Employees for Acquiring, or in
Conjunction with Selling, Goods or Services, and
Statement of Financial Accounting Standard ("SFAS") No. 123(R),Share-Based Payment. The fair value of these options at the measurement dates was
estimated using the Black-Scholes pricing model.

Total
stock-based compensation for options granted to non-employees for the years ended December 31, 2008, 2007 and 2006, was $58,000, $119,000, and $203,000,
respectively. As of December 31, 2008 and 2007, 1,076,031 and 455,937 options remained outstanding, respectively.

The
following table summarizes total stock options outstanding at December 31, 2008:

Options outstanding

Options exercisableExercise price

Options
outstanding

Weighted-
average
remaining
contractual life
(in years)

Weighted average
exercise price

Options
exercisable

Weighted-
average
exercise
price$0.00 - $2.00


1,914,717


8.1

$
1.03


868,668

$
1.23$2.01 - $4.00


2,231,998


6.9

$
2.97


1,662,143

$
2.92$4.01 - $6.00


386,499


5.3

$
4.95


386,499

$
4.95$6.01 - $8.00


68,750


4.4

$
6.22


68,750

$
6.22$8.01 - $22.00


14,750


0.5

$
15.59


14,750

$
15.594,614,714


7.2

$
2.42


3,000,810

$
2.83


At
December 31, 2008, the aggregate intrinsic value of options outstanding was $9,000, the aggregate intrinsic value of options exercisable was $2,000, and the weighted average
remaining contractual term of options exercisable was 6.3 years.

At
December 31, 2007, the aggregate intrinsic value of options outstanding was $150; the aggregate intrinsic value of options exercisable was $150 and the weighted average
remaining contractual term of options exercisable was 6.1 years.

F-29

---



Table of Contents

INOVIO BIOMEDICAL CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

10. Stockholders' Equity (Continued)

Stock
option activity under our stock option plans was as follows:

Number of
shares

Weighted-average
exercise priceBalance, December 31, 2005


2,383,888

$
3.55Granted


872,750


2.56Exercised


(148,628
)

1.69Cancelled


(309,110
)

4.64Balance, December 31, 2006


2,798,900


3.22Granted


963,125


3.20Exercised


(94,563
)

2.31Cancelled


(202,000
)

4.57Balance, December 31, 2007


3,465,462


3.15Granted


1,474,500


0.86Exercised


(1,250
)

0.87Cancelled


(321,998
)

3.14Balance, December 31, 2008


4,616,714

$
2.42


The
weighted average exercise price was $3.56 for the 233,185 options which expired during the year ended December 31, 2008, $6.36 for the 118,250 options which expired during the
year ended December 31, 2007 and $5.53 for the 167,687 options which expired during the year ended December 31, 2006.

The
weighted average grant date fair value per share was $0.46 for options granted during the year ended December 31, 2008, $2.51 for options granted during the year ended
December 31, 2007 and $2.18 for options granted during the year ended December 31, 2006.

The
aggregate intrinsic value of options exercised was $138 during the year ended December 31, 2008; $95,000 during the year ended December 31, 2007 and $158,000 during the
year ended December 31, 2006.

A
summary of the Company's nonvested restricted shares as of December 31, 2008 and activity during the year is as follows:

Number of
shares

Weighted-
average
grant-date
fair valueNonvested at January 1, 2008


101,250

$
3.69Granted


75,000


0.87Vested


(37,500
)

2.28Nonvested at December 31, 2008


138,750

$
2.55


As
of December 31, 2008, there was $179,000 of total unrecognized compensation cost related to nonvested stock-based compensation arrangements. That cost is expected to be
recognized over a weighted-average period of 1.1 years.

F-30

---



Table of Contents

INOVIO BIOMEDICAL CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

11. Commitments

On January 28, 2005, the Company moved into its headquarters of 22,867 square feet in San Diego, California. This lease runs through February 28, 2010. The annual rent for
this leased property was $433,901 in the first two years and $452,767 in year three and four of the original lease term. The annual rent for the fifth and final year of the original lease term is
$480,207. At the end of the original lease term, we have the option of renewing this lease for an additional five-year lease term at an annual rate equal to the fair market rental value of
the property, as defined in the lease agreement.

In
January 2008, we entered into a new facility lease in Oslo, Norway to support our research and development activities conducted through our subsidiary Inovio AS. The term of the lease
is for three years and may be terminated with three months notice. Monthly rent is approximately $3,000 per month.

Rent
expense was $422,000, $490,000, and $489,000 for the years ended December 31, 2008, 2007 and 2006, respectively. This amount is net of sublease income of $103,000, $38,000
and $38,000, respectively. Future minimum lease payments under non-cancelable operating leases as of December 31, 2008 are as follows:

2009

$
539,8252010


138,1522011


5,640Thereafter


Total

$
683,617


In
the normal course of business, the Company is a party to a variety of agreements pursuant to which we may be obligated to indemnify the other party. It is not possible to predict the
maximum potential amount of future payments under these types of agreements due to the conditional nature of our obligations and the unique facts and circumstances involved in each particular
agreement. Historically, payments made by us under these types of agreements have not had a material effect on our business, consolidated results of operations or financial condition.

12. Litigation

From time to time the Company becomes involved in various lawsuits, claims and proceedings relating to the conduct of our business. The Company is currently involved in the following
litigation:

Pyrce v. Inovio Biomedical Corporation, Genetronics Biomedical Corporation, Genetronics, Inc., Inovio AS, DOES 1 to 50, Superior Court of California,
County of San Diego, Case No. 37-2007-000758899-CU-BC-CTL (Hon. Ronald L. Styn). The plaintiff, a former
consultant to Inovio AS, commenced this civil lawsuit against the Company and various subsidiaries in state court on September 28, 2007. Plaintiff's original counsel withdrew from the case,
plaintiff was proceedingpro seuntil obtaining a new attorney who appeared in September of 2008 and filed a nine-count amended complaint.
The Court dismissed three of Plaintiff's counts and Plaintiff thereafter filed a nine-count second amended complaint by which Plaintiff seeks approximately $780,000 in damages. The
plaintiff has not
yet served Inovio AS. The Company disputes the allegations and intends to vigorously defend against them.

F-31

---



Table of Contents

INOVIO BIOMEDICAL CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

13. Income Taxes

In accordance with SFAS 109,Accounting for Income Taxes, a deferred tax asset or liability is determined based on the difference
between the financial statement and tax basis of assets and liabilities as measured by the enacted tax rates which will be in effect when these differences reverse. We provide a valuation allowance
against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax asset will be realized.

The
components of the provision (benefit) for income taxes are shown below:

As of
December 31,
2008

As of
December 31,
2007

As of
December 31,
2006Current:Federal

$


$


$
State








Foreign








$


$


$
Deferred:Federal

$


$


$
State








Foreign


(63,000
)

327,000


(63,000
)(63,000
)
$
327,000

$
(63,000
)


The
reconciliation of income tax attributable to operations computed at the statutory tax rates to income tax expense (recovery), using a 35% statutory tax rate, is:

Year ended
December 31,
2008

Year ended
December 31,
2007

Year ended
December 31,
2006Income taxes at statutory rates

$
(4,538,000
)
$
(3,786,000
)
$
(4,368,000
)State income tax, net of federal benefit


(668,000
)

(742,000
)

(659,000
)Change in valuation allowance


5,328,000


(6,445,000
)

4,636,000IRC Section 382 limitation





12,749,000


Fair value warrant


50,000


(1,192,000
)

Other


(235,000
)

(257,000
)

328,000$
(63,000
)
$
327,000

$
(63,000
)


The
income tax expense (recovery) has been recorded as a reduction to general and administrative expenses, as its effect is immaterial.

F-32

---



Table of Contents

INOVIO BIOMEDICAL CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

13. Income Taxes (Continued)

Significant
components of our deferred tax assets and liabilities as of December 31, 2008 and 2007 are shown below:

As of
December 31,
2008

As of
December 31,
2007Deferred tax assets:Capitalized research expense

$
3,566,000

$
929,000Net operating loss carry forwards


24,891,000


23,019,000Research and development and other tax credits


2,152,000


1,356,000Other


4,049,000


4,028,00034,658,000


29,332,000Valuation allowance


(34,658,000
)

(29,332,000
)Total deferred tax assets





Deferred tax liabilities:Acquired intangibles


(887,000
)

(950,250
)Net deferred tax liabilities


(887,000
)
$
(950,250
)


The
net deferred tax liability of $887,000 as of December 31, 2008, resulted from the acquisition of Inovio AS and reflects the net effect of temporary differences between the
carrying amount of intangible assets for financial statement reporting purposes and the amount used for income tax purposes. The liability will be amortized over the life of the underlying intangible,
which is 18 years and will be accounted for as an income tax recovery.

As
of December 31, 2008, we had federal and California tax net operating loss carry forwards of approximately $59.4 million and $58.0 million, respectively. The
federal loss carry forwards will begin to expire in 2019 unless previously utilized. The California loss carry forwards will begin to expire in 2013. The difference between the federal and California
tax loss carry forwards is primarily attributable to
the capitalization of research and development expenses for California income tax purposes and the 50% to 60% limitation of California loss carry forwards. In addition, we have federal and state
research tax credit carry forwards of $1.2 million and $1.5 million, respectively. The federal tax credit carry forwards will begin to expire in 2022. The California research tax credit
carry forwards do not expire. At December 31, 2008, the Company had foreign tax loss carry forwards related to the acquisition of Inovio AS of approximately $2.1 million. The foreign net
operating loss carry forwards begin to expire in 2011.

Utilization
of the NOL and tax credit carryforwards will be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986, and similar state
provisions due to ownership change limitations that have occurred previously or that could occur in the future. These ownership changes will limit the amount of NOL and tax credit carryforwards and
other deferred tax assets that can be utilized to offset future taxable income and tax, respectively. In general, an ownership change, as defined by Section 382, results from transactions
increasing ownership of certain stockholders or public groups in the stock of the corporation by more than 50 percentage points over a three-year period. An analysis was performed
of ownership activity through December 31, 2008 which indicated that multiple ownership changes have occurred in previous years which created annual

F-33

---



Table of Contents

INOVIO BIOMEDICAL CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

13. Income Taxes (Continued)

limitations
on the Company's ability to utilize NOL and tax credit carryovers. Such limitations will result in approximately $12.7 million of tax benefits related to NOL and tax credit
carryforwards that will expire unused. Accordingly, the related NOL and R&D credit carryforwards have been removed from deferred tax assets accompanied by a corresponding reduction of the valuation
allowance. Due to the existence of the valuation allowance, limitations created by future ownership changes, if any, related to our operations in the U.S. will not impact our effective tax rate.

In
July 2006, the FASB issued FIN 48, which clarifies the accounting for uncertainty in income taxes recognized in a company's financial statements in accordance with Statement of
Financial Accounting Standards No. 109,Accounting for Income Taxes.FIN 48 prescribes a recognition threshold and measurement process for
recording in the financial statements uncertain tax positions taken or expected to be taken in a tax return. Additionally, FIN 48 provides guidance on the de-recognition,
classification, interest and penalties, accounting in interim periods, and disclosure requirements for uncertain tax positions. We adopted the provisions of FIN 48 beginning January 1,
2007. The adoption of FIN 48 did not impact the Company's financial condition, results of operations or cash flows. As of December 31, 2008, the Company has not recorded any uncertain
tax benefits.

We
file income tax returns in the U.S. and various foreign and state jurisdictions. Due to our losses incurred, we are essentially subject to income tax examination by tax authorities
from our inception to date. Our policy is to recognize interest expense and penalties related to income tax matters as tax expense. At December 31, 2008, we do not have any significant accruals
for interest related to unrecognized tax benefits or tax penalties.

14. 401(k) Plan

In 1995, our U.S. subsidiary adopted a 401(k) Profit Sharing Plan (the "Plan") covering substantially all of its employees. The defined contribution plan allows the employees to
contribute a percentage of their compensation each year. We currently match 50% of our employees' contributions, up to 6% of their annual compensation. Our contributions are recorded as expense in the
accompanying consolidated statements of operations and totaled $58,000, $55,000 and $45,000 for the years ended December 31, 2008, 2007 and 2006, respectively.

15. Segment Information

The Company operates in one business segment in the United States and Europe. Revenues are attributable to the geographical area based on the location of the customer. During the year
ending December 31, 2008 revenues in Europe and the United States totaled $285,000 and $1.8 million, respectively. During the year ending December 31, 2007 revenues in Europe and
the United States totaled $267,000 and $4.5 million, respectively, and during the year ending December 31, 2006 revenues in Europe and the United States totaled $262,000 and
$3.2 million, respectively. Long-lived assets within the United States consist primarily of patents and other intellectual property. Long-lived assets outside the United
States consist primarily of goodwill and intangible assets. As of December 31, 2008, long-lived assets in Europe and
the United States totaled $7.1 million and $2.7 million, respectively. As of December 31, 2007, long-lived assets in Europe and the United States totaled
$7.7 million and $2.8 million, respectively, and as of December 31, 2006, long-lived assets in Europe and the United States totaled $7.9 million and
$2.9 million, respectively.

F-34

---



Table of Contents

INOVIO BIOMEDICAL CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

16. Related Party Transactions

In March 2004, we announced the selection of Quintiles Transnational Corp., a global pharmaceutical services organization, as the clinical research organization ("CRO") for our clinical
trials in the U.S. and Europe. In addition, the investment division of this CRO, Qfinance, Inc., was an investor in our Series A, B and C Preferred Stock. During the year ended
December 31, 2006, Qfinance, Inc. converted 50, 100 and 109 shares respectively, of our Series A, B and C Preferred Stock into a total of 725,788 of our common shares. Total
clinical trial expenses paid to Quintiles Transnational Corp. for the years ended December 31, 2008, 2007, and 2006, were $0, $23,000 and $371,000, respectively.

17. Supplemental Disclosures of Cash Flow Information

Year ended
December 31,
2008

Year ended
December 31,
2007

Year ended
December 31,
2006Supplemental schedule of financing activities:Conversion of minority interest into common stock

$


$
5,349,995

$
Interest paid

$
31,170

$


$
Imputed dividends on preferred stock

$


$


$
1,851,056Common stock issued in connection with declared dividends on preferred stock

$


$


$
22,264Cashless exercise of warrants

$


$
38

$
Conversions of preferred stock to common stock

$
113

$
961

$
1,764Issuance of common stock for patents and other assets

$


$


$
128,922Issuance of common stock in exchange for shareholder note receivable

$


$


$
86,030Leasehold improvements financed by landlord

$
35,211

$
92,486

$
172,054Investment received in exchange for licensing agreement

$


$


$
125,000


18. Inovio AS

On December 31, 2007, the Company's wholly-owned Norwegian subsidiary Inovio AS transferred certain patent and other intellectual property rights ("IPR") to our wholly owned U.S.
subsidiary Genetronics Inc. The value assigned to these rights was $1.9 million, which was determined by and was the responsibility of management of Inovio, who considered in part
preliminary work performed by a valuation specialist in Norway. All Norwegian tax gains associated with this transfer of the patents and IPR was offset by prior year tax loss carry forwards.
Subsequent to year-end, the Company changed the name of Inovio AS to Inovio Tec AS. Simultaneously, the Company incorporated a new Norwegian wholly-owned subsidiary under the name Inovio
AS, for the purpose of organizing a research effort directed towards the development of specific cancer vaccine candidates. The Company expects funding for this program to be about $5.0 million
over the next several years. In January 2008, all employees, employee agreements, lease agreements and fixed assets were transferred from Inovio Tec AS to Inovio AS.

19. Quarterly Financial Information (Unaudited)

The following unaudited quarterly financial information reflects all normal recurring adjustments, which are, in the opinion of management, necessary for a fair statement of the results
of the interim

F-35

---



Table of Contents

INOVIO BIOMEDICAL CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

19. Quarterly Financial Information (Unaudited) (Continued)

periods.
The four quarters for per share figures may not add for the year because of the different number of shares outstanding during the year. The results of operations for any period are not
necessarily indicative of the results to be expected for any future period. Summarized unaudited quarterly data for the years ended December 31, 2008 and 2007, are as follows:

Quarter Ended
December 31,
2008

Quarter Ended
September 30,
2008

Quarter Ended
June 30,
2008

Quarter Ended
March 31,
2008Consolidated Statement of Operations:Revenue:License fee and milestone payments

$
179,823

$
214,825

$
203,924

$
192,829Revenue under collaborative research and development arrangements


(81,240
)

239,912


459,110


460,185Grants and miscellaneous revenue


228,264








Total revenue


326,847


454,737


663,034


653,014Operating Expenses:Research and development


1,199,455


1,274,387


1,679,264


1,597,388General and administrative


2,588,989


1,928,928


3,086,180


2,401,505Total operating expenses


3,788,444


3,203,315


4,765,444


3,998,893Loss from operations


(3,461,597
)

(2,748,578
)

(4,102,410
)

(3,345,879
)Interest income, net


56,708


97,008


191,371


298,749Other income, net


(170,844
)

307,162


(112,733
)

25,421Net loss attributable to common stockholders

$
(3,575,733
)
$
(2,344,408
)

(4,023,772
)

(3,021,709
)Amounts per common sharebasic and diluted:Net loss attributable to common stockholders

$
(0.08
)
$
(0.05
)
$
(0.09
)
$
(0.07
)Weighted average number of common sharesbasic and diluted


44,011,800


43,929,654


43,874,739


43,837,739


F-36

---



Table of Contents

INOVIO BIOMEDICAL CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

19. Quarterly Financial Information (Unaudited) (Continued)



Quarter Ended
December 31,
2007

Quarter Ended
September 30,
2007

Quarter Ended
June 30,
2007

Quarter Ended
March 31,
2007Consolidated Statement of Operations:Revenue:License fee and milestone payments

$
2,212,854

$
136,870

$
209,265

$
234,489Revenue under collaborative research and development arrangements


1,054,031


265,970


286,312


247,990Grants and miscellaneous revenue


54,854


83,671





21,423Total revenue


3,321,739


486,511


495,577


503,902Operating Expenses:Research and development


1,866,322


2,335,378


2,907,836


2,516,411General and administrative


3,266,767


3,177,723


2,344,551


2,291,161Total operating expenses


5,133,089


5,513,101


5,252,387


4,807,572Loss from operations


(1,811,350
)

(5,026,590
)

(4,756,810
)

(4,303,670
)Interest income, net


357,514


405,023


286,792


223,068Other income, net


427,906


1,927,064


727,305


339,305Net loss


(1,025,930
)

(2,694,503
)

(3,742,713
)

(3,741,297
)Imputed and declared dividends on preferred stock








(8,244
)

(15,091
)Net loss attributable to common stockholders


(1,025,930
)
$
(2,694,503
)
$
(3,750,957
)
$
(3,756,388
)Amounts per common sharebasic and diluted:Net loss attributable to common stockholders

$
(0.02
)
$
(0.06
)
$
(0.09
)
$
(0.10
)Weighted average number of common sharesbasic and diluted


43,812,905


43,699,683


40,674,947


37,694,634


F-37

---